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Background and aims: Hypertensive disorders of pregnancy (HDP) are one of the 
most common gestational complications. HDP may be chronic (pre-dating pregnancy 
or diagnosed before 20 weeks’ gestation) or arise de novo (either preeclampsia or 
gestational hypertension). Of these, preeclampsia is one of the leading cause of 
maternal mortality and morbidity. Evidence suggests an association between HDP and 
neurodevelopmental outcomes; however, results are limited and inconsistent. The aim 
of the current thesis was to examine the association between HDP (in particular, 
preeclampsia) and neurodevelopmental disorders in the offspring, including autism 
spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), child 
development and behavioural outcomes. This would be achieved by systematically 
reviewing existing literature, and conducting a range of robust analyses using Swedish 
National Registry data, and data from a nationally representative study of children 
living in Ireland.  
Structure and methods: This thesis includes a brief introductory chapter (Chapter 1), 
and a detailed methods chapter describing study designs, data sources, exposure and 
outcome variables, statistical modelling, and the role of bias, confounding and chance 
in epidemiology (Chapter 2). Published literature on the relationship between HDP 
and neurodevelopmental disorders in the offspring were synthesised using a 
systematic review and meta-analysis, based on a pre-prepared protocol (Chapters 3 
and 4). This was followed by a narrative literature review to provide a perspective on 
how maternal inflammation may lead to altered neurodevelopmental outcomes in 
preeclampsia-exposed offspring (Chapter 5).  
Data from Swedish National Registers were analysed to examine the association 
between preeclampsia and ASD and ADHD, using Cox proportional hazards 
21 
 
regression analysis, adjusting for several perinatal and sociodemographic factors. 
Sibling-matched analysis was used to also control for shared genetic and familial 
confounding (Chapters 6 and 7). These associations were further explored by 
examining the intergenerational association between preeclampsia and ASD and 
ADHD (Chapter 8). Data from Growing Up in Ireland (GUI), a nationally 
representative study of children living in Ireland, were analysed to examine the 
association between preeclampsia and child development using the Ages and Stages 
Questionnaire (ASQ) at age 9-months, and behavioural outcomes using the Strengths 
and Difficulties Questionnaire (SDQ) at age 3 years, 5 years and 7-8 years. 
Multivariate logistic regression, linear regression and linear spline multilevel 
modelling were applied for this analysis (Chapter 9). Finally, the systematic review 
and meta-analysis was updated and included in this thesis (Chapter 10), along with 
discussion of findings, strengths and limitations of the thesis, and recommendations 
for future research (Chapter 11). 
Results: Updated systematic review and meta-analysis: Among ASD studies, adjusted 
pooled results indicated that exposure to HDP is associated with a 33% increased odds 
of ASD when compared to those unexposed (OR: 1.33, 95% CI: 1.17, 1.52). Results 
of a subgroup analysis, examining a preeclampsia-ASD relationship in isolation 
provided an OR of 1.36 (95% CI: 1.18, 1.58), while the other HDP-ASD relationship 
was statistically non-significant with an OR of 1.29 (95% CI: 0.97, 1.71). Among 
ADHD studies, adjusted pooled results suggested that offspring exposed to HDP are 
26% more likely to have ADHD compared to those unexposed (OR: 1.26, 95% CI: 
1.15, 1.38). For the subgroup analysis examining the preeclampsia-ADHD 
relationship, the OR was 1.23 (95% CI: 1.13, 1.35), and for other HDP-ADHD 
relationship, the OR was 1.80 (95% CI: 1.25, 2.59). 
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Swedish National Registers: The adjusted Cox model suggested that preeclampsia was 
associated with 25% increased odds of ASD (Hazard ratio (HR): 1.25, (95% CI: 1.19, 
1.30). The sibling-matched analysis reduced the HR to 1.17 (95% CI: 1.06, 1.28). The 
HR for preeclampsia and SGA combined (used as a crude proxy for preeclampsia with 
placental dysfunction) was 1.66 (95% CI: 1.49, 1.85) in the adjusted Cox model and 
1.95 (95% CI: 1.53, 2.48) in the sibling-matched analysis. In the adjusted Cox model, 
preeclampsia was associated with a 15% increase in likelihood of ADHD (HR: 1.15, 
95% CI: 1.12, 1.19), while the HR for preeclampsia and SGA combined was 1.43 
(95% CI: 1.31, 1.55) in the adjusted model, compared to those unexposed to 
preeclampsia/SGA. The sibling-matched analysis did not materially change these 
associations. 
Similar to the findings outlined above, the intergenerational analysis suggested that 
exposure to preeclampsia was associated with an increased likelihood of ASD and 
ADHD in offspring. In addition to this, results suggested that preeclampsia in both the 
child’s mother and grandmother was associated with a 58% increased likelihood of 
ASD (HR: 1.58, 95% CI: 1.02, 2.46) and 34% increased likelihood of ADHD (HR: 
1.34, 95% CI: 1.01, 1.80) in the child. 
GUI study: Multivariate logistic regression suggested that preeclampsia was not 
associated with failing any ASQ domain. Preeclampsia was associated with abnormal 
SDQ cut-off of Emotional (score of ≥5) and Hyperactivity (score of ≥7) domains at 
age 5 years only. In the linear spline model, mean SDQ score was higher at age 3, 5 
and 7-8 years in exposed groups, however did not always reach statistical significance.  
Conclusions: This thesis rigorously investigates the association between HDP (in 
particular, preeclampsia) and neurodevelopmental disorders in offspring using a range 
of analytic approaches, and adjusting for a wide variety of potential confounders. 
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Pooled estimates from previous literature suggested an association between HDP and 
ASD and ADHD. Furthermore, the data from Swedish National Registers indicate that 
exposure to preeclampsia or preeclampsia and SGA combined (i.e. SGA baby exposed 
to preeclampsia) was associated with ASD and ADHD. The stronger association with 
preeclampsia and SGA combined than preeclampsia alone suggests that placental 
pathology may be a mechanism for the increased likelihood of ASD and ADHD. 
Results of the current thesis also suggest that preeclampsia may be associated with 
adverse neurodevelopmental outcomes across generations. 
While we did not find strong evidence of associations between preeclampsia and child 
developmental and behavioural outcomes overall in the GUI study, exposure to 
preeclampsia was associated with an increased likelihood of subtle behavioural issues 
in the emotional and hyperactivity domain of the SDQ.  
The overall conclusion of this thesis suggests an association between HDP and 
neurodevelopmental outcomes in offspring. It is important to note however, that we 












1.1.1 Hypertensive Disorders of Pregnancy 
Hypertensive disorders of pregnancy (HDP) are among the most common 
complications of pregnancy, estimated to effect up to 10% of all pregnancies(1). They 
are classified by the International Society for the Study of Hypertension in Pregnancy 
(ISSHP) as “chronic hypertension”, “white-coat hypertension”, “masked 
hypertension”, “transient gestational hypertension”, “gestational hypertension” and 
“preeclampsia” (de novo or superimposed on chronic hypertension)(2) (Figure 1.1) 
(figures and tables are located at the end of each chapter). 
Chronic hypertension refers to a diagnosis of hypertension (defined as systolic blood 
pressure ≥140 and/or diastolic blood pressure ≥90 mmHg) before pregnancy or within 
the first 20 weeks of pregnancy. White-coat hypertension refers to elevated blood 
pressure during a clinic visit (≥140/90mmHg) but normal blood pressure measured at 
home or work (<135/85mmHg); while masked hypertension is a form of chronic 
hypertension that refers to blood pressure readings that are normal at a clinic visit, 
however elevated at other times(2).  
Transient gestational hypertension, gestational hypertension and preeclampsia are new 
onset hypertension (blood pressure ≥140mmHg systolic or ≥90mmHg diastolic) 
typically arising at or after 20 weeks of pregnancy(2). Transient gestational 
hypertension generally arises in the second or third trimester but resolves without any 
treatment. Gestational hypertension is persistent hypertension that develops without 
features of preeclampsia, while preeclampsia can be de novo or superimposed on 
chronic hypertension (i.e. women with chronic hypertension who develop 
preeclampsia). Of these, preeclampsia is one of the leading causes of maternal 




Preeclampsia, which affects approximately 5% of all pregnancies(4) is a serious 
obstetric complication, and is responsible for more than 500,000 fetal and neonatal 
deaths, and 70,000 maternal deaths each year, worldwide(2).  
Past hypotheses of preeclampsia have varied considerably, and are thought to date 
back to 400BC when it was hypothesised that preeclampsia was a result of an 
imbalance in the four humors (blood, phlegm, yellow bile, and black bile)(5).  
The introduction of the word ‘eclampsia’ (derived from the Greek word eklampsis, 
meaning lightning) did not appear until 1619 however, and was thought to be a form 
of epilepsy. It was not until the 18th century when eclampsia was differentiated from 
epilepsy by Boissier de Sauvages, an important difference being the nature of 
convulsions (acute in the case of eclampsia, and chronic in epilepsy with convulsions 
recurring over time)(5, 6).   
The late 1800s saw the theory of toxins emerge where it was believed that increased 
secretion of waste and debris, for example from the bowels, and maternal and fetal 
systems, would prevent accumulation of toxins in the blood that could potentially lead 
to convulsions. As a result, treatment for pregnant women with headaches and edema 
involved bleeding and purging(5).  
Classification of the disorder was refined throughout the late 18th and 19th century, 
as symptoms such as headache, temporary loss of vision, severe stomach pain, and 
edema in the upper body became recognised as a preeclamptic state (before 
convulsions) that should also heed the attention of clinicians. However, it was not until 
the introduction of Scipione Riva-Rocci’s mercury sphygmomanometer in 1896, 
allowing the measurement of systolic blood pressure, that increased understanding that 
preeclampsia was a hypertensive disorder(5, 7). 
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To this day, the exact etiology of preeclampsia remains unknown. However, it is 
understood that the placenta can play a role in pregnancies complicated by 
preeclampsia through the release of vasoactive factors into the maternal circulation. 
Such factors include soluble fms-like tyrosine kinase-1 (sFlt-1), cytokines, angiotensin 
II and type 1 receptor autoantibodies which target the maternal vascular endothelium, 
resulting in the clinical manifestations of the disorder(6). These clinical manifestations, 
as recently redefined by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP), include hypertension (blood pressure ≥140/90mmHg at or after 
20 weeks’ gestation) accompanied by one or more of the following: 
1. Proteinuria. 
2. Maternal organ dysfunction, including:  
 Acute kidney injury (creatinine > 90umol/L; 1mg/dL).   
 Liver involvement (elevated transaminases, for example alanine 
aminotransferase (ALT) or aspartate transaminase (AST) >40 international 
units/litre (IU/L)) with or without right upper quadrant or epigastric abdominal 
pain). 
 Neurological complications (for example, eclampsia, altered mental status, 
blindness, stroke, clonus, severe headaches, persistent visual scotomata) 
 Haematological complications (thrombocytopenia – platelet count below 
150,000/uL, disseminated intravascular coagulation (DIC), hemolysis). 
 3. Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical 
artery Doppler wave form analysis, or stillbirth)(2). 
Despite the precise etiological mechanisms of preeclampsia yet to be uncovered, 
several risk factors such as prior preeclampsia, chronic hypertension, multiple 
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gestation, pre-gestational diabetes, maternal obesity, and antiphospholipid antibody 
syndrome are well documented(2, 8). 
Previous epidemiological studies have used varying data collection methods to 
determine if a diagnosis of preeclampsia was present, such as self-reported data(9-11), 
medical records(12, 13) and population-based registries(14, 15). A common method of 
classifying preeclampsia in medical records and registry data is the International 
Classification of Diseases (ICD) coding system. This thesis uses data from Swedish-
based registries, classifying preeclampsia according to the Swedish version of ICD-8 
[code 637], ICD-9 [code 642], and ICD-10 [code O14 or O15](16) (chapters 6, 7 and 
8). In addition, self-reported data on preeclampsia from a longitudinal study of 
children living in Ireland is also used (chapter 9).  
 
1.1.3 HDP and neurodevelopmental outcomes 
1.1.3.1 The Fetal Origins Hypothesis 
The Fetal Origins Hypothesis which is associated with the English physician and 
epidemiologist David Barker, proposes that the in utero experience is a critical period 
and can result in lifelong consequences for the offspring(17). While the hypothesis 
originally outlined a link between fetal undernutrition and coronary heart disease, it is 
now well recognised that the environment during fetal development may have an 
effect on a range of health outcomes, including neurodevelopment(18). For example, 
previous literature suggests that in utero exposure to environmental toxicants(18), birth 
by caesarean section(19), and advanced maternal age are associated with adverse 
neurodevelopment(20). Similarly, evidence alludes to an association between HDP and 
neurodevelopmental outcomes in offspring(21, 22).  
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1.1.3.2 HDP and Autism Spectrum Disorder 
Two neurodevelopmental outcomes that can typically present during childhood are 
autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). 
ASD is characterised by persistent impairments in interpersonal interaction and 
restricted or repetitive patterns of behaviour(23). Recent decades have observed a 
significant rise in the prevalence of ASD. For example, at the end of the 20th century, 
global prevalence was estimated to be approximately 0.62%(24). However, the current 
global prevalence is approximately 1%, increasing to 1.5% in developed countries(25, 
26).  
Several possible explanations have been proposed to account for this rise, such as 
increased awareness of ASD, with an estimated 60% of the increase occurring as a 
result of changes in diagnostic criteria(27). In addition to this, while there is a general 
consensus that genes play a major role in the development of ASD, the environmental 
contribution is estimated to be about 17-50%, however the potential etiological factors 
are not well understood(28, 29). 
Previous literature suggests an association between HDP and ASD; however, findings 
are inconsistent. For example, two case control studies conducted in Sweden and 
California allude to a positive relationship between preeclampsia and ASD(13, 14), while 
a further two cohort studies, both of which were conducted in the United States, also 
suggest a significant association between preeclampsia and ASD(9, 30). In addition to 
these, there are studies suggestive of a positive relationship, but fail to reach statistical 
significance(12, 31). Conversely, other studies indicate a protective association between 




Similarly, the epidemiological evidence examining other categories of HDP and 
likelihood of ASD is conflicted, with some studies indicative of a positive association. 
For instance, Curran et al. and Polo-Kantola et al. studied the association between 
HDP (which may have included preeclampsia) and ASD using data from the United 
Kingdom and Finland respectively, with both study authors finding significant 
positive associations(21, 35). However, in contrast to this, Lyall et al. and Langridge et 
al. found an inverse association between pregnancy induced hypertension and ASD(9, 
36).  
 
1.1.3.3 HDP and Attention Deficit Hyperactivity Disorder 
Attention deficit hyperactivity disorder (ADHD) is characterised by inattention, 
hyperactivity and impulsivity, and has an estimated global prevalence of 
approximately 5%(37, 38).  
Akin to ASD studies, conflicting findings are observed amongst previous 
epidemiological literature examining a preeclampsia-ADHD relationship. There are 
studies that conclude positive associations(39-43); Silva et al. and Getahun et al. (two 
large case-control studies from Western Australia and Southern California 
respectively), used existing medical records data to conclude a positive association 
between preeclampsia and ADHD. Furthermore, Mann and McDermott conducted a 
cohort study from Medicaid billing records and found a 20% increased odds of ADHD 
in preeclampsia-exposed offspring(41).  
There are also studies that suggest a positive association, although span the null 
value(44-46), while conversely, there is evidence of a negative relationship between 
preeclampsia and ADHD(47, 48), but these studies do not control for potential 
confounders(47, 48). While fewer studies examine a relationship between other 
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categories of  HDP and ADHD, the presence of a positive association between self-
reported HDP (which may include preeclampsia) and ADHD is outlined in Bohm et 
al.(22).  
 
1.1.3.4 A Need for Further Research 
In addition to conflicting results of studies examining a HDP-ASD and HDP-ADHD 
association, residual or unmeasured confounding is of particular concern in the 
literature. For example, two separate case-control studies(11, 49) and one cohort study(50) 
conducted in the United States, India and Canada examined the association between 
pregnancy induced hypertension and ASD but failed to control for potential 
confounding factors. Furthermore, a case-control study conducted in Poland 
investigating a chronic hypertension-ASD relationship, although matched on year of 
birth, sex and general practitioners, did not control for potential confounders in the 
analysis phase of the study(12). Similar issues are observed among ADHD studies as 
validity of findings are often limited by residual confounding(42, 47, 48). 
Furthermore, previous epidemiological literature on this topic does not control for 
genetic factors shared by siblings, a limitation that should be addressed before 
reaching conclusions that are more definitive. One such method to address this is a 
sibling-matched design. In brief, this method uses stratified Cox regression, and is an 
extension of the paired binomial model, taking into account different lengths of 
follow-up time. It can estimate the probability of ASD/ADHD within the family, while 
also taking account of unmeasured confounding factors shared by siblings, including 




Lastly, evidence suggests that certain non-communicable disease-risk may be 
intergenerational. For example, cardiovascular disease in grandparents is associated 
with congenital heart disease in grandchildren(52), while type 2 diabetes in one 
generation may be linked to birthweight across two subsequent generations(53). 
However, whether there is any intergenerational link between preeclampsia and ASD 
and ADHD is unknown. Therefore, given the long-term consequences of preeclampsia 
for both mother and child(54-56), examining the intergenerational association between 
preeclampsia and ASD and ADHD is warranted. 
 
1.1.3.5 HDP and Other Neurodevelopmental Outcomes 
There is some evidence of an association between HDP and impaired cognitive 
functioning, behavioural issues and intellectual disability(57-59). For example, some 
patterns of association can be observed between preeclampsia and cognitive 
impairment when confined to specific populations such as growth restricted, preterm 
and low birthweight babies(57, 60, 61). Similarly, there is some epidemiological evidence 
that is suggestive of a potential link between HDP and intellectual disability(36, 62, 63). 
However, there is a lack of overall consistent findings as some studies have not found 
significant associations(13, 22, 64, 65), while others suggest a protective association(66, 67). 
In addition to this, much of the research examining a preeclampsia-child development 
relationship has been conducted on specific populations such as preterm and very low 
birthweight infants with small sample sizes. As a result, generalisability of findings is 




1.1.4 Biological Mechanisms 
Several potential mechanisms have been proposed in an attempt to explain the 
association between HDP and neurodevelopmental outcome (Figure 1.2). For 
example, placental dysfunction, associated with HDP, may result in suboptimal 
nutrient and oxygen availability for the fetus, potentially affecting the developing 
brain, and increasing the likelihood of adverse neurodevelopmental outcome(13, 30, 70-
72).   
Furthermore, the inflammatory response associated with preeclampsia could act as a 
mediator between preeclampsia and neurodiversity given that maternal inflammation 
is a recognised risk factor for adverse neurodevelopmental outcome(73-75) (see chapter 
5 for a narrative review of evidence on how maternal inflammation may lead to altered 
neurodevelopmental outcomes in preeclampsia-exposed offspring). For example, 
research by Spann et al. suggests a negative association between maternal interleukin 
(IL)-6 (a pro-inflammatory cytokine) and brain connectivity in toddlers(76), while 
Rasmussen et al. has demonstrated an inverse association between maternal IL-6 and 
offspring cognition at 12 months of age(77). In addition to this, a Finnish population-
based study, with data on over one million pregnancies, have demonstrated how the 
inflammatory biomarker, C-reactive protein (CRP) which is associated with 
preeclampsia, is associated with a 43% increased risk of ASD in offspring(78, 79). 
Likewise for ADHD, despite high heritability estimates, gene environment 
interactions may also play a role(80), and while fewer hypotheses have been put forward 
addressing the biological mechanisms of ADHD specifically, similar mechanisms may 





1.1.5 Overall Aims and Objectives 
Given the lack of overall consistent findings, and threats to validity, for example due 
to unmeasured and residual confounding, the overall aim of this thesis was to examine 
the association between HDP, (in particular, preeclampsia), and neurodevelopmental 
disorders in offspring (as outlined in Figure 1.3). Specifically, the objectives of the 
thesis were as follows: 
 
1. Based on a pre-prepared protocol, synthesise the available published literature on 
the relationship between HDP and neurodevelopmental disorders in the offspring in 
the form of a systematic review and meta-analysis. 
 
2. Review evidence and provide a perspective on how maternal inflammation may 
lead to altered neurodevelopmental outcomes (in particular ASD) in preeclampsia-
exposed offspring. 
 
3. Examine the association between preeclampsia and ASD using data from Swedish 
National Registers, controlling for several important confounders, including 
confounding due to shared genetics and familial environment through sibling-matched 
analysis. 
 
4. Examine the association between preeclampsia and ADHD using data from Swedish 
National Registers, controlling for several important confounders including 





5. Examine the intergenerational association between preeclampsia and ASD and 
ADHD using data from Swedish National Registers. 
 
6. Examine the association between preeclampsia and child development, and 
behavioural outcomes using data from Growing Up in Ireland, a nationally 
representative study of children living in Ireland. 
 
7. Update the systematic review and meta-analysis for ASD and ADHD, including the 
current results and any newly published studies.  
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Figure 1-3 Thesis overview including overall aim, specific objectives and corresponding chapters 
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Chapter 2: METHODS 
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2.1 Chapter Overview 
This chapter provides a brief outline of the methods used in this thesis (a full 
description of the methods used for each study can be found within each paper).  In 
particular, this chapter describes the following:  
2.2 Study designs used. 
2.3 Data sources used (where applicable).  
2.4 Main exposure and outcome variables used.  
2.5 Statistical modelling used.  
2.6 Bias, confounding and chance in epidemiology. 
 
2.2 Study Design 
2.2.1 Systematic Review Protocol 
Chapter 3 is comprised of a systematic review protocol outlining the rationale, 
research question, and planned methods of the systematic review. This is to ensure the 
decisions guiding the systematic review were a priori, preventing arbitrary decisions, 
and ensuring a transparent process. In addition to publishing the review protocol in the 
BMJ Open(83), the protocol was registered on PROSPERO (registration number: 
CRD42017068258) to prevent unintended duplication by other systematic reviewers.  
The following PICO was used to determine inclusion/exclusion criteria: 
Population: Pregnant women and their children. 
Intervention/Exposure: Diagnosis of any HDP (any definition in previous literature). 
Comparison: No diagnosis of HDP. 
Primary Outcomes: ASD and ADHD (any definition in previous literature). 
Secondary Outcomes: Other neurodevelopmental disorders.  
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2.2.2 Systematic Review and Meta-analysis and Narrative Review 
Chapter 4 is comprised of a systematic review and meta-analysis (based on the 
protocol in chapter 3). This was conducted to systematically locate and synthesise 
published epidemiological literature on the association between HDP and 
neurodevelopmental disorders in the offspring. The following PICO was used in the 
review: 
Population: Pregnant women and their children. 
Intervention/Exposure: Diagnosis of any HDP (any definition in previous literature). 
Comparison: No diagnosis of HDP. 
Primary Outcomes: ASD and ADHD (any definition in previous literature).  
Secondary Outcomes: Neurodevelopmental and other behavioural or cognitive 
outcomes. 
Data were analysed using Review Manager 5.3. Random-effects meta-analyses 
calculated overall pooled estimates of the relationship between combined HDP, 
preeclampsia only, and other HDP, and the outcomes of ASD and ADHD. We used 
the generic inverse variance method (GIVM) to allow studies that do not report raw 
data to be included in the meta-analyses. Forest plots were used to display crude and 
adjusted estimates for ASD and ADHD, while standalone estimates were reported for 
secondary outcomes. 
Conversely, chapter 5 contains a narrative review summarising existing evidence of 
how maternal inflammation may lead to altered neurodevelopmental outcomes in 
preeclampsia-exposed offspring. This was to provide a perspective on a potential 





2.2.3 Cohort Studies using Swedish National Registers 
Chapters 6, 7 and 8 are comprised of population-based cohort studies, using Swedish 
National Registers. These chapters were informed by the systematic review in chapter 
4 which identified several limitations of previous literature that should be addressed 
in future research studies. Therefore, the aim of these studies was to examine the 
association between preeclampsia and ASD, and preeclampsia and ADHD, while 
addressing the key limitations identified in the systematic review. 
A prospective cohort study and case-control study are also viable options that could 
potentially address these research areas, and both have strengths and limitations. For 
example, prospective cohort studies recruit participants at baseline, (during which time 
no one has been diagnosed with the outcome of interest), and follows them forward in 
time to determine who experiences the outcome of interest. These type of studies can 
be used to calculate the incidence and prevalence of the study outcome, while it is also 
possible to collect information on multiple potential confounders, which can be easily 
adjusted-for in the analysis phase of the study. Furthermore, prospective cohort studies 
are flexible in that they can be used to examine the association between an exposure 
and multiple outcomes. Conversely, prospective cohort studies tend to be a lengthy 
process with long follow-up periods, therefore tend to be a more expensive option and 
generally not suited to studies with rare outcomes.  
Case-control studies identify those with the outcome of interest, match them to 
suitable controls and examine past exposures. Case-control studies can be conducted 
faster than prospective cohort studies, and are therefore a less expensive option making 
them suitable for studying rare outcomes. However, case-control studies are 
particularly prone to selection bias due to issues in recruiting appropriate controls, 
while confounding in case-control studies may also be an issue. For example, if 
44 
 
confounding is addressed in the design phase of the study through matching, this 
should be taken into account in the analysis phase of the study by conducting 
conditional logistic regression.  In addition to this, case-control studies cannot be used 
to estimate the incidence or prevalence of an outcome.  
Retrospective cohort studies are similar to prospective cohort studies, however an 
important difference being that retrospective studies use historical data where the 
exposure and outcome of interest has already occurred in some individuals. A 
limitation of a retrospective study is that data on potential confounders is limited to 
what is available in the existing dataset. Moreover, if using existing data that was not 
collected to answer a specific research questions, the researcher cannot be certain of 
the processes used to collect the data. 
 A population-based cohort study, which contains some of the features of prospective 
and retrospective, was used for this thesis. For example, in a population-based cohort 
study, data are recorded prospectively, limiting the likelihood of recall bias; however 
it shares with the retrospective design the fact that you are limited to what variables 
are available in the dataset.  
 A population-based cohort study was chosen for the following reasons: 
1. Swedish population-based registry data was available which could be used to 
address this piece of research, saving on resources such as time and financial cost 
associated with collecting primary data. 
2. The registers contain data on a wide range of perinatal and sociodemographic 
factors, allowing adjustment for several potential confounders. 
3. The large sample size (more than two million children) allowed the research to be 
conducted with sufficient power. 
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4. A personal identity number (PIN), assigned to each Swedish resident allowed for 
individuals and family members to be linked across national registers. Therefore, we 
were able to adjust for shared genetic and familial confounding using sibling-matched 
analysis, while also examine an intergenerational association between preeclampsia 
and ASD and ADHD. 
 
2.2.4 Cohort Study using Growing Up in Ireland 
Chapter 9 examines the associations between preeclampsia and child development and 
behavioural outcomes, and is a secondary analysis of the prospective cohort study, 
Growing Up in Ireland. Similar to above, a cohort study or case-control study are valid 
options to investigate this research topic. However, a secondary analysis of a 
prospective cohort study was used for the following reasons: 
1. Data on exposures and outcomes of interest were readily available in the Growing 
Up in Ireland data, therefore collecting primary data, which can take several years and 
require large financial costs, was not necessary.  
2. Data on behavioural outcomes were measured at several time-points, making a case-
control study a less viable option. 
3. National registers such as those in Sweden lack information on child development 
and behavioural outcomes; however, this information was available in the Growing 
Up in Ireland dataset, thus complementing the Swedish data studies.  
4. Growing Up in Ireland also contains a wide range of perinatal and 
sociodemographic data, allowing adjustment for several potential confounders. 
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2.3 Data Sources 
2.3.1 The Swedish National Registers 
2.3.1.1 Personal Identification Numbers 
Since 1947, every permanent resident of Sweden is assigned PIN when they register 
their birth, or move to Sweden and intend to stay for at least one year. This PIN is a 
unique number consisting of three parts: date of birth, a sex-specific three-digit birth 
number, and a ‘check digit’ that verifies the first two parts are correct. The PIN was 
originally introduced to identify individuals resident in Sweden. However, it is now 
also used as a means of linking individuals across national registers, allowing 
researchers to examine a vast range of research questions, including those that require 
long periods of follow-up(84).   
 
2.3.1.2 The Medical Birth Register 
Founded in 1973, the Medical Birth Register has data on over 96% of all births in 
Sweden, and contains information on prenatal care, delivery, neonatal care, as well as 
maternal sociodemographic and lifestyle factors. It is compulsory for all healthcare 
providers to report to the register, however, data on approximately 1-4% of births are 
either missing completely or incomplete(85).  
While the basic structure of the register has not changed much since 1973, there have 
been some modifications to content and methods of data collection. For example, from 
1973-1982 medical secretaries at obstetric clinics summarised medical records on 
standardised forms, which were then sent to the National Board of Health for 
computerisation. However, after a content evaluation in 1976, it was decided that basic 
records of antenatal care of the mother, delivery records, and infant examination 
records would be sent to the National Board of Health directly for inputting into the 
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Medical Birth Register, to prevent any discrepancies when transferring data. This new 
procedure came into effect in 1982, during which time the content of the register was 
also expanded to include information on maternal factors such as smoking status and 
body mass index (BMI)(86).  
 
2.3.1.3 The National Patient Register 
The National Patient Register was founded in 1964 when it started collecting 
information on somatic inpatient care in six Swedish counties. The register also 
contained information on inpatient psychiatric care from the 1960s. However, all 
psychiatric data originating before 1973 were removed when the register was 
reconstructed in the 1990s. During this time, the decision was made to include the PIN 
as the unique identifier in all hospital discharges and efforts were made to link earlier 
hospital discharges to the PIN. Therefore, the National Patient Register now contains 
information on inpatient psychiatric diagnoses from 1973, and has obtained complete 
national coverage from 1987(87).  
Every year data on approximately 1.5 million discharges are collected. Each discharge 
record contains information on patient-related data (such as PIN, sex and age), data 
about the caregiver (such as hospital code and department), administrative data (such 
as admission and discharge date), and medical data (such as primary and additional 
diagnoses, which can be co-morbidities and/or complications of the primary 
diagnosis)(87). Several validation studies of inpatient data in the National Patient 
Register have been conducted, and a review of these studies suggests high validity, 
concluding a positive predictive value of 85-95% for most diagnoses(87).  
Since 2001, the National Patient Register was expanded to include outpatient data 
from both public and private caregivers, with increasingly better coverage until 
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2006(88). In 2010, it was estimated that coverage of data from private caregivers was 
approximately 80%, coverage from public caregivers was almost 100%, while primary 
health care data are still not reported on a national level(87).  
 
2.3.1.4 The Prescribed Drug Register 
The Prescribed Drug Register was founded on 1st July 2005, and the unique PIN was 
used to allow linkage to other registers(89). Prior to this, establishing a Prescribed Drug 
Register was met with political resistance as it was thought to be a threat to patient 
confidentiality more so than other national registers. However, lobbying from patients’ 
and older people’s organisations led to the introduction of the Prescribed Drug 
Register(90). The register collects information on all dispensed prescribed drugs in 
outpatient care and coverage is almost 100% complete. It also contains information on 
dosage, age, sex, place of residence, date of prescribing and dispensing, healthcare 
provider and profession of prescriber for more than six million Swedish residents each 
year(89, 90). However, the register does not contain information on over-the-counter 
medications, medications used in hospital care, and is not complete with regard to 
drugs used in nursing homes. In addition to this, the register does not collect 
information on indication for the prescription, or drugs that have been issued by 
physicians but not dispensed(90). 
 
2.3.1.5 The Multi-generation Register 
The first version of the Multi-generation Register was created in 2000, and replaced 
what was known as the Second Generation Register kept by Statistics Sweden from 
1994-1999. It is part of the Total Population Register (see below) and is made up of 
people who have been registered in Sweden at some point since 1961, and those who 
49 
 
were born in 1932 or later. Each year, a new version of the register is created, and 
includes new people who immigrated, or were born during that year(91). The purpose 
of the Multi-generation Register is to connect people with their biological parents, 
with information on mothers available in 97% of cases, and on fathers in 95% of 
cases(92).  
 
2.3.1.6 The Total Population Register 
The Total Population Register was created in 1968, and is maintained by the 
government agency Statistics Sweden. The register contains background information 
such as age, sex, municipality and country of birth, in addition to information on 
number of live births, stillbirths, deaths, immigrations and emigrations, migrations 
within Sweden, changes in civil status, and changes in citizenship. It is estimated that 
approximately 100% of births and deaths, 95% of immigrations and 91% of 
emigrations are reported to the Total Population Register within 30 days, with these 
figures increasing over time. However, underreporting of emigration data is estimated 
to be up to 0.5% of the registered total population in Sweden(93). 
 
2.3.1.7 The Register of Education 
The Register of Education contains data on graduation and educational background 
such as highest education level and completion year. As well as this, the register 
collects information on demographics including age, sex, and municipality of 
residence. The educational data contained in the register was updated using the 
Population and Housing Census 1990, and has improved the quality of the register 




2.3.2 Growing Up in Ireland 
2.3.2.1 Study population 
Growing Up in Ireland (GUI) is a nationally representative longitudinal study of 
children, funded by the Irish Government, carried out jointly by The Economic and 
Social Research Institute and Trinity College Dublin, and managed by the Department 
of Children and Youth Affairs and Central Statistics Office. The study, which started 
in 2006, follows two separate cohorts over a number of years: a child cohort, (which 
began 2006) when children were 9 years, and an infant cohort (which began in 2008) 
when children were 9 months(95).  
The GUI study consists of various waves of data collection. This thesis uses data from 
waves 1-4 of the Infant Cohort only. Wave 1 (baseline) was conducted when the 
children were nine-months, wave 2 follow-up data were collected when the children 
were 3 years old, wave 3 follow-up data were collected when the children were 5 years 
old and wave 4 follow-up data were collected when the children were 7-8 years old. 
In waves 1-3, data were collected through face-to-face interviews conducted by trained 
interviewers, while a postal survey is used in wave 4.  
 
2.3.2.2 Sampling frame 
The Child Benefit Register was used as the sampling frame for the GUI study. The 
Child Benefit Register contains information on Child Benefit payments in Ireland. 
Child Benefit is paid each month for all children under 16 years (regardless of income) 
to the person who cares for the child, and must be claimed within six months of the 
child being born or within six months of the family coming to reside in Ireland. 
Therefore, the Child Benefit Register is considered an up-to-date and comprehensive 
database of children residing in Ireland(96). Non-married subgroups were oversampled 
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to ensure that there was an adequate absolute number of respondents in these groups. 
In addition, to ensure non-national infants and their families were adequately 
represented, a supplementary sample of 700 non-national families were selected (after 
selection of the main sample). 
 
2.3.2.3 Weighting the data 
Survey data needs to be re-weighted because a simple random sample method is rarely 
used when conducting survey based studies. Therefore, GUI data was re-weighted to 
ensure the sample was representative of the national sample of infants aged less than 
one year, and who were on the Child Benefit Register in the 2008 calendar year.  
Re-weighting the data allows for the recruited sample to become more comparable 
with the population of interest, compensating for imbalances in the structure of the 
recruited sample. Such imbalances may occur due to the lack of availability of an 
optimal sampling frame, or differential response patterns within subgroups of the 
population under study(96). Furthermore, if you fail to re-weight the survey data, 
estimated standard errors will likely be underestimated, and possibly lead to results 
that seem to be statistically significant, when in fact, they are not(97). 
The GUI data weighting was constructed by adjusting the distribution of the sample 
to known population figures using Irish Census data and the Child Benefit Register by 
ensuring that the distribution of individuals in the completed sample matched a set of 




2.4 Main Exposure and Outcome Variables 
2.4.1 Exposures 
2.4.1.1 Preeclampsia 
In Swedish data studies (chapters 6, 7 and 8), data on preeclampsia were obtained from 
the Medical Birth Register, and classified according to the Swedish version of 
International Classification of Disease (ICD-8)  (through 1986), ICD-9 (1987-1996) 
and ICD-10 (from 1997 onwards)(16).   
In the GUI study (chapter 9), data on preeclampsia were self-reported through a 
questionnaire-based face-to-face interview. The mother was asked the following 
question: “Were there any of the following complications with the pregnancy?” and 
instructed to tick all that apply from a list of complications. This included “raised 
blood pressure and protein in the urine (Preeclampsia)”. If the mother ticked this box, 
then a diagnosis of preeclampsia was assumed.                                                                                                                                                                                                                                                                                                                                                      
 
2.4.1.2 Preeclampsia and Small for Gestational Age 
Preeclampsia and small for gestational age (SGA) were combined (i.e. SGA baby 
exposed to preeclampsia) as a crude proxy for preeclampsia with placental 
dysfunction. In Swedish data studies, SGA was classified according to the Swedish 
weight-based fetal growth standard (defined as birthweight <2 standard deviations 
below the mean of the sex-specific and gestational age distributions)(98) (Chapters 6 
and 7). 
In the GUI study (chapter 9), SGA was based on maternal-reporting of child’s 
birthweight, gestational age and sex, and defined as birthweight <10th percentile for 





2.4.2.1 Autism Spectrum Disorder 
In Swedish data studies (chapters 6 and 8), data on ASD were obtained from the 
National Patient Register, and classified according to ICD-9, available since 1987 and 
ICD-10, available since 1997(19). 
 
2.4.2.2 Attention Deficit Hyperactivity Disorder 
In Swedish data studies (chapters 7 and 8), data on ADHD were obtained from the 
National Patient Register and Prescribed Drug Register. A diagnosis of ADHD was 
determined in one of two ways:  
1. If a diagnosis of ADHD was present in the National Patient Register, classified 
according to ICD-10, available since 1997(88).  
2. If the subject was in receipt of ADHD medication in the Prescribed Drug Register, 
available since 2005. ADHD medication data was classified according to Anatomical 
Therapeutic Chemical classification system, and included amphetamine (N06BA01), 
dexamphetamine (N06BA02), psychostimulants methyphenidate (N06BA04) and 
noradrenergic reuptake inhibitor atomoxetine (N06BA09)(88). 
 
2.4.2.3 Ages and Stages Questionnaire 
In the GUI study (chapter 9), data on child development were collected using the Ages 
and Stages Questionnaire (ASQ). The ASQ was maternal-reported when infants were 
9-months, and contains 30 items relating to five developmental domains: 




2.4.2.4 Strengths and Difficulties Questionnaire 
In the GUI study (chapter 9), data on behavioural outcomes were collected using the 
Strengths and Difficulties Questionnaire (SDQ). The SDQ was maternal-reported 
when infants were 3 years, 5 years, and 7-8 years, and consists of a 25-item 
questionnaire with five subscales: emotional, conduct, hyperactivity, peer problems 
and prosocial behaviours(100). 
 
2.5 Statistical modelling 
2.5.1 Cox Proportional Hazards Regression Analysis 
Cox proportional hazards regression analysis or Cox regression for short is a form of 
survival analysis whereby time to an event is taken into consideration when 
investigating longitudinal associations. Individuals within a cohort can enter a study 
at different times, for example, admission to hospital or date of birth. They are then 
followed-up until they experience an outcome of interest, they are censored (when 
individuals are no longer followed-up for reasons other than experiencing the outcome 
of interest), or the study period ends. Possible reasons for censoring may include death, 
emigration, or loss-to-follow-up.   
Chapters 6, 7 and 8 of this thesis employs Cox regression to examine the association 
between preeclampsia and ASD and ADHD because children were born and 
diagnosed at different time points, therefore can enter and exit the study at different 
times. Results from a Cox regression model can be used to estimate a hazard ratio 
(HR), which can be interpreted in the same way as a relative risk (RR). The following 




where h(t) is the hazard function at time t, h0(t) is the baseline hazard at time t, and β1 
to βp  is the estimated increase in the risk of the outcome, per unit increase in the value 
of the exposure variables X1 to Xp, (where X1 = 1 in the exposed group, and X1 = 0 in 
the unexposed group)(101).  
 
Assumptions of Cox regression 
 Proportional hazards assumption: where the ratio of hazards in exposed 
compared to unexposed group remains constant over time. 
 Non-informative censoring: the reason individuals are being censored is not 
related to the exposure or outcome of interest.  
 
2.5.2 Sibling-Matched Study 
Sibling-matched analysis can be conducted using a stratified Cox regression model, 
commonly stratified according to families, while also taking different lengths of 
follow-up time into account. The model assumes family-specific baseline hazards, 
along with a constant effect of exposure across families on the hazard ratio scale(102). 
In an attempt to control for familial lifestyle factors and genetics shared by siblings, 
this thesis uses sibling-matched analysis in chapters 6 and 7. The analysis includes full 
and half siblings on the maternal side consisting of a separate stratum for each family, 
matched on maternal ID. While each family has its own baseline probability of the 
outcome (ASD/ADHD), reflecting their shared genetic and social factors, the exposure 
groups (i.e. preeclampsia v non-exposure to preeclampsia) are made within the family, 
estimating the probability of ASD/ADHD within the family(51). 
While conducting a sibling-matched analysis allows to control, at least in part, for 
shared genetic and familial factors, this analysis only accounts for shared factors that 
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remain constant between pregnancies. It is possible that some factors may change 
between pregnancies, and siblings would have a different exposure status. Therefore, 
these would not be accounted for in the sibling-matched analysis.  
 
2.5.3 Binary Logistic Regression 
Binary logistic regression is commonly used when the outcome (dependent variable) 
has two categories (e.g. dead/alive, pregnant/not pregnant). This method can be used 
to investigate the relationship between one binary outcome variable and one or more 
exposures (independent variables). It is commonly used to determine the odds ratio 
(OR) of an outcome for a one-unit change in the exposure variable. The odds of an 
event occurring are estimated by transforming the odds using the natural log (ln) of 
the probability of an event. The following equation is used to estimate a logistic 
regression model: 
ln(p/1-p)=β0 + β1X1  
where p is the probability of an event occurring, 1-p is the probability of the event not 
occurring, and p/1-p is the odds of the event occurring, β0 is the intercept (value of y 
when x=0), and β1 is the estimated increase in the odds of the outcome, per unit 
increase in the value of the exposure variable X1 (i.e. exposure variable association 
with the outcome). 
Chapter 9 includes binary logistic regression to examine the association between 
preeclampsia and pass/fail of ASQ domains, and preeclampsia and normal/abnormal 
SDQ domains. It was not possible to use Cox regression analysis in the GUI study as 
time to event data was not available. Children entered and exited the study at similar 
times (i.e. exposure status was measured at baseline (9 months), and children were 
followed-up at age 3 years, 5 years and 7-8 years to measure their outcome status).  
57 
 
Therefore, as information on when the outcome of interest occurred was not available, 
logistic regression was deemed an appropriate analysis.  
 
Assumptions of binary logistic regression 
 The outcome variable must be binary (i.e. two categories). 
 P(Y=1) is the probability of the event occurring, therefore it is necessary that 
the outcome variable is coded accordingly (i.e. 0=does not have the outcome, 
1=has the outcome).  
 Large sample sizes are required because maximum likelihood estimates (which 
is how logistic regression models are fit) are less powerful than ordinary least 
squares (e.g. linear regression). Some statisticians recommend a minimum 
sample size of 100, and minimum observation to predictor ratio of 10:1). 
 Observations are independent (i.e. can only be in one group)(103, 104).  
 
2.5.4 Linear Regression 
Linear regression is commonly used when the outcome of interest is continuous. This 
method uses least-squares to calculate the best-fitting line for the observed data, and 
estimates the regression coefficients for the associated change in the outcome variable 
for a given value or change in an exposure/predictor variable. In other words, linear 
regression models the average change in an outcome variable for a given change in an 
exposure variable. Chapter 9 uses linear regression as part of a sensitivity analysis to 
estimate the effect of preeclampsia on both maternal-reported and teacher-reported 
SDQ score on a continuous scale. By applying linear regression, the average change 
in SDQ score for a one-unit change in the categorical preeclampsia variable (i.e. from 
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non-exposed=0 to exposed=1) was estimated(105). The following equation is used in a 
linear regression:  
y=β0 + β1X1 + β2X2…+ βpXp + error 
where y is the outcome variable, β0 the intercept, β1 is the partial regression coefficient 
or unknown constant for the exposure variable X1, and β1 and β2 are partial regression 
coefficients for covariates/potential confounders X2…. Xp. 
 
Assumptions of linear regression 
 The outcome variable must be continuous. 
 The relationship between exposure and outcome variable should be linear. 
 Data should be normally distributed. 
 Multi-collinearity should be kept to a minimum. (Multi-collinearity occurs 
when the independent variables are too highly correlated with each other, or 
are measuring similar things). 
 Homoscedasticity (equal variance): the variance of errors/residuals are similar 
across the values of the independent variables. 
 Observations are independent of one another.  
 
2.5.5 Linear Spline Multilevel Modelling 
In longitudinal studies, measurements are sometimes repeated on the same subjects 
over time creating a two level hierarchy with measurement repetitions or occasions at 
one level and subjects at another level. As outlined above, an assumption of linear 
regression is that observations are independent of one another. Therefore, repeated 
measurements of the same subjects over time will violate this assumption. 
Furthermore, if multiple measures are included in the same model, the problem of 
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multi-collinearity can arise due to strong correlations between measurements from the 
same individual(106). Therefore, more complex methods are needed to overcome these 
issues.  
Multilevel models are one approach that can be used. Multilevel models take non-
independence of repeated measures on the same individual into account, therefore 
addressing the issue of multi-collinearity(106, 107). The multilevel approach can also 
estimate trajectories for all participants regardless of the number of their 
measurements. Therefore, all individuals with at least one observation can contribute 
to the model. In addition to this, multilevel modelling takes non-linearity in the 
trajectory into account. This is an important function of multilevel modelling as 
associations are not always linear, although it is an assumption of the standard linear 
regression(108).  
As SDQ was measured at three time points (ages 3, 5 and 7-8 years), chapter 9 of this 
thesis employs linear spline multilevel modelling to model trajectories for 
preeclampsia-SDQ score and preeclampsia+SGA-SDQ score (on a continuous scale). 
We used mixed effects models (i.e. containing both fixed effects and random effects), 
with random effects at two levels: measurement occasion and individual. The linear 
splines were joined at knot points placed at age 5 and 7-8 years, allowing trajectories 
to vary between each knot point and each individual. 
These models estimate the average intercept and average slope between each knot 
point (representing the fixed effects), as well as the individual-specific trajectories 
(representing the random effects), since random effects allow each individual to have 
different intercepts and slopes(106). For example, in single level regression models, the 
average trajectory for the total cohort is modelled. Conversely, multilevel models, not 
only model the average trajectory, but also individual trajectories with random 
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intercepts and slopes (i.e. the multilevel model allows each individual to have their 
own unique baseline SDQ score and differing rates of change)(106). The following 
equation is used in a multilevel model: 
yij=β0 + u0j+β1 x (age)ij + u1j  x (age)ij + e0ij 
where yij is the SDQ score for individual j at time i, β0 and β1 represent the fixed 
estimates for the average intercept and slope, u0j and u1j represent the random estimates 
(i.e. the deviation from the average intercept and average slope for individual j) and 
e0ij is the occasion level residual.  
 
2.5.6 Handling of Missing Data 
The best possible method of handling missing data is to prevent the problem in the 
first instance with meticulous planning of the study and collecting the data carefully. 
However, this is not always possible and missing data can be an issue even in well-
designed studies. This can potentially lead to reduced statistical power, reduced 
representativeness of the sample, erroneous estimates, and invalid conclusions(109). 
Several methods have been proposed to handle missing data, all of which are 
accompanied by their own strengths and limitations. For example, complete case 
analysis (also known as listwise deletion) is a simple and most common approach to 
handling missing data which involves omitting observations with the missing data and 
analysing the remaining data. This method assumes that data are missing completely 
at random (MCAR), for example due to faulty equipment, or data being destroyed in 
a fire. However, if the assumption of MCAR is violated (which is sometimes seen as 
an unreasonable assumption for many studies), it may introduce bias, while statistical 
power is also reduced by omitting the observations with missing data(109). Another 
method of handling missing data is to use a method known as ‘last observation carried 
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forward.’ This method replaces missing values with the last observed value from the 
same individual, however may lead to biased estimates(109). A more sophisticated 
method of handling missing data includes multiple imputation. This method 
substitutes the missing values with a set of plausible values and produces different 
versions of the missing data. It begins by predicting the missing data using existing 
data from other variables. The missing values are then replaced with the predicted 
values, creating multiple imputed datasets. This method may be more difficult to 
comprehend than other methods however, and can require more formal training(109).   
In this thesis, where a categorical variable had missing data, an extra category was 
added for the missing values, and included in the various analyses by means of an 
indicator variable. This method has been proposed for missing confounder data in 
etiologic research(110). It ensures all observations are included in the analysis, and if 
the proportion of missing data are small, it may not have a large impact on effect 
estimates(111). However, while this is a relatively simple method to handle missing 
data, it may introduce bias in non-randomised studies(110). In addition to the indicator 
variable method, sensitivity analyses were also conducted when data was not available 
for specific time periods. For example, in chapter 7, the study population was restricted 
to 2001-2010 as a sensitivity analysis as outpatient data on ADHD was not available 
prior to 2001.  
 
2.6 Bias, Confounding, and Chance in Epidemiology 
One of the central concerns of epidemiology is to identify causal associations between 
an exposure and outcome. While it is not possible to make definitive causal claims in 
observational studies, if researchers can account for external factors that may be 
leading to an observed association, it may provide evidence for a potential causal 
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relationship. Therefore, it is important to try to rule out other factors that could be at 
play that would potentially explain the observed association. Such factors may include 
bias, confounding and chance. By attempting to account for these factors, which can 
take place in the design and/or analysis phase of the research study, the potential for a 
causal-claim may be improved(112).  
 
2.6.1 Bias 
Bias refers to systematic error resulting from methodological imperfection. It is 
independent of study size, and can occur during the design phase of an epidemiological 
study, resulting in a conclusion, which is different from the truth. Therefore, when 
investigating the association between an exposure and an outcome, it is important to 
take steps that would prevent any systematic error being built into the study design, 
while it is also important to consider the presence of bias when interpreting results(112).   
Two common types of bias include selection bias and information bias. Selection bias 
refers to differences in characteristics between those who participate in a study and 
those who do not (i.e. the people included in the study are meaningfully different than 
all who were eligible). For example, mothers and children in a cohort study examining 
the association between preeclampsia and neurodevelopmental outcomes in offspring 
may be more likely to drop-out of the study if their child experiences the outcome of 
interest, potentially biasing results towards the null(113). 
Information bias is caused by measurement errors in the ascertainment of the exposure, 
outcome or potential confounders(112). The three main types of information bias 
include  
1. Recall bias: This occurs when cases may remember their exposure status differently 
to controls. For example, in a case-control study, mothers of children, who are aware 
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of the study hypothesis, whose children have a neurodevelopmental outcome may 
remember past exposures more accurately than mothers of children without the 
outcome of interest, potentially overestimating the effect size.  
2. Interviewer bias: This occurs when the researcher questions cases and controls 
differently about their past exposures. For example, in a case-control study, the 
researcher may ask probing questions about a diagnosis of preeclampsia (or other 
HDP) to the mothers of children with a neurodevelopmental disorder, potentially 
overestimating the effect size.  
3. Misclassification bias: This occurs when participants in a study are assigned to the 
wrong exposure or outcome category. Misclassification bias can be differential or non-
differential. Differential misclassification is when errors in measurement are only in 
one direction (i.e. the probability of being misclassified differs between groups in a 
study)(114). For example, if only cases are incorrectly assigned to the exposed group, 
this can potentially lead to an overestimate of the effect size(112). In comparison, non-
differential misclassification occurs when errors in assignment to a group occurs in 
more than one direction (i.e. the probability of individuals being misclassified is equal 
across all groups in the study)(114). For example, the proportion of cases and controls 
incorrectly assigned to the exposure group are similar, potentially leading to an 
underestimate of the effect size(112). 
 
2.6.2 Confounding 
Confounding is one of the most important issues in epidemiology when attempting to 
establish a potential causal relationship. Confounding refers to the mixing of the effect 
on an outcome with the effect of another factor that is associated with the exposure, 
resulting in a distortion of the true relationship(115). 
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The three general criteria for a confounder are as follows:  
1. Confounders should be associated with the outcome of interest. 
2. Confounders should be associated with, but independent of, the exposure of interest. 
3. Confounders should not be caused by the exposure (i.e. not on the causal pathway) 
or the outcome.  
There are several ways to control for confounding, and these can take place in the 
design and/or analysis phase of a research study. During the design phase, three 
common methods of controlling for confounding include randomisation, restriction 
and matching. Randomisation takes place in randomised controlled trials. It reduces 
the potential for confounding by generating groups that are comparable with respect 
to known and unknown confounding factors. Restriction eliminates variation in a 
confounder. For example, restricting the study sample to children of mothers who do 
not smoke to avoid confounding due to maternal smoking. Matching is conducted in 
case-control studies and involves selecting a comparison group that is forced to 
resemble cases within a study with respect to one or more potential confounders.  
During the analysis phase of a study, stratification and multivariate methods can be 
used to control for potential confounding factors. Stratification evaluates the exposure-
outcome association within each stratum of the confounder. For example, results may 
be stratified by gestational age. Multivariate analyses, based on statistical modelling, 
can handle large numbers of confounders simultaneously, and is the main method for 
controlling for potential confounders used in this thesis. However, when a potential 
confounder has not been measured or accounted for (possibly because it is unknown 
or cannot be measured), it can lead to what is known as residual confounding.  As it is 
not possible to rule out the presence of residual confounding in observational research, 




In comparison to bias, chance is caused by random error and can lead to imprecise 
results. When assessing the role of chance in a study, we are examining how likely it 
is that the results are a true finding. While random error can occur in all 
epidemiological studies, it is likely reduced by increasing the study’s sample size (i.e. 
errors from chance will cancel each other out in the long run).  
Statistical methods can be used to avoid reporting associations that may be occurring 
due to chance. Confidence intervals reflect the amount of random error that is present 
in the sample, and contains a range of likely values of the point estimate, with a 
specified level of confidence. The level of confidence calculated can vary, for example 
some researchers use 90% or 99%, however the most commonly used level is 95%. 
The way to interpret 95% confidence intervals is that if samples of the same size were 
repeatedly drawn from a population, and their 95% confidence intervals were 
calculated, then 95% of the confidence intervals would be expected to include the true 
value of the association(116). Therefore, if the 95% confidence interval does not include 
a null association, it is said to be “statistically significant,” and unlikely to have 
occurred by chance.  
The following chapters in this thesis outline the studies examining the association 
between HDP (in particular, preeclampsia) and neurodevelopmental disorders in 
offspring, including ASD, ADHD, child development and behavioural outcomes. This 
is achieved by reviewing existing literature, and conducting a range of robust analyses 
using Swedish National Registry data, and data from a nationally representative study 
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Introduction: Hypertensive disorders of pregnancy (HDP), that is chronic 
hypertension, gestational hypertension, preeclampsia (de novo or superimposed on 
chronic hypertension) and white coat hypertension, affect up to 10% of pregnancies. 
HDP-exposure has been linked to an increased likelihood of autism spectrum disorder 
(ASD), attention deficit/hyperactivity disorder (ADHD), and other 
neurodevelopmental disorders in children. However, findings are inconsistent and a 
clear consensus on the impact of HDPs on the likelihood of neurodevelopmental 
disorders is needed. Therefore, we aim to synthesise the published literature on the 
relationship between HDPs and the risk of neurodevelopmental disorders in the form 
of a systematic review and meta-analysis. 
Methods and analysis: We will include cohort, case-control and cross-sectional 
studies in which diagnosis of a HDP was reported and neurodevelopmental disorders 
were the outcome of interest based on a pre-prepared protocol. A systematic search of 
PubMed, CINAHL, EMBASE, PsycINFO and Web of Science will be conducted in 
accordance with a detailed search strategy. Two authors will independently review the 
titles and abstracts of all studies, perform data extraction using a standardised data 
collection form, and assess study quality using a bias classification tool. Meta-analyses 
will be performed to calculate overall pooled estimates using the generic inverse 
variance method. This systematic review will be reported according to the Meta-
analysis of Observational Studies in Epidemiology (MOOSE) guidelines. 
Ethics: This proposed systematic review and meta-analysis is based on published data, 
therefore, does not require ethics approval.  





Hypertensive disorders of pregnancy (HDP) are the most common complications of 
pregnancy estimated to affecting up to 10% of all pregnancies(117, 118). HDP are 
classified into four categories, as recommended by the International Society for the 
Study of Hypertension in Pregnancy (ISSHP)(119): “chronic hypertension”, 
“gestational hypertension”, “preeclampsia – de novo or superimposed on chronic 
hypertension” and “white coat hypertension”. While HDP are not fully understood, 
risk factors include advanced maternal age and elevated body mass index, both of 
which are increasingly common in modern society(120). HDP are associated with 
multiple pathophysiological changes including reduced placental blood flow, maternal 
inflammation, and oxidative stress(6). These can potentially alter fetal developmental 
trajectories, which may increase the risk of long-term vascular, cognitive, and 
psychiatric sequelae in the offspring(71, 72, 120, 121). 
Neurodevelopmental disorders including autism spectrum disorder (ASD) and 
attention deficit hyperactivity disorder (ADHD) are a group of conditions with onset 
during the developmental period, and may lead to impairments in personal, social, 
academic, or occupational functioning(23, 122). Though these disorders have a strong 
genetic basis(29, 123), there is increasing evidence suggesting that environmental risk 
factors during prenatal development may also play a role(10, 13, 29, 30, 39, 41, 124). In support 
of this, a population-based study conducted on a Swedish population estimated that 
the environmental contribution of ASD is estimated to be between 17-50%(28, 29). 
Furthermore, recent work  demonstrated focal patches of abnormal laminar 
architecture and laminar disorganization in the prefrontal and temporal cortices of 
children with ASD suggesting there may be alterations in brain development at 
prenatal stages, as cortical lamination is on-going during the second trimester of 
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pregnancy(125, 126). Moreover there is some evidence for alterations in brain structural 
and vascular anatomy(81) and reduced cognitive functioning(127) in offspring 
of pregnancies complicated by preeclampsia pregnancies, highlighting the need to 
determine the impact of HDP-exposure on the risk of adverse neurodevelopmental 
outcomes in the children. 
 
Early identification and intervention 
There is a growing consensus that early identification and intervention are key to 
improving long-term neurodevelopmental outcomes(128, 129). Previously published 
work has indicated that early behavioural intervention if commenced before 30 months 
old, can lead to improvements in cognitive and adaptive behaviour among individuals 
with ASD(130, 131). Despite this increasing recognition for surveillance, the average age 
of ASD-diagnosis, for example, remains at approximately 4-5 years, meaning the 
window for early intervention has closed(128, 132, 133). However, research suggests that 
a stable diagnosis can be made as young as two years, allowing earlier access to 
specialised services(134). Therefore, by examining the potential impact of HDP on 
neurodevelopment in offspring, it can inform the need for increased paediatric 
surveillance of infants who have been exposed to HDP. This in turn could allow for 
early intervention which may aid improvement of neurodevelopmental outcome(128, 
130, 131, 135). 
 
Rationale for current systematic review 
Evidence suggests that HDP may lead to an increased likelihood of ASD, ADHD as 
well as other neurodevelopmental disorders in children(30, 136, 137). Conversely other 
studies have reported no associations(124, 136), highlighting the need for further study in 
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this area. Therefore, the aim of this systematic review and meta-analysis is to 
summarise the available evidence examining the association between HDP, and 
subsequent likelihood of neurodevelopmental disorders in exposed children, and if 
possible to identify an overall pooled estimate of association. The systematic review 
is based on the following requirements: 
Population: Pregnant women and their children 
Intervention/Exposure: HDP 
Comparison: No HDP 
Outcomes: Primary outcome 1: ASD 
Primary outcome 2: ADHD 




To conduct a systematic review and meta-analysis to examine the association between 
HDP and neurodevelopmental disorders in the offspring.  
 
3.3 Methods and Design 
The systematic review and meta-analysis follows the Meta-analysis of Observational 
Studies in Epidemiology (MOOSE) guidelines(138). 
 
Criteria for considering studies for the review 
Inclusion criteria 
► We will include cohort, case-control or cross-sectional studies in which a diagnosis 
of HDP was reported and neurodevelopmental disorders are the outcome of interest. 
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► Examining the association between HDP and neurodevelopmental disorders must 
be part of the main objective of the study. (This includes studies that aimed to look at 
other perinatal risk factors in addition to HDP). 
► Data must be from an original study, and HDP may be confirmed through medical 
records or doctor-diagnosed self-reporting. 
► We will include studies published in English only, including all years from 
inception of the electronic databases until June 2017. 
► Peer-reviewed literature only will be included. 
► Neurodevelopmental and other behavioural or cognitive outcomes will be the focus 
of this review. Motor disorders have been included in the search strategy to capture 
studies that have included these outcomes.  
 
Exclusion criteria 
► Studies which are not in English. 
► Studies where the participants are not human. 
► Case reports, case-series, letters, commentaries, notes, editorials and conference 
abstracts. 
 
Search strategy for identifying relevant studies 
Bibliographic database searches 
1. One reviewer (GMM) will conduct a systematic search of the literature in the 
following electronic databases: PubMed, CINAHL, EMBASE, PsycINFO and Web 
of Science. A detailed search strategy has been compiled and these terms will be 
searched according to the principles of Boolean Logic (AND, OR, NOT) and using 
Medical Subject Headings (MeSH). For example, (“Preeclampsia” OR “gestational 
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hypertension”) AND (“autism spectrum disorder” OR “attention deficit/hyperactivity 
disorder” OR “neurodevelopmental disorder”). (Appendix 1). 
2. Searches of the electronic databases will be supplemented by hand-searching the 
reference lists of included studies for further potentially eligible studies. 
 
Selection of studies for inclusion in the review 
Titles and abstracts of studies retrieved from each database search will be stored and 
managed in Endnote reference manager©. Two review authors (GMM, ASK) will 
independently review the titles and abstracts of all studies. Full texts will be obtained 
where necessary to screen for eligibility in the systematic review and meta-analysis in 
accordance with the pre-defined inclusion/exclusion criteria. Where consensus on 
eligibility cannot be achieved, a third review author (GWOK) will be involved in the 
discussion.  
 
Data extraction and management 
Using a standardised data collection form, two reviewers (GMM, GWOK) will 
independently extract data from the eligible studies including the author and year of 
publication, study design, definition of exposure and outcome used, sample size, 
confounders adjusted for (if any) as well as crude and adjusted estimates. 
Discrepancies will be resolved by a third reviewer (ASK) if necessary.  
 
Appraisal of the quality of included studies 
Quality assessment of the included studies will be conducted by two reviewers (GMM, 
PMK) independently and agreed upon subsequently using an appropriate quality 
assessment tool. Discrepancies will be resolved by a third reviewer (ASK) if 
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necessary. A bias classification tool described in detail elsewhere will be used(139). In 
summary, this tool uses a checklist to assess common features of the six types of bias 
most often associated with observational studies (selection, exposure, outcome, 
analytic, attrition and confounding). Study bias is then classified as minimal, low, 
moderate, high or not reported for each of the six types of bias and an overall 
likelihood of bias based on the total of the six types of bias will be measured and 
reported. For example, selection bias will be minimised if the sample was taken from 
a ‘consecutive unselected population’, while conversely a study with high selection 
bias will arise if sample selection is ambiguous and the sample is not likely 
representative. (Appendix 2). 
 
Data synthesis including assessment of heterogeneity 
Where the data allow, meta-analyses will be performed to calculate overall pooled 
estimates of the relationship between combined HDP, preeclampsia and other 
categories of HDP, and different disorders of neurodevelopment. Both crude and 
adjusted results will be displayed where possible using the generic inverse variance 
method (GIVM). Adjustment will be based on the definition outlined in each identified 
study. A fixed-effects model will be used where heterogeneity is low (I2 value of less 
than 50%), and a random-effects model where heterogeneity is high (I2 value of 50% 
or more) according to the Cochrane Handbook criteria(140). 
We will also perform the following subgroup/sensitivity analyses where the data 
allow, using RevMan 5.3:  
1) According to study design (cohort vs case-control vs cross-sectional). 
2) According to studies that report estimates for the association between 
preeclampsia and other HDP, and each neurodevelopmental disorder. 
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3) According to location (for example: Europe vs United States). 
4) According to income level of country (low/middle/high). 
5) According to study quality (minimal/low vs moderate/high). 
6) According to measurement of exposure and outcome data (self-reported vs 
medical records based on varying clinical coding systems). 
Publication bias will be assessed using a funnel plot provided at least 10 or more 
studies are included in the meta-analysis. The trim and fill method will also be used to 
identify and correct for funnel plot asymmetry arising from publication bias(141). 
Where any other subgroup/sensitivity analyses are identified in the process of the 
meta-analysis, such as analyses to explore potential high heterogeneity or publication 
bias, these will be clearly labelled as post-hoc analyses. 
 
Presenting and reporting the results 
A flow diagram will be included to outline the step-by-step study selection process, 
and a rationale provided for excluded studies. The characteristics and quality 
assessment of the included studies will be presented in tables. Pooled estimates will 
be presented using forest plots. Where a study is eligible for inclusion in the systematic 
review but does not provide adequate data to include in a meta-analysis, we will 
contact the corresponding authors in an attempt to obtain raw data where appropriate. 




The systematic review and meta-analysis will summarise existing literature examining 
the association between HDP and different disorders of neurodevelopment based on 
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this pre-prepared protocol. By identifying the possible contributors to adverse 
neurodevelopmental outcomes, it may lead to early identification and intervention. 
Therefore, by examining potential etiologies of neurodevelopmental disorders, it may 
inform the need for greater paediatric surveillance of HDP-exposed infants to allow 
early intervention, which may aid improvement of neurodevelopmental outcome(128, 
130, 131, 135). 
Potential limitations: It is anticipated that publication bias may pose as a limitation 
for this review. Studies that show an effect have an increased likelihood of being 
published, as well as being published in English. Due to limited resources, the 
systematic review search will be confined to studies published in the English language 
only, potentially resulting in publication bias as well as relevant indexed studies being 
overlooked. If possible, a funnel plot will be used to assess the presence of publication 
bias.  
Furthermore, the presence of confounding is a major concern in observational studies. 
Potential confounders may include infant sex, family’s socio-economic status, 
ethnicity, maternal age, parity, maternal smoking and alcohol consumption, (during 
pregnancy or during the preconception period) and maternal mental illness, while 
preterm delivery could potentially play a confounding or mediating role. As mentioned 
above, our meta-analyses will display both crude and adjusted results where possible 
using the GIVM, basing adjustment on the definition outlined in each identified study. 
Ethics: Given that this is a protocol for a systematic review and based on published 
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Importance: While research suggests an association between hypertensive disorders 
of pregnancy (HDP) and autism spectrum disorder (ASD), attention deficit 
hyperactivity disorder (ADHD) and other neurodevelopmental disorders in offspring, 
there is a lack of consensus. Given that HDP is one of the most common complication 
of pregnancy, it is important to examine its impact on neurodevelopmental outcome. 
Objective: Synthesise the published literature on the relationship between HDP and 
risk of neurodevelopmental disorders in the offspring in the form of a systematic 
review and meta-analysis. 
Data sources: Based on a pre-prepared protocol, a systematic search of PubMed, 
CINAHL, EMBASE, PsycINFO and Web of Science was performed from inception 
through June 7, 2017, supplemented by hand-searching reference lists. 
Study Selection: Two reviewers independently reviewed titles, abstracts, and full-text 
articles. English-language, cohort and case-control studies were included in which 
HDP and neurodevelopmental disorders were reported. 
Data Extraction and Synthesis: Data extraction and quality appraisal was performed 
independently by two reviewers. MOOSE Guidelines were followed throughout. 
Main Outcome(s) and Measure(s): Random effects meta-analyses estimated HDP-
ASD and HDP-ADHD pooled-odds ratios. Standalone estimates were reported for all 
other neurodevelopmental disorders.  
Results: Of 1,166 studies identified, 61 articles met inclusion criteria. Twenty studies 
reported estimates for ASD. Eleven of these (including 777,518 participants) reported 
adjusted estimates, with pooled adjusted odds ratio of 1.35 (95% CI: 1.11, 1.64). Ten 
studies reported estimates for ADHD. Six of these (including 1,395,605 participants) 
reported adjusted estimates, pooled adjusted odds ratio 1.29 (95% CI: 1.22, 1.36). 
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Subgroup analyses according to type of exposure (i.e. preeclampsia or other HDP), 
showed no statistically significant differences for ASD or ADHD. Thirty-one studies 
met inclusion criteria for all other neurodevelopmental disorders. Individual estimates 
were reported for these.  
Conclusions and Relevance: Exposure to HDP is associated with an increase in the 
likelihood of ASD and ADHD. If these findings are causal, they highlight the potential 
need for greater paediatric surveillance of infants exposed to HDP to allow early 



















The International Society for the Study of Hypertension in Pregnancy (ISSHP) classify 
hypertensive disorders of pregnancy (HDP) into the following categories: “chronic 
hypertension” (essential/secondary), “white-coat hypertension”, “masked 
hypertension”, “transient gestational hypertension”, “gestational hypertension” and 
“preeclampsia” (de novo/superimposed on chronic hypertension)(2). HDP affect up to 
10% of all pregnancies, therefore are among the most common prenatal 
complications(117, 118). HDP create adverse in utero conditions, which can alter fetal 
development, and may increase the risk of long-term vascular, cognitive, and 
psychiatric sequelae in the offspring(71, 72, 120, 121).  
Neurodevelopmental disorders, including autism spectrum disorder (ASD) and 
attention deficit hyperactivity disorder (ADHD), are a group of conditions with onset 
during the developmental period that can impair personal, social, academic, or 
occupational functioning(23, 122). It is widely accepted that genetics plays a key role(29, 
123) with familial co-aggregation implying shared genetic risk factors(142), however 
environmental factors may contribute to their etiology(143-145). A study conducted using 
Swedish National Registries estimated that environmental contribution of ASD is 
between 17-50%(28, 29) highlighting the importance of identifying the environmental 
factors that contribute to the risk of neurodevelopmental disorders in the offspring. 
Overall, epidemiological evidence examining the association between HDP and 
neurodevelopmental disorders remains largely inconsistent(10, 22, 30, 39, 45, 136), and 
residual or unmeasured confounding is of particular concern in the literature(33, 34, 42, 
47-49). Given the increasing prevalence of HDP, partially due to rising levels of obesity, 
metabolic syndrome and advanced maternal age(118, 120), collating the existing evidence 
of the impact of HDP on neurodevelopmental outcome is timely. The objective of this 
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study was to synthesise the available published literature on the relationship between 
HDP and the risk of neurodevelopmental disorders in the offspring in the form of a 
systematic review and meta-analysis.   
 
4.3 Methods 
The systematic review was based on the following requirements: 
Population: Pregnant women and their children 
Intervention/Exposure: HDP 
Comparison: No HDP 
Outcomes: Primary outcome 1: ASD 
Primary outcome 2: ADHD 
Secondary outcomes: Neurodevelopmental and other behavioural or cognitive 
outcomes 
 
Data sources and search strategy 
The protocol for this systematic review and meta-analysis was registered on 
PROSPERO, the international prospective register of systematic reviews 
(CRD42017068258) and was subsequently published(83). In accordance with Meta-
analysis of Observational Studies in Epidemiology (MOOSE) guidelines(138), one 
reviewer (GMM) conducted a systematic literature search in the following electronic 
databases: PubMed, CINAHL, EMBASE, PsycINFO and Web of Science from 
inception through June 7, 2017. Search terms relating to HDP, ASD, ADHD and other 
neurodevelopmental disorders were combined according to the principles of Boolean 
Logic (AND, OR, NOT) and using Medical Subject Headings (MeSH). For example, 
(“Preeclampsia” OR “gestational hypertension”) AND (“autism spectrum disorder” 
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OR “attention-deficit/hyperactivity disorder” OR “neurodevelopmental disorder”). 
(Appendix 1). Results were limited to English language studies, conducted on 
humans. No restrictions were placed on publication date, location of study or age of 
participants. Searches of the electronic databases were supplemented by hand-
searching the reference lists of included studies for further potentially eligible studies, 
and contact with authors was made when a conference proceeding only was located. 
A post-hoc search of PubMed was also conducted adding the keywords “perinatal 




Two review authors (GMM, ASK) independently reviewed the titles and abstracts of 
all studies, obtaining full texts where necessary. Where consensus on eligibility could 
not be achieved, a third review author (GWOK) was involved in the discussion. 
Eligibility criteria for inclusion in the systematic review included: 
► Cohort, case-control or cross-sectional studies in which a diagnosis of HDP was 
reported and neurodevelopmental disorders were the outcome of interest. 
► The association between HDP and neurodevelopmental disorders were part of the 
main objective of the study. (This includes studies that aimed to look at other perinatal 
risk factors in addition to HDP). 
► Data were from an original study and HDP confirmed through medical 
records/doctor-diagnosed self-reporting. 
► Peer-reviewed literature only. 
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► Neurodevelopmental and other behavioural or cognitive outcomes only. (Motor 




Two reviewers (GMM, GWOK) independently extracted data from eligible studies 
using a standardised data collection form. Information extracted included author, year 
of publication, study design, definition of exposure and outcome used, sample size, 
confounders adjusted for (if any) and crude and adjusted estimates. Any discrepancies 
were resolved by consensus with a third reviewer (ASK). Authors of two studies were 
contacted for further information, with a reply received from one. 
 
Bias and quality assessment 
Publication bias was evaluated by visually assessing a funnel plot and Egger’s test for 
asymmetry of the funnel plot, where 10 or more studies were included in the meta-
analysis(146). Quality assessment of included studies was conducted by two reviewers 
(GMM, MM) independently using an appropriate quality assessment tool, and agreed 
upon subsequently. Any discrepancies were resolved by a third reviewer (ASK). A 
bias classification tool(139), consisting of a checklist to assess six types of bias most 
often associated with observational studies (selection, exposure, outcome, 
confounding, analytic and attrition) was used. Study bias was classified as minimal, 
low, moderate, high or not reported for each type of bias. An overall likelihood of bias 
based on the total of the six types of bias was then measured and reported. For 
example, selection bias was minimised if the sample was taken from a ‘consecutive 
unselected population’, while conversely selection bias was categorised as high if 
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Data were analysed using Review Manager 5.3 and Eggers test was conducted in 
Stata/MP 14.2. Random-effects meta-analyses were performed to calculate overall 
pooled estimates of the relationship between combined HDP, preeclampsia only, and 
other HDP, and the outcomes of ASD and ADHD, using the generic inverse variance 
method (GIVM). GIVM was used to allow studies that do not report raw data to be 
included in the meta-analyses(140). Partially adjusted estimates, as a result of matching, 
were included as crude results and studies that adjusted for confounders in the analysis 
phase were included as adjusted results. Forest plots were used to display crude and 
adjusted estimates, with adjustment based on the definition outlined in each identified 
study.  
Subgroup/sensitivity analysis: The following subgroup/sensitivity analysis were 
decided a priori: according to type of HDP (preeclampsia and other HDP), study 
design, location, income level of country, study quality and measurement of exposure 





The original search produced 796 unique results after removal of duplicates (Figure 
4.1). Of these, 33 full text articles were reviewed following screening of titles and 
abstracts. Eleven studies were excluded because they did not meet the inclusion 
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criteria. Reasons for exclusion are outlined in Figure 4.1. This resulted in 22 papers. 
After reviewing reference lists, 38 additional studies were identified. One additional 
ASD paper was subsequently published and included in the review. A total of 61 
papers were included in the systematic review: 20 for ASD (8 identified from original 
search, 11 from reference lists and 1 subsequently published), 10 for ADHD (4 
identified from original search and 6 from reference lists), and 31 for other 
neurodevelopmental outcomes (10 identified from original search and 21 from 
reference lists). 
 
Characteristics of studies included in the systematic review 
A summary of included studies for ASD and ADHD is available in Appendix 3 and 
Appendix 4. A summary of studies that report on other neurodevelopmental 
outcomes, (including cognitive functioning/developmental delay, behavioural 
outcomes and intellectual disability) along with main findings, is available in 
Appendix 5.  
 
Results of the meta-analyses 
ASD: Primary analysis: A total of 20 studies were identified in which a diagnosis of 
HDP was reported and ASD was the outcome of interest(9-15, 21, 30-36, 49, 50, 62, 147, 148). 
The prevalence of HDP among ASD cohort studies ranged from 1.3-9.1%, (mean: 
6.2%, median: 6.9% and interquartile range (IQR): 5.3%). Twenty-three estimates 
from 19 unique studies included crude estimates(9-15, 21, 30-36, 49, 50, 147, 148) and 13 
estimates from 11 unique studies included adjusted estimates(9, 10, 13-15, 21, 30, 31, 35, 36, 147) 
and were included in the meta-analysis(9, 10, 13-15, 21, 30, 31, 35, 36, 147). Figure 4.2 displays 
crude and partially adjusted estimates (as a result of matching), producing a pooled 
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odds ratio (OR) of 1.41 (95% CI: 1.22, 1.64). A subgroup analysis, examining a 
preeclampsia-ASD and other HDP-ASD relationship separately, resulted in an OR of 
1.37 (95% CI: 1.07, 1.75), and 1.43 (95% CI: 1.17, 1.73) respectively. (Test for 
subgroup differences: 0.80). 
Adjusted estimates reduced the overall HDP-ASD estimate to 1.35 (95% CI: 1.11, 
1.64) (Figure 4.2). Subgroup analysis examining the preeclampsia-ASD relationship 
resulted in an OR of 1.50 (95% CI:  1.26, 1.78), while the relationship between other 
HDP-ASD produced a non-significant OR of 1.25 (95% CI: 0.90, 1.73). However, test 
for subgroup differences does not indicate a statistically significant difference, p=0.33. 
ADHD: Primary analysis: Ten studies were identified in which a diagnosis of HDP 
was reported and ADHD was the outcome of interest(22, 39-42, 44-48). The prevalence of 
HDP among ADHD cohort studies ranged from 0.13-20.8%, (mean: 7.8%, median: 
5.5%, IQR: 12.7%). Twelve estimates from nine unique studies included crude results 
examining the HDP-ADHD relationship(22, 39-42, 44, 45, 47, 48) and eight estimates from 
six unique studies included adjusted estimates(22, 39-41, 45, 46). (Figure 4.3). Crude pooled 
estimates produced an OR of 1.32 (95% CI: 1.20, 1.45). In subgroup analysis 
examining the preeclampsia-ADHD relationship only, the OR was 1.31 (95% CI: 1.19, 
1.44), and the OR for the relationship between other HDP and ADHD was 1.62 (95% 
CI: 1.07, 2.47), (p=0.33). 
Adjusted estimates remain relatively unchanged (Figure 4.3). (Overall pooled OR: 
1.29 (95% CI: 1.22, 1.36)). Results of the subgroup analysis examining the 
preeclampsia-ADHD relationship (OR: 1.28, 95% CI: 1.22, 1.36), and other HDP-




Other neurodevelopmental outcomes: Due to varying outcome measures, assessment 
methods and summary scales used, it was not appropriate to pool results of these 
studies. Therefore, standalone estimates were reported for 31 unique studies (plus 
seven studies that were also included as ASD or ADHD outcomes) examining the 
relationship between HDP and neurodevelopmental, cognitive or behavioural 
outcomes. A summary of the main findings of these studies is available in Appendix 
5. Overall, results were largely inconsistent, however, there are few patterns of 
association. For example, six-out-of-ten studies suggest a positive association between 
preeclampsia and cognitive impairment within specific populations(57, 58, 60, 61, 69, 149), 
while four-out-of-five studies suggest a potential link between HDP and intellectual 
disability(36, 62, 63, 150). 
 
Bias and heterogeneity 
Visual inspection of the funnel plot, including adjusted studies only, did not indicate 
publication bias (Appendix 6) (Eggers test: p=0.43). There was moderate 
heterogeneity for ASD (I2 = 63%) and low heterogeneity for ADHD (I2 = 0%) based 
on adjusted estimates. Heterogeneity among ASD studies was possibly due to 
differences in confounder adjustments as heterogeneity reduced to 0% when studies 
that adjusted for maternal age, maternal smoking and parity/birth order were analysed 
separately (Appendix 7). The majority of studies were classified as ‘low’ or 







Subgroup/sensitivity analysis: (ASD) 
Table 4.1 shows pooled estimates for all studies that reported crude estimates, 
adjusted estimates, and adjusted estimates according to category of HDP for both ASD 
and ADHD. Results of the following subgroup analysis are also outlined in Table 4.1: 
Study design: There were six case-control studies(10, 13-15, 35, 147), (seven estimates), 
which resulted in a pooled OR=1.47 (1.18, 1.84). Five cohort studies(9, 21, 30, 31, 36), (six 
estimates) provided an overall non-significant OR=1.26 (0.93, 1.70) (p=0.41). 
Location: There were six studies (seven adjusted estimates) from North America(9, 10, 
13, 30, 31, 147) OR=1.39 (1.09, 1.77), four studies from Europe(14, 15, 21, 35) (five estimates) 
OR=1.53 (1.26, 1.87) and one study from Australia(36), OR=0.64 (0.43, 0.95) 
(p=0.0005). 
Income level of country: All ASD studies were conducted in high-income countries.   
Study quality: Fourteen studies (16 estimates) were assessed as being minimal/low 
risk of bias(10, 13-15, 21, 30, 31, 33-36, 49, 50, 148), resulting in a significant OR=1.39 (1.17, 1.65). 
Five studies (seven estimates) assessed as being moderate/high risk of bias(9, 11, 12, 32, 
147), resulted in a non-significant OR=1.18 (0.81, 1.74) (p=0.46). 
Exposure measurement: Four studies relying on self-reported measurements of HDP(9, 
10, 13, 21) produced five adjusted estimates, resulting in a pooled OR=1.54 (1.07, 2.22). 
Pooled OR observed among the seven studies (with eight estimates) that relied on 
medical records for confirmation of HDP(14, 15, 30, 31, 35, 36, 147) was 1.27 (0.99, 1.64) 
(p=0.39). 
Outcome measurement: Two studies (with three adjusted estimates) used maternal-
reporting of ASD(9, 21) and produced an OR=1.32 (0.91, 1.91). However, individual 
point estimates for these studies ranged from 0.96 to 2.10. Pooled results were similar 
amongst the nine studies (ten estimates) that used medical records to determine ASD 
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status in the offspring(10, 13-15, 30, 31, 35, 36, 147), producing an OR=1.37 (1.07, 1.75) 
(p=0.86).  
Length of follow up: Five studies had a potential 2-7 years of follow-up(10, 13, 21, 30, 147) 
with a pooled OR=1.71 (1.23, 2.38) and six studies (eight estimates) had a potential 
2-21 years follow-up(9, 14, 15, 31, 35, 36) with a pooled OR=1.22 (0.98, 1.52) (p=0.09). 
 
Subgroup/sensitivity analysis: (ADHD) 
Study design: Three case-control studies(39, 40, 46) (with four adjusted estimates) were 
identified and pooled OR=1.34 (1.25, 1.43), while three cohort studies(22, 41, 45) (four 
adjusted estimates) resulted in a pooled OR=1.21 (1.10, 1.32) (p=0.08). 
Location: Two North American studies(40, 41), two European studies(22, 45) (three 
estimates) and two ‘other’ location studies(39, 46) (three estimates) were identified. 
Results were similar for all subgroups: OR=1.27 (1.13, 1.43), OR=1.26 (1.06, 1.49) 
and OR=1.27 (0.95, 1.70) respectively, (p=0.99). 
Income level of country: Five studies (seven adjusted estimates) were conducted in 
high-income countries(22, 39-41, 45) compared to one study conducted in an upper-middle 
income country(46). Results of a sensitivity analysis, including results from high-
income countries only, did not change the pooled results, OR=1.29 (1.22, 1.36). 
Study quality: Seven studies (nine estimates) were assessed as being of minimal/low 
risk of bias(22, 39, 40, 45, 46). The pooled estimate for these studies was a significant 
OR=1.29 (1.22, 1.36). Pooled estimate for the three studies (four estimates) assessed 
as being moderate/high risk of bias(42, 47, 48) was a non-significant OR=0.95 (0.32, 2.76) 
(p=0.57). 
Exposure measurement: Two studies used self-reporting of HDP status(22, 46), resulting 
in a pooled OR=1.70 (1.06, 2.72), while pooled results of four studies (six estimates) 
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using medical records to obtain exposure status(39-41, 45), resulted in a pooled estimate 
of 1.28 (1.22, 1.36) (p=0.24) 
Outcome measurement: Five studies (seven adjusted estimates) used medical records 
to measure ADHD status in the offspring(39-41, 45, 46), compared to one study that used 
maternal-reporting(22).  However, results of a sensitivity analysis (including medical 
records only) did not change pooled results, OR=1.28 (1.22, 1.36). 
 
4.5 Discussion 
The aim of this systematic review was to synthesise the published literature on the 
relationship between HDP and the risk of neurodevelopmental disorders in the 
offspring. This has yielded three principal findings. First, our adjusted pooled results 
indicate that exposure to HDP is associated with a 35% increased odds of ASD when 
compared to those unexposed. Results of a subgroup analysis, examining a 
preeclampsia-ASD relationship in isolation provided an OR of 1.50, while the other 
HDP-ASD relationship was non-significant with an OR of 1.25. Although subgroup 
analysis may suggest that the type of HDP may play a role in determining the impact 
on neurodevelopmental outcome, subgroup differences were not statistically 
significant.  
Second, adjusted pooled results suggest that offspring exposed to HDP are 30% more 
likely to have ADHD compared to those unexposed. Examining a preeclampsia-
ADHD relationship in isolation did not change the estimate, while the odds of ADHD 
was associated with a 70% increase in relation to other HDP. This subgroup difference 
was not statistically significant however.  
These reported effect sizes are similar to other obstetric risk factors for ASD. For 
example, caesarean section and advancing maternal age (>35 years) are associated 
91 
 
with a 23-26% and 30% increased odds of ASD respectively(20, 151, 152), while breech 
presentation and Apgar score <7 may increase the risk of ADHD by 14% and 30%(137).  
Third, literature examining the relationship between HDP and other 
neurodevelopmental, cognitive or behavioural outcomes remain inconsistent. 
(Appendix 5). Some patterns of association were observed between preeclampsia and 
cognitive impairment when confined to specific populations such as growth restricted, 
preterm and low birthweight babies(57, 58, 60, 61, 69, 149). Similarly, the epidemiological 
evidence examined is suggestive of a potential link between HDP and intellectual 
disability(36, 62, 63, 150). However, methodological differences between studies, 
particularly differences in population and outcome assessment methods, may partially 
explain the overall lack of consistent findings.  
While this study is suggestive of a link between HDP and neurodevelopmental 
disorders in the offspring, it is difficult to rule out the possibility that antihypertensive 
medication during pregnancy may be associated with adverse effects in the 
offspring(153). However, several potential mechanisms have been proposed in attempts 
to explain the relationship between HDP and neurodevelopmental outcome. For 
example, placental dysfunction, associated with HDP, may result in reduced placental 
perfusion and oxidative stress(70). In turn, suboptimal nutrient and oxygen availability 
for the fetus, due to placental insufficiency, may affect the developing brain, 
increasing the risk of a poor neurodevelopmental outcome(13, 30, 71, 72).   
Maternal inflammation may also play a key role. Results of a population-based study 
in Finland, with data on over one million pregnancies, have shown that inflammatory 
biomarker, C-reactive protein (CRP) associated with preeclampsia, is significantly 
associated with a 43% increased risk of autism in offspring, when maternal CRP levels 
in the highest quintile were compared to the lowest quintile(78, 79). Fewer hypotheses 
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have been put forward addressing the biological mechanisms of ADHD specifically, 
however, it is also possible that similar mechanisms may be involved(22, 81, 82).  
In summary, the literature examining HDP and ASD is suggestive of a small increase 
in the likelihood of ASD in offspring exposed to HDP(9, 11, 13, 14, 21, 30, 35, 50), however 
some studies fail to meet statistical significance(10, 12, 14, 15, 31, 49, 148). In contrast, other 
studies suggest a protective HDP-ASD association(9, 33, 34, 62, 147), with only two 
reaching statistical significance(32, 36). Similarly, the literature alludes to a positive 
relationship between HDP and ADHD, with some studies indicating significant 
associations(22, 40-42), and others producing non-significant positive estimates(39, 44-46). 
In comparison, two HDP-ADHD studies suggest reduced odds of ADHD in HDP-
exposed offspring(47, 48). Notably however, neither study reaches statistical 
significance or control for potential confounders.  
 
Strengths and limitations 
This systematic review had several strengths. It was based on a pre-prepared protocol 
and MOOSE Guidelines were followed throughout(83). It included a comprehensive 
search of five relevant databases, supplemented by hand-searching the reference lists 
of included studies for further potentially eligible studies.  
However, there are also several limitations, including limitations of the current 
literature. Results were limited to English-language studies only, potentially leading 
to relevant, non-English studies being overlooked. While the full search strategy was 
published along with the protocol, it may have been lacking in keywords such 
“perinatal complication” OR “prenatal complication” OR “obstetric* complication”, 
as hand-searching the reference lists identified a larger number of relevant studies 
compared to searching the electronic databases. Therefore, we conducted a post-hoc 
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search of PubMed, adding these words to the search strategy. While this increased the 
number of hits retrieved five-fold, identifying more eligible studies than the original 
search strategy, no new studies were identified in the process.  
Sample size calculations are lacking in the literature examining the HDP-ASD and 
HDP-ADHD relationship and may therefore lack statistical power. For example, five 
out of twenty ASD-studies(11, 12, 33, 49, 147), and three out of ten ADHD-studies had fewer 
than ten exposed cases(45, 47, 48).  
Validated questionnaires were not always used to obtain data, potentially introducing 
misclassification bias(9, 10, 13, 21, 22, 46), while varying HDP and ASD/ADHD diagnostic 
criteria may increase clinical heterogeneity between studies(154).  
Finally, residual or unmeasured confounding is of particular concern in observational 
studies, and therefore possible that important confounding factors were not always 
considered or available(155). The vast majority of studies included in our meta-analyses 
identified potential confounders a priori based on previous literature, and only two 
studies(10, 13) appear to have aided this method with directed acyclic graphs to evaluate 
and assess suspected confounding(156). Other studies in our review however, fail to 
control for confounding or do not provide justification for included confounders. Only 
one ASD-study(21) and one ADHD-study(40) controlled for a combination of key 
variables such as maternal age, socio-economic status, ethnic origin and family history 
of mental illness. Therefore, while an apparent association exists between HDP-ASD, 
and HDP-ADHD, future research examining the association between HDP and 
neurodevelopmental outcomes needs to identify a comprehensive set of confounders 
to assess whether this association is causal or whether it is due to residual or 
unmeasured confounding. Furthermore, this research focused specifically on ASD, 
ADHD and other neurodevelopmental, behavioural or cognitive outcomes. Future 
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research could explore the association between HDP and mental disorders not 




Our systematic review indicates that exposure to HDP is associated with a small 
increase in the likelihood of ASD and ADHD. If the observed associations were 
causal, they highlight the potential need for increased developmental screening of 
HDP-exposed infants to allow early intervention which may improve 
neurodevelopmental outcome. However, before more definitive conclusions can be 






Table 4.1 Subgroup meta-analyses for HDP-ASD and HDP-ADHD 
ASD Number of studies N Outcomes Odds Ratio 95% CI I2 (%) Test for 
subgroup 
differences 
Overall unadjusted 19 (23 estimates) 941285 9331 1.41 (1.22, 1.64) 55 p=0.80b 
Overall adjusteda 11 (13 estimates) 777518 6866 1.35  (1.11, 1.64) 63 p=0.33b  
Category of HDPa 
Preeclampsia 6 (6 estimates) 378991 4254 1.50  (1.26, 1.78) 15 p=0.33 
Other HDP 7 (7 estimates) 472268 4621 1.25  (0.90, 1.73) 72 
Study designa 
Case-control 6 (7 estimates) 16975 3812 1.47  (1.18, 1.84) 21 p=0.41 
Cohort 5 (6 estimates) 760543 3054 1.26 (0.93, 1.70) 78 
Locationa 
North America 6 (7 estimates) 372527 3555 1.39  (1.09, 1.77) 59 p=0.0005 
Europe 4 (5 estimates) 28010 2859 1.53 (1.26, 1.87) 0 
Australia 1 (1 estimate) 376981 452 0.64  (0.43, 0.95) n/a 
Study qualityc 
Minimal/low risk of bias 14 (16 estimates) 873772 8041 1.39 (1.17, 1.65) 47 p=0.46 
Moderate/high risk of bias 5 (7 estimates) 67513 1263 1.18 (0.81, 1.74) 69 
Exposure measurementa 
Self-reported 4 (5 estimates) 81242 2026 1.54 (1.07, 2.22) 68 p=0.39 
Medical records 7 (8 estimates) 696276 4840 1.27 (0.99, 1.64) 65 
Outcome measurementa 
Maternal-reported 2 (3 estimates) 79543 992 1.32  (0.91, 1.91) 72 p=0.86 
Medical records 9 (10 estimates) 697975 5874 1.37  (1.07, 1.75) 63 
Length of follow-upa 
Up to seven years 5 (5 estimates) 102838 1823 1.71  (1.23, 2.38) 41 p=0.09 
Up to 21 years 6 (8 estimates) 674680 5043 1.22 (0.98, 1.52) 64 
ADHD Number of studies N Outcomes OR 95% CI I2 (%) Test for 
subgroup 
differences 
Overall unadjusted 9 (12 estimates) 1428209 37635 1.32  (1.20, 1.45) 48 p=0.33b 
Overall adjusteda 6 (8 estimates) 1395605 37128 1.29  (1.22, 1.36) 0 p=0.24b  
Category of HDPa 
Preeclampsia 5 (6 estimates) 1382105 36962 1.28  (1.22, 1.36) 0 p=0.24 




Case-control 3 (4 estimates) 124988 26728 1.34 (1.25, 1.43) 0 p=0.08 
Cohort 3 (4 estimates) 1270617 10400 1.21  (1.10, 1.32) 0 
Locationa 
North America 2 (2 estimates) 166399 21524 1.27  (1.13, 1.43) 70 p=0.99 
Europe 2 (3 estimates) 1185896 2489 1.26  (1.06, 1.49) 0 
Other 2 (3 estimates) 43310 13115 1.27  (0.95, 1.70) 0 
Study qualityc        
Minimal/low risk of bias 7 (9 estimates) 1427617 37365 1.29  (1.22, 1.36) 0 p=0.57 
Moderate/high risk of bias 3 (4 estimates) 840 394 0.95  (0.32, 2.76) 67 
Exposure measurementa 
Self-reported 2 (2 estimates) 13748 290 1.70  (1.06, 2.72) 0 p=0.24 
Medical records 4 (6 estimates) 1381857 36838 1.28  (1.22, 1.36) 0 
Abbreviations: OR=odds ratio. 95% CI=95% confidence interval. 
aIncludes all studies that adjusted for confounders in the analysis phase.  
bTest for subgroup differences between preeclampsia and other HDP.  






























aPlus six studies which are also included in ASD and one in ADHD.  
ASD papers  
n=20 
 
ADHD papers  
n=10 
 
Records identified through 
database search n=1166 
 
Records after duplicates 
removed n=796 
 Records removed after reviewing  
titles and abstracts n=763 
 Full text articles reviewed 
n=33 
 
Records removed after reviewing full texts n=11 
1 excluded because number exposed in both 
groups was 0. 
1 excluded as data not sufficient to compute 
estimates.  
1 excluded as preeclampsia not included as 
risk factor.  
2 excluded because they were conference 
abstracts only. 
3 excluded due to lack of comparison group. 
2 excluded as it was a review and not an 
original study.  
1 excluded because it did not include outcome 
of interest. 
 






Additional records identified 
through hand-searching 





Total number of papers for 
inclusion in systematic review 
n=61 
 
An additional ASD paper 
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Preeclampsia is a leading cause of maternal death and maternal and perinatal 
morbidity. Whilst the clinical manifestations of preeclampsia often occur in late 
pregnancy, the molecular events leading into the onset of this disease are thought to 
originate in early pregnancy and result in insufficient placentation. Although the 
causative molecular basis of preeclampsia remains poorly understood, maternal 
inflammation is recognised as a core clinical feature.  While the adverse effects of 
preeclampsia on maternal and fetal health in pregnancy is well-recognised, the long-
term impact of preeclampsia exposure on the risk of autism spectrum disorder (ASD) 
in exposed offspring is a topic of on-going debate. In particular, a recent systematic 
review has reported an association between exposure to preeclampsia and increased 
risk of ASD, however the molecular basis of this association is unknown.  
Here we review recent evidence for; 1) maternal inflammation in preeclampsia; 2) 
epidemiological evidence for alterations in neurodevelopmental outcomes in offspring 
exposed to preeclampsia; 3) long-term changes in the brains of offspring exposed to 
preeclampsia; and 4) how maternal inflammation may lead to altered 
neurodevelopmental outcomes in preeclampsia-exposed offspring. Finally, we discuss 








Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder, 
characterised by impairments in social and communication skills, as well as restricted 
and repetitive patterns of behaviour(25, 157, 158). ASD is among the most common 
neurodevelopmental conditions with a prevalence of approximately 1% globally, and 
1.5% in developed countries(25, 26).  
While there is a general consensus that genetics play the major role in the etiology of 
ASD(29), the environmental contribution is estimated to be between 17-50%(28, 29). 
Therefore, it is important to investigate factors potentially contributing to the 
likelihood of development of ASD.  Several environmental risk factors, including 
prenatal and perinatal factors have been examined in an attempt to explain the etiology 
of ASD(25). In particular, a recent systematic review examining the association 
between hypertensive disorders of pregnancy (HDP) and neurodevelopmental 
disorders reported an association between preeclampsia and ASD in exposed 
offspring(56). However, the molecular basis of this association is not known. Therefore, 
the objectives of this paper are to review and provide a perspective on the:  
1. Evidence for maternal inflammation in preeclampsia;  
2. Epidemiological evidence for alterations in neurodevelopmental outcomes in 
offspring exposed to preeclampsia;  
3. Evidence for long-term changes in the brains of offspring exposed to 
preeclampsia; 
4. Evidence for how maternal inflammation may lead to altered 





Hypertensive disorders of pregnancy 
Hypertensive disorders of pregnancy (HDP) may be chronic (pre-dating pregnancy or 
diagnosed before 20 weeks’ gestation) or arise de novo (either preeclampsia or 
gestational hypertension). HDP are one of the most common gestational complications 
affecting 3-10% of all pregnancies and are made up of a collection of hypertensive 
conditions including pre-existing hypertension (chronic hypertension), gestational 
hypertension, white coat hypertension and preeclampsia(2).  Of these, preeclampsia is 
one of the leading cause of maternal mortality and morbidity and has recently been 
redefined by the International Society of Hypertension in Pregnancy (ISSHP) as 
gestational hypertension (systolic BP >140 and/or diastolic BP >90 mmHg) 
accompanied by one or more of the following new-onset conditions at or after 20 
weeks’ gestation(2):  
1. Proteinuria;  
2. Other maternal organ dysfunction, including: 
 Acute kidney injury (creatinine >90umol/L; 1mg/dL)  
 Liver involvement (elevated transaminases e.g. ALT or AST >40 IU/L) 
with or without right upper quadrant or epigastric abdominal pain) 
 Neurological complications (examples include eclampsia, altered 
mental status, blindness, stroke, clonus, severe headaches, persistent 
visual scotomata) 
 Haematological complications (thrombocytopenia – platelet count 
below 150,000/uL, DIC, hemolysis) 
3. Uteroplacental dysfunction (such as fetal growth restriction, abnormal 
umbilical artery Doppler wave form analysis, or stillbirth).  
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Previously thought to be simply due to impaired trophoblast invasion followed by the 
development of the clinical manifestations of the disease, it is now appreciated that 
the underlying etiology of preeclampsia is far more complex. Beginning with genetic 
susceptibility, followed by an abnormal immune adaptation to pregnancy, this in turn 
leads to impaired placentation and perfusion of the intervillous space by oxygenised 
arterial blood resulting in excessive or deficient placental derived factors in the 
maternal circulation(6, 159). The endothelial dysfunction, resulting from placental 
ischemia and release of placental products which occurs in preeclampsia appears to 
occur as a result of oxidative stress and is mediated by high levels of free radicals and 
low levels of antioxidants(160-165). Vasoactive factors released include soluble fms-like 
tyrosine kinase-1 (sFlt-1), cytokines, angiotensin II and type 1 receptor autoantibodies 
(166-170). These factors target the maternal vascular endothelium giving rise to the 
maternal syndrome of hypertension, proteinuria, organ and uteroplacental dysfunction 
which may be followed by acute atherosis in the spiral arteries predisposing to spiral 
artery thrombosis and placental infarcts(171, 172).  In addition, there is an increasing 
awareness that preeclampsia leads to a state of exaggerated maternal inflammation(6) 
meaning that it may be one of the most common causes of maternal inflammation 
during pregnancy, a recognised risk factor for adverse neurodevelopmental 
outcomes(173). Consequently, there has been a growing interest in studying maternal 
inflammation and subsequently neurodevelopmental outcomes in offspring exposed 
to preeclampsia.  
 
5.3 Maternal inflammation in preeclampsia: a role for Interleukin-6? 
In uncomplicated pregnancies there is a normal systemic inflammatory response in 
which cytokines promote the infiltration of the spiral arteries by invading trophoblast 
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cells(73). This is an important feature of normal placentation and occurs early in 
pregnancy. However this normal inflammatory response becomes exaggerated in 
preeclampsia resulting in disruptive activation of monocytes, granulocytes and the 
endothelium resulting in a state of maternal inflammation(174). Interestingly many 
clinical studies have now reported that women with preeclampsia have increased 
levels of inflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor 
(TNF)-α, IL-12 and IL-16, which cause structural and functional changes in 
endothelial cells, promote the formation of endothelin and reduce acetylcholine 
induced vasodilatation(166, 175-184). A systematic review and meta-analysis published in 
2013 tested the association between preeclampsia and maternal circulating levels of 
IL-6 (n = 425 preeclampsia and n = 363 normotensive), IL-10 (n = 180 preeclampsia 
and n = 175 normotensive) and TNF-α (n = 1015 preeclampsia and n = 925 
normotensive)(185). Third trimester maternal circulating levels of IL-6, IL-10 and TNF-
 were significantly higher in women with preeclampsia compared to normotensive 
controls(185). Subsequently a number of studies have extended and corroborated these 
findings. 
A study by Mihu et al.(186) examined maternal cytokine concentrations between 28 and 
41 weeks’ gestation in a normal pregnancy group (n = 78), a preeclampsia group (n = 
80), and a non-pregnant control group (n = 72) and reported elevations in IL-6 and 
TNF- in the preeclampsia group(186). In support of this, a study by Valencia-Ortega 
et al.(187) also examined IL-6 levels in age-matched pregnant women with 
preeclampsia (n = 50) and without preeclampsia (n = 50). They reported that maternal 
serum concentrations of IL-6 were significantly higher in late-onset preeclampsia, 
compared to early-onset preeclampsia or normal pregnancy(187). Moreover while mid-
gestation circulating IL-6 levels were associated with preeclampsia, IL-6 was only 
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significantly associated with term preeclampsia, suggesting that elevations in IL-6 
may be a late stage feature of preeclampsia(188). This is consistent with a study of 
women with preeclampsia (n = 208) and normotensive controls (n = 411) which 
showed that first and second trimester levels of IL-6 were not associated with preterm 
preeclampsia(189). Interestingly given that we and others have reported that the stage 
of pregnancy in which offspring are exposed to maternal inflammation is a key 
determinant of neurodevelopmental outcomes in exposed offspring(190-195), it is 
possible that the effects of preeclampsia on offspring neurodevelopmental outcomes 
may vary depending on the severity and clinical course of the disease. 
These findings are supported by animal modelling of the pathophysiological 
mechanisms that underlie the development of preeclampsia. Specifically, the reduced 
uterine perfusion pressure (RUPP) rat model of placental ischemia mimics many of 
the clinical characteristics of preeclampsia. Placental ischaemia generated by 
reductions in uterine perfusion pressure in pregnant rats increases blood pressure, 
reduces glomerular filtration rate (GFR), increases sFlt-1 concentrations, elevates 
production of pro-inflammatory cytokines and reactive oxygen species (ROS) and 
leads to intrauterine growth restriction (IUGR)(196). Recent studies in the RUPP model 
have described an immune imbalance characterised by increased pro-inflammatory 
CD4+ T cells and pro-inflammatory cytokines in addition to a reduction in regulatory 
T cells and anti-inflammatory cytokines(197). Specifically there is substantial evidence 
of increased serum levels of pro-inflammatory cytokines IL-6(198) and TNF-α(199) in 
response to placental ischemia in the RUPP model compared to sham controls. A study 
by Gadonski et al.(198) examined the role of IL-6 in generating preeclampsia-like 
characteristics by infusing pregnant rats with IL-6 for 5 days resulting in a 2-3 fold 
increase in serum IL-6 levels. As a result of the increase in circulating IL-6 levels these 
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rats had elevated mean arterial pressure, reduced renal plasma flow and reduced 
glomerular filtration rates(198). Interestingly, these preeclampsia-like characteristics 
were not evident in virgin rats infused with IL-6(198). These data indicate that 
elevations in maternal IL-6 may be part of the maternal inflammatory pathophysiology 
of preeclampsia. 
 
5.4 The epidemiological evidence for alterations in neurodevelopmental outcomes 
in offspring exposed to preeclampsia 
We recently conducted a systematic review synthesising published, epidemiological 
evidence examining the association between HDP and neurodevelopmental disorders 
in the offspring(56). The primary outcomes included in the review were ASD and 
attention deficit hyperactivity disorder (ADHD). Secondary outcomes included 
behavioural outcomes such as Asperger’s Syndrome, Pervasive Developmental 
Disorder - Not Otherwise Specified (PDD-NOS), behavioural difficulties using 
standardised checklists, as well as cognitive functioning, developmental delay and 
intellectual disability. In total, 61 papers were included in the review: 20 for ASD (six 
cohort studies and 14 case-control studies), 10 for ADHD (five cohort studies and five 
case-control studies) and 31 secondary outcome papers (25 cohort studies and six case-
control studies).  
Pooled results from this study showed that exposure to HDP (including preeclampsia, 
gestational hypertension and chronic hypertension) was associated with a 35% 
increase in the odds of ASD when compared to those unexposed to HDP (OR=1.35; 
95% CI: 1.11-1.64)(56). Subgroup analysis examining preeclampsia alone and ASD 
increased the odds ratio to 1.50 (95% CI: 1.26-1.78), whereas all other HDP (which 
may include preeclampsia) were associated with a non-significant increase in the odds 
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of ASD (OR: 1.25, 95% CI: 0.90-1.73)(56). (Table 5.1). However, it is important to 
note that the epidemiological evidence in this area is largely inconsistent. For example, 
some studies suggested that exposure to preeclampsia may be associated with a 
statistically significant increase in the likelihood of ASD, when compared to 
unexposed offspring(9, 13, 14, 30), while others proposed a positive other HDP-ASD 
relationship(11, 21, 35, 50). Similarly, there are studies that alluded to a positive 
preeclampsia-ASD relationship(12, 14, 31, 148), and other HDP-ASD relationship(10, 14, 15, 
49) but failed to meet statistical significance. Conversely, some older studies are 
suggestive of a protective association between preeclampsia and ASD(9, 32-34, 147), and 
other HDP-ASD(9, 36), but only two of these found a statistically significant 
relationship(32, 36).  
Given the non-significant pooled estimate seen with other HDP and ASD, it is difficult 
to hypothesise whether the type of HDP is an important factor in determining the 
impact on ASD risk in exposed offspring. The subgroup analysis by Maher et al, 
2018(56) reported a statistically significant association between preeclampsia and ASD 
but a non-significant risk of ASD with other HDP (which may include preeclampsia). 
This may suggest that the association observed occurs not as a result of exposure to 
hypertension but as a result of exposure to a mediator of the complex syndrome of 
preeclampsia such as inflammation. More research is needed on the association 
between type of HDP and ASD in order to examine whether preeclampsia only or all 
HDP display a significant association with ASD. 
Although the findings show an apparent HDP-ASD relationship, results may need to 
be interpreted with caution as several limitations were identified among ASD studies. 
Firstly, misclassification bias could have resulted from a lack of validated 
questionnaires and maternal reporting of exposure and ASD status when determining 
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exposure and outcome status of subjects(9, 10, 13, 21). Secondly, confounding is of 
particular concern in observational studies due to the lack of randomisation process, 
potentially leading to spurious findings. The vast majority of studies identified in the 
systematic review failed to control for a combination of key variables, calling into 
question the validity of findings. For example, only one study controlled for a 
combination of key variables such as maternal age, socio-economic status, ethnic 
origin and maternal depression(21).  Finally, several studies contained small sample 
sizes, evident in 5 of 20 studies which had fewer than 10 cases of ASD exposed to 
HDP(11, 12, 33, 49, 147). However, results of larger studies (>10 exposed cases) that 
controlled for at least one potential confounder in the analysis phase of the study 
ranged from an OR of 1.36 to 2.36 for preeclampsia and 0.96 to 2.83 for other HDP 
(which may have included preeclampsia)(56).  
In addition, while the results of the systematic review also suggest an association 
between preeclampsia and ASD, this association may not be specific to ASD(56). For 
example, adjusted pooled results in Maher et al.(56) also proposed that offspring 
exposed to HDP were 30% more likely to have ADHD compared to those unexposed. 
Subgroup analyses investigating a preeclampsia-ADHD relationship in isolation did 
not change this estimate, while the odds of ADHD was associated with a 70% increase 
in relation to other HDP(56). Moreover, while the evidence remains inconsistent among 
secondary outcome studies included in the review, there were some patterns of 
association between HDP and intellectual disability despite methodological 
differences between studies(36, 62, 63, 150). For example, results from Griffith et al. 
2011(63) suggested that preeclampsia/eclampsia was associated with a 38% increase in 
the odds of intellectual disability (95% CI: 1.16, 1.64)(63). Similarly, the relative risk 
for an eclampsia-‘mental retardation’ relationship classified according to ICD coding 
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was 3.03 in Danish offspring less than 15 years old(62). Langridge et al.(36) measured 
intellectual disability using the American Association on Mental Retardation 
classification system and suggested an association between HDP and moderate 
intellectual disability in Western Australia (OR: 1.39, 95% CI: 1.25, 1.54)(36). Lastly, 
Salonen et al.(150)  used a standardised set of tests for mental performance and 
suggested that HDP was associated with an increased likelihood of ‘mental 
retardation’ in children aged 9-10 years in Eastern Finland (RR: 6.1, 95% CI: 1.3, 
28.9)(150). 
Collectively, the epidemiological evidence points to an apparent relationship between 
preeclampsia exposure in particular, and ASD risk in exposed offspring. However, the 
specificity of the effects of preeclampsia on ASD risk, could in fact be associated with 
poor neurodevelopmental outcome in general as opposed to being specific to ASD(200). 
Given the available evidence that preeclampsia and other HDPs may impact 
neurodevelopmental outcomes(56), there has been an increasing focus on identifying 
any neuroanatomical alterations in the brain of offspring exposed to preeclampsia. 
 
5.5 Evidence for long-term changes in the brains of offspring exposed to 
preeclampsia 
An increasing body of work has now shown that the brains of women with 
preeclampsia can undergo structural and functional changes as a result of preeclampsia 
with the suggestion that this may predispose to developing neurological deficits later 
in life (for a comprehensive review see Ijomone et al(201)). However, aside from the 
maternal neurological changes, there is increasing interest in how preeclampsia 
exposure can lead to long-term changes in brains of exposed offspring.  
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A recent imaging study has examined regional brain volumes and cerebral vasculature 
of children aged 7 to 10 years after exposure to preeclampsia(127). Specifically children 
that had been exposed to preeclampsia (mean age = 9.79 ± 0.89 years; n = 10; 5 male, 
5 female) were matched based on age and sex to those born from an uncomplicated 
pregnancy (mean age = 9.66 ± 1.07 years; n = 10; 5 male, 5 female). This cohort then 
underwent magnetic resonance (MR) imaging to identify any brain structural and 
vascular anatomic differences. While there were no significant differences in total 
intracranial brain volume between the control group and children from mothers 
exposed to preeclampsia, the preeclampsia group had significant larger regional brain 
volumes in five of twenty-one regions analysed that included the cerebellum, temporal 
lobe, left amygdala, right amygdala and the brain(127). It is important to note however 
that there were no significant differences in gestational age (controls = 39.47 ± 1.38 
weeks vs. preeclampsia = 37.16 ± 3.34 weeks), there was a significant difference in 
birthweight (controls = 3.42 ± 0.36 kg vs. preeclampsia = 2.67 ± 0.79 kg) in this study 
which may have confounded these results(127). For example, children born at 37 weeks’ 
gestation were found to have poorer school performance compared to those born at 
39-41 weeks’ gestation, an effect that was independent of birthweight(202).  
Interestingly, however, these alterations in regional brain volumes have also been 
reported in children with ASD(203, 204). In particular, the increases in amygdala volume 
has been reported in a number of studies(205). In addition, a recent follow up study in 
this same cohort in the Ratsep et al.(127) study employed diffusion tensor MR imaging 
(DTI) to examine myelination patterns and white matter connectivity and six brain 
regions of interest were identified for analysis by tractography (middle occipital gyrus, 
caudate nucleus and precuneus, cerebellum, superior longitudinal fasciculus, and 
cingulate gyrus)(206). They reported increased tract volumes in a number of these brain 
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regions including the superior longitudinal fasciculus, which is strongly related to 
language and communication pathways(207). Interestingly, while the molecular 
mechanisms underlying these neuroanatomical changes are unknown, a recent study 
has shown that exposure of fetal cortical neurons to serum of women with established 
preeclampsia lead to increases in axonal growth and branching(21). This suggests that 
preeclampsia exposure may alter neurodevelopmental trajectories, but to our 
knowledge this causative basis of altered brain volumes in offspring exposed to 
preeclampsia are currently unknown and these studies require confirmation in larger 
patient cohorts. 
 
5.6 How might maternal inflammation in preeclampsia alter neurodevelopmental 
outcome? 
Given the epidemiological evidence for an association between preeclampsia and 
neurodevelopmental outcome, then a key question is what are the mechanisms that 
mediate this association? Given that maternal inflammation is a core feature of the 
maternal pathophysiology of preeclampsia(185) and systematic evidence has reported 
maternal inflammation as a risk factor for ASD(208), it is possible that preeclampsia-
induced maternal inflammation is a determinant of fetal neurodevelopmental outcome.  
Arguably IL-6 is the best characterised mediator of the impacts of maternal 
inflammation on fetal neurodevelopmental outcome. Animal models of maternal 
inflammation have shown that maternal administration of the viral mimetic, poly(I:C), 
lead to elevations in maternal and fetal IL-6 levels, and alter neurobehavioural 
outcomes in the offspring(195). Blocking IL-6 signalling through maternal co-
administration of anti-IL-6 antibodies with poly(I:C), prevented the poly(I:C)-induced 
social deficits and transcriptional changes in the brains of exposed 
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offspring(209).  Interestingly there is also increased IL-6 expression and signalling in 
the placenta in the poly(I:C) model suggesting that conditions that increase maternal-
placental IL-6 signalling may lead to detrimental effects in the fetal brain(210). This has 
recently been addressed in an elegant study by Wu et al.(211) who addressed the role of 
maternal IL-6. The authors crossed il-6+/+ males with il-6-/- females (resulting in a 
pregnant dam who cannot mount an IL-6 response), and in parallel crossed il-6-/- males 
with il-6+/+ females (resulting in a pregnant dam who can mount an IL-6 response). 
Poly(I:C) administration to these pregnant dams led to increases in fetal brain IL-6 
levels only in offspring from il-6+/+ females(211). Moreover, conditional deletion of the 
IL-6 receptor in the placental trophoblast prevented the maternal poly(I:C)-induced 
fetal brain inflammatory response, neuroanatomical changes and anti-social and 
repetitive/anxiety-like behaviour in exposed offspring(211).  
While the majority of these studies have been carried out in rodent models, a recent 
study in humans reported the association between maternal IL-6 in pregnancy and the 
structural connectivity of frontolimbic circuitry, which is critical for socioemotional 
and cognitive development, in 30 infants(77). Specifically, diffusion tensor imaging 
revealed that maternal IL-6 levels averaged across pregnancy were inversely 
associated with fractional anisotropy (a measure of brain connectivity) and offspring 
cognition at 12 months of age(77). Other studies have also show that third trimester 
maternal IL-6 levels, are associated with neonatal functional connectivity and with 
both fetal heart rate variability and toddler cognitive development(76). This is in 
agreement with the report that higher average maternal IL-6 was prospectively 
associated with larger right amygdala volume and selected stronger bilateral amygdala 
connectivity(212). Interestingly, larger newborn right amygdala volume and stronger 
left amygdala connectivity mediated the association between 
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higher maternal interleukin-6 concentrations and lower impulse control at 24 months 
of age(212). Collectively these data support the premise that preeclampsia-induced 
alterations in maternal IL-6 and maternal-placental IL-6 signalling may be key 
determinants of any neuroanatomical and neurobehavioural changes in offspring 
exposed to preeclampsia-induced maternal inflammation. (Figure 5.1). 
 
5.7 Conclusions and future perspectives 
Future epidemiological research examining the association between preeclampsia and 
ASD in particular and neurodevelopmental disorders in general, should address the 
limitations and gaps in the current literature we have recently discussed(56). In 
particular, large population-based cohort studies with valid methods to identify 
women with HDP and children with ASD are needed. It is important that such studies 
be able to adjust for key potential confounders such as maternal age, maternal body 
mass index, socio-economic status factors, family history of mental disorders, and 
ethnic origin. In addition, such studies should attempt to assess whether observed 
associations between HDP and ASD is HDP type specific, whether the association is 
specific to ASD, or ASD and other neurodevelopmental and psychiatric disorders. 
Whether other pregnancy complications and early life events have effect modification 
or mediation role in the HDP-ASD association is worth investigating as such analyses 
may improve our understanding of the association and the potential mechanisms. 
Moreover an important gap in the literature is the potential impact of antihypertensive 
medications on any observed association. In other words, is the observed association 
between preeclampsia and ASD related to the HDP or pharmacological treatments 
used during pregnancy. This is an important question for future research. 
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In future work it will also be important to examine neuroanatomical and 
neurobehavioural outcomes across the life span using both the RUPP model of 
preeclampsia, and in clinical cohorts. While the longitudinal nature of these studies 
are challenging in humans, imaging and developmental assessments of adequately 
powered cohorts of offspring exposed to preeclampsia and appropriate matched 
controls will be important given recent studies showing changes in the brains of 
preeclampsia-exposed offspring(127, 206). Combining this with animal modelling will 
allow the role of maternal inflammation and in particular IL-6 as mediator of the 
association to be determined, using elegant approaches reported by Wu et al.(211). 
Moreover, given a recent study showing that most significant genetic variants 
associated with schizophrenia, converge on a developmental trajectory sensitive to 
events that affect the placental response to in utero stressors, including 
preeclampsia(213), understanding the placental response in preeclampsia and how this 
may predict or be associated with neurodevelopmental outcomes in preeclampsia-
exposed offspring(214), will be important questions for future research. 
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Table 5.1 Summary of studies examining the association between preeclampsia and ASD 
Author Design N Prenatal Stressor Outcomes Results cOR/RR (95% CI) aOR/RR (95% CI) 
Walker et al, 
2015(13) 
Case-control 867 PE from medical records or 






2.58 (1.31, 5.11) 2.36 (1.18, 4.72) 
Mrozek-Budzyn 
et al, 2013(12) 
Case-control 288 PE from medical records or 
self-reporting 
ICD-10 ↑ odds ASD 2.05 (0.58, 7.28) 
 
- 
Lyall et al, 2012(9) Cohort 66445 Toxemia self-reported in 
questionnaire 
Maternal-reported ↑ odds 
ASD* 
1.24 (0.99, 1.55) 1.36 (1.04, 1.78) 
Burstyn et al, 
2010(31) 
Cohort 216342 PE from APHP delivery 
records 
ICD-9 ↑ odds ASD 1.91 (1.30, 2.81) 1.49 (1.00, 2.22) 
Mann et al, 
2010(30) 
Cohort 87677 PE/eclampsia from billing 
records for Medicaid-eligible 
women (ICD-9) 
ICD-9  from Medicaid 




1.85 (1.38, 2.48) 1.69 (1.26, 2.27) 
Buchmayer et al, 
2009(14) 
Case-control 7296 PE from MBR (ICD-9, ICD-
10) 
ICD-9,  ICD-10 ↑ odds 
ASD* 
1.41 (0.98, 2.03) 1.64 (1.08, 2.49) 
Larsson et al, 
2005(148) 
Case-control 18148 PE from MBR ICD-8 and ICD-10 
from PCR 
↑ odds ASD 1.54 (0.83, 2.86) - 
Glasson et al, 
2004(34) 
Case-control 1627 PE (ICD-9) DSM ↓ odds ASD 0.90 (0.50, 1.62) - 
Eaton et al, 
2001(62) 
Case-control 103021 Eclampsia from MBR ICD from PCR ↓ odds ASD 0.82 (NR) - 
Matsuishi et al, 
1999(33) 
Case-control 232 Toxemia DSM-III-R ↓ odds ASD 0.82 (0.18, 3.79) - 
Mason-Brothers 
et al, 1990(32) 
Case-control 285 Toxemia from medical 
records 
DSM-III ↓ odds ASD 0.36 (0.16, 0.83) - 
Deykin et al, 
1980(147) 
Case-control 364 Toxemia from medical 
records and interview data 
≥1 symptoms of 





↓ odds ASD 0.83 (0.25, 2.70) 0.90 (0.50, 1.62) 
*Adjusted result was statistically significant. 
Abbreviations: cOR/RR=crude odds ratio/relative risk. aOR/RR=adjusted odds ratio/relative risk. 95% CI=95% confidence interval. PE=preeclampsia. ADOS=Autism 
Diagnostic Observation Schedule. ADI-R=Autism Diagnostic Interview, Revised. ICD=International Classification of Disease. APHP=Alberta Perinatal Health Program. 
DDSN=Department of Disabilities and Special Needs, South Carolina. MBR=Medical Birth Register. PCR=Psychiatric Central Register. DSM=Diagnostic and Statistical 
Manual of Mental Disorders. NR=not reported. DSM-III-R=Diagnostic and Statistical Manual of Mental Disorders–3rd Edition Revised. 
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Figure 5-1 Schema showing an overview of how preeclampsia may impact 
neurodevelopmental outcomes in exposed offspring 
 
While physiological levels of maternal inflammation plays a role in normal pregnancy, the decrease in 
placental perfusion in preeclampsia leads to the increased production of pro-inflammatory cytokines 
including IL-6 and TNF-. These cytokines may disrupt placenta signalling and/or cross to the fetal 
circulation to alter fetal neurodevelopmental trajectories, which may increase the risk of sub-optimal 
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6.1 Abstract 
Background: The environmental contribution of autism spectrum disorder (ASD) is 
approximately 17-50%, highlighting the importance of investigating factors 
potentially contributing to the likelihood of its development, and of gaining a greater 
understanding of the pathogenesis surrounding ASD. The objective of this study was 
to examine the association between preeclampsia and ASD using a population-based 
cohort study. 
Methods: All singleton live births in Sweden from 1982-2010 were included, using 
data from Swedish National Registers. Exposures of interest included:  1. 
Preeclampsia (classified according to ICD-8, ICD-9 and ICD-10) 2. Preeclampsia and 
small for gestational age (SGA) combined, used as a proxy for preeclampsia with 
placental dysfunction. ASD status was based on ICD-9 and ICD-10. 
The cohort consisted of 2,842,230 children, with 54,071 cases of ASD. Follow-up 
began from the child’s first birthday and data were censored at first diagnosis of ASD, 
death, migration or end of study period (31st December 2016). We conducted 
multivariate Cox proportional hazards regression analysis, adjusting for several 
perinatal and sociodemographic factors, selected a priori. We further controlled for 
shared genetic and familial confounding using sibling-matched analysis. 
Results: In the adjusted Cox proportional hazards regression analysis, preeclampsia 
was associated with a 25% increase in the likelihood of ASD (Hazard Ratio (HR): 
1.25, 95% CI:1.19, 1.30) compared to those unexposed to preeclampsia, while in the 
sibling-matched analysis the HR was 1.17 (95% CI:1.06, 1.28). The HR for 
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preeclampsia and SGA combined  was 1.66 (95% CI:1.49, 1.85) in the adjusted Cox 
model and 1.95 (95% CI:1.53, 2.48) in the sibling-matched analysis. 
Conclusions: Exposure to preeclampsia or preeclampsia/SGA (i.e. SGA baby exposed 
to preeclampsia) was associated with ASD. The stronger association with 
preeclampsia/SGA than preeclampsia alone suggests that placental pathology may be 























Autism spectrum disorder (ASD) is characterised by persistent impairments in 
interpersonal interaction and restricted or repetitive patterns of behaviour(23). The 
prevalence of ASD is approximately 1.5%(26, 215), and while genetics play a major role 
in the development of ASD, the environmental contribution is estimated to be between 
17-50%(28, 29). This highlights the importance of investigating factors contributing to 
the likelihood of its onset, and potentially facilitate the development of appropriate 
interventions(74). Furthermore, while often comorbid with intellectual disability, 
previous results indicate that risk factors for ASD with and without intellectual 
disability may differ, and is therefore important to examine ASD according to the 
presence or absence of intellectual disability(36, 216). 
Preeclampsia is one of the leading causes of maternal morbidity and mortality and has 
recently been redefined by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) as new-onset hypertension (blood pressure ≥140/90 mmHg 
on/after 20 weeks’ gestation) accompanied by proteinuria and/or other maternal organ 
dysfunction and/or uteroplacental dysfunction(2). Preeclampsia is associated with 
maternal inflammation, poor placentation and oxidative stress, which may also 
represent some of the potential etiological pathways in the development of ASD(71, 79, 
217). 
While there is conflicting evidence regarding a preeclampsia-ASD relationship, 
pooled estimates from epidemiological research suggest preeclampsia is associated 
with a 50% increase in odds of ASD(56). However, several limitations of the existing 
literature, including residual confounding (for example, family lifestyle factors such 
as diet), small sample sizes, and poor phenotyping and use of definitions of 
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hypertensive disorders of pregnancy versus preeclampsia, need to be addressed before 
more definitive conclusions can be reached.  
Therefore, the objective of this study was to examine the association between 
preeclampsia and ASD (overall, and stratified by ASD with and without intellectual 
disability), while addressing the key limitations in the literature outlined above. 
 
6.3 Methods 
Study Population  
The study population consisted of all singleton live births in Sweden from 1982 to 
2010 using data from the Swedish Medical Birth Register. The Medical Birth Register 
was linked to the National Patient Register, Multi-generation Register, Total 
Population Register and Register of Education using personal identification numbers 
(PIN) assigned to each Swedish resident, in order to conduct the study. 
Similar to previous ASD-studies conducted on this population(19, 29), follow-up began 
from the child’s first birthday (or 1st January 1987, when the ICD-code for ASD 
became available). Data were censored at first diagnosis of ASD, death, migration or 
end of study period (i.e. 31st December 2016). This is in contrast to Sandin et al. and 
Curran et al. who included follow-up data until the end of 2009 and 2011 
respectively(19, 29).  
Ethical approval was previously obtained from the Stockholm Regional Ethical 
Review Board (number 2010/1185-31/5), and informed consent was waived by the 







Preeclampsia: Data on preeclampsia was obtained from the Medical Birth Register. 
The Medical Birth Register, established in 1973, contains data on over 97% of all 
births in Sweden, and includes information on prenatal care, delivery, neonatal care 
and maternal socio-demographic and lifestyle factors(85). However, since 1982, 
standardised copies of antenatal, obstetric and pediatric records were used to collect 
data, while quality data on obesity and smoking status during pregnancy also became 
available, marking the beginning of our study(16).  
A doctor reviews discharge records and notes a diagnosis of preeclampsia at the time 
of discharge from the hospital using a standard form, containing the definition of 
preeclampsia, accompanied by an ICD-code and checkbox. These are forwarded to the 
National Board of Health and Welfare for inclusion in the Birth Register. Preeclampsia 
is classified according to the Swedish version of ICD-8 (through 1986), ICD-9 (1987-
1996) and ICD-10 (from 1997 onwards)(16).  
1. Preeclampsia: ICD-8 [code 637]: Gestational hypertension (blood pressure 
≥140/90mmHg on/after 20 weeks’ gestation), accompanied by proteinuria (≥0.3g/day 
or ≥1 on a urine dipstick) or edema (positive predictive value (PPV)=50%)(16).  
ICD-9 [code 642]: Gestational hypertension accompanied by proteinuria 
(PPV=96%)(16). 
ICD-10 [code O14 or O15]: Gestational hypertension accompanied by proteinuria. 
2. Preeclampsia with placental dysfunction: We combined preeclampsia and small for 
gestational age (SGA) as a proxy for preeclampsia with placental dysfunction, as SGA 
is closely associated with uteroplacental dysfunction(218). SGA was classified 
according to the Swedish weight-based fetal growth standard (defined as birthweight 
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Data on ASD and intellectual disability were obtained from the National Patient 
Register. The National Patient Register contains information on inpatient psychiatric 
diagnoses from 1973 (obtaining complete national coverage in 1987)(87, 215). 
Outpatient data is available in the National Patient Register since 2001(215) (coverage 
of data from private caregivers is approximately 80%, and public caregivers almost 
100%)(87). ASD is classified according to ICD-9 [code 299], available since 1987 and 
ICD-10 [code F84], available since 1997 (PPV=94.3%)(19). Therefore, index persons 
(IP) who turned one year of age before 1987 began follow-up on 1st January 1987, 
when an ICD-code for ASD first became available.  
As risk factors for ASD with/without intellectual disability may differ(36, 216), we 
examined ASD overall, and also stratified results by ASD with intellectual disability 
(defined as IQ<70)(215, 219) and ASD without intellectual disability. For example, if 
cases of ASD did not receive a diagnosis of intellectual disability throughout the study 
period, they were considered to have ASD without intellectual disability. (Intellectual 




Confounders were based on previous literature, and limited to the data available in the 
National Registers. They were examined through the use of a directed acyclic graph 
to gain a visual representation of the potential confounder pathways. (Appendix 11). 
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We obtained year of birth, infant sex, maternal age, maternal and paternal country of 
birth, birth order, maternal smoking status, body mass index (BMI) at first antenatal 
visit, and gestational weight gain from the Medical Birth Register. Similar to a 
previous ASD study conducted on this population(19), we also controlled for maternal 
and paternal depression, bipolar disorder, and non-affective psychiatric disorders, 
obtained from the National Patient Register. Socioeconomic factors including family 
income and parental level of education were obtained from the Total Population 
Register and Register of Education. Information on all confounders was available for 
the entire study period with the exception of parental level of education, available 
since 1990. (Appendix 12). 
 
Statistical Analysis 
Data were analysed using Stata/MP 14.2. Multivariate Cox proportional hazards 
regression analysis was performed to estimate HR and 95% confidence intervals, for 
preeclampsia; preeclampsia and SGA (i.e. SGA baby exposed to preeclampsia); and 
preeclampsia without SGA, and likelihood of ASD (overall and with/without 
intellectual disability). The proportional hazards assumption was assessed graphically 
and based on Schoenfeld residuals. Partially adjusted models were stratified by year 
of birth in order to satisfy the proportional hazard assumption (model 1). Fully 
adjusted models (model 2) controlled for year of birth, infant sex, maternal age, 
maternal and paternal country of birth, birth order, parental depression, bipolar 
disorder and non-affective psychiatric disorders, maternal smoking status, BMI at first 
antenatal visit, gestational weight gain, family income and parental level of education. 
To account for the possibility of increased diagnosis of ASD in recent years, and due 
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to a reliance on inpatient psychiatric diagnoses until 2001, we also stratified results by 
decade of birth. 
Sibling-matched analysis: To control for unmeasured confounding factors shared by 
siblings, including family environment, lifestyle factors such as diet, maternal 
characteristics, and genetic factors, we conducted a sibling-matched analysis (model 
3) using stratified Cox regression. This method is an extension of the paired binomial 
model, taking into account different lengths of follow-up time. The analysis included 
full and half siblings on the maternal side consisting of a separate stratum for each 
family, matched on maternal ID. While each family has its own baseline probability 
of ASD, reflecting their shared genetic and social factors, the exposure groups (i.e. 
preeclampsia v non-exposure to preeclampsia) are made within the family, estimating 
the probability of ASD within the family(51). We adjusted for the same potential 
confounders as model 2 with the exception of maternal country of birth as this is the 
same across sibling pairs.  
Post-hoc analysis: We examined the association between SGA-alone and ASD 
compared to non-exposure to SGA/preeclampsia. 
Sensitivity analyses: As the definition of preeclampsia from 1982-1986 does not 
correspond to later years, and the National Patient Register obtained complete national 
coverage in 1987, we performed a sensitivity analysis restricting the study population 
to 1987-2010. In addition, we excluded births after 2006 to ensure each individual was 
followed-up for a minimum of 10 years.  
Classifying preeclampsia into ‘mild’ or ‘severe’ is not recommended in clinical 
practice. However, preeclampsia may present with or without severe features(2). As 
delivery is the only effective cure for preeclampsia, gestational age is often used as a 
proxy for severity. For example, preeclampsia could be considered severe if delivery 
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occurred before 34 weeks’ gestation(220). As a result, sensitivity analyses were 
conducted examining the relationship between preeclampsia-ASD (in those born ≥34 
weeks’ gestation) and preeclampsia-ASD (in those born <34 weeks’ gestation) 
compared to deliveries at ≥34 weeks’ gestation in mothers with no preeclampsia, using 
the full cohort.  
Further sensitivity analyses included ‘preeclampsia without chronic hypertension’ as 
the exposure, and ‘preeclampsia with chronic hypertension’ as the exposure. We 
examined the association between preeclampsia-ASD excluding those with a family 
history of mental illness, while we also included caesarean section in a multivariate 
model. Furthermore, we analysed the relationship between preeclampsia with 
low/intermediate APGAR score at five minutes. We examined a preeclampsia-ASD 
relationship by maternal age, in addition to preeclampsia-ASD by BMI group at time 
of first antenatal visit. Finally, subgroup analyses examined a preeclampsia-ASD 
relationship by gestational age and gender while controlling for potential confounders. 
(Gestational age was defined according to ultrasound measurements, or from 
information of the last menstrual period)(221). 
 
6.4 Results 
Descriptive Statistics  
Table 6.1: There were 2,941,628 live births recorded in the Swedish Medical Birth 
Register between 1st January 1982 and 31st December 2010. After exclusions, (figure 
1) 2,842,230 children remained in the final cohort. Of these, 1,460,940 (51.4%) were 
male and 1,381,290 (48.6%) were female. There were 77,600 (2.7%) children exposed 
to preeclampsia. There were 54,071 (1.9%) cases of ASD with a median age of 
diagnosis of 14 years. Of these, 2,024 were exposed to preeclampsia. 
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Association between Preeclampsia and ASD  
Table 6.2: In the fully adjusted model (model 2) preeclampsia was associated with a 
25% increase in the likelihood of ASD (HR: 1.25, 95% CI: 1.19, 1.30) compared to 
those unexposed to preeclampsia, and this association was reduced in the sibling-
matched analysis (model 3) (HR 1.17, 95% CI: 1.06, 1.28). The HR for preeclampsia 
and SGA combined was 1.66 (95% CI: 1.49, 1.85) in model 2 and 1.95 (95% CI: 1.53, 
2.48) in model 3, and the HR for preeclampsia without SGA was 1.20 (95% CI: 1.14, 
1.26) in model 2 and 1.11 (95% CI: 1.01, 1.23) in model 3.  
 
Preeclampsia and ASD with intellectual disability 
Table 6.2: Preeclampsia was associated with a 56% increase in the likelihood of ASD 
with intellectual disability (HR: 1.56, 95% CI: 1.41, 1.73) in model 2 and 32% increase 
in model 3 (HR: 1.32, 95% CI: 1.07, 1.62). Those exposed to preeclampsia and SGA 
were nearly 3 times more likely to have ASD with intellectual disability in model 2 
(HR: 2.95, 95% CI: 2.40, 3.64), with similar results observed in model 3 (HR: 3.07, 
95% CI: 1.97, 4.79). The HR for preeclampsia without SGA was 1.40 (95% CI: 1.24, 
1.57) in model 2 and 1.15 (95% CI: 0.91, 1.45) in model 3. 
 
Preeclampsia and ASD without intellectual disability 
Table 6.2: The HR for preeclampsia was 1.19 (95% CI: 1.13, 1.25) in model 2, and 
1.13 (95% CI: 1.01, 1.26) in model 3. Preeclampsia and SGA were associated with a 
42% increase in likelihood of ASD without intellectual disability (HR: 1.42, 95% CI: 
1.25, 1.62) in model 2, and 63% in model 3 (HR: 1.63, 95% CI: 1.22, 2.19). The HR 
for preeclampsia without SGA was 1.17 (95% CI: 1.10, 1.23) in model 2, and 1.10 
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(95% CI: 0.98, 1.23) in model 3. Stratifying results by decade did not materially 
change results (Table 6.3).  
 
Post-Hoc Analysis 
The adjusted HR for an SGA only-ASD relationship was 1.60 (95% CI: 1.53, 1.67), 




When the study population was restricted to 1987-2010, as association between 
preeclampsia and ASD was still observed. Similarly, excluding births after 2006 did 
not materially change results. Fully adjusted results of the sensitivity analysis 
suggested that preeclampsia exposure in those born at ≥34 weeks’ gestational age was 
associated with an 18% increase in the likelihood of ASD (HR: 1.18, 95% CI: 1.13, 
1.24) when compared to those unexposed to preeclampsia, and born at a similar 
gestational age. The fully adjusted result for preeclampsia in those born at <34 weeks’ 
gestational age (used as a proxy for preeclampsia with severe features) was 2.04 (95% 
CI: 1.81, 2.30) when compared to non-exposure to preeclampsia in those born at ≥34 
weeks’ gestation. The HR for a preeclampsia-ASD relationship, excluding those with 
chronic hypertension, was 1.26; and including those with both preeclampsia and 
chronic hypertension was a non-significant 0.91. The fully adjusted HR for 
preeclampsia (excluding those with family history of mental illness) was 1.28, while 
including caesarean section in the multivariate model resulted in a HR of 1.21. 
Preeclampsia with a low/intermediate APGAR score at five minutes increased the 
likelihood of ASD by 30% compared to non-exposure to preeclampsia and 
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low/intermediate score. Finally, preeclampsia among mothers <20 years of age and 
mothers with a BMI of <20 was associated with the highest odds of ASD (HR: 1.37 
and 1.29 respectively) compared to those of similar maternal age and BMI at first 
antenatal visit.  (See Appendix 13 and Appendix 14 for full description of results). 
 
Subgroup Analyses 
Adjusted subgroup analysis suggested a statistically significant increase in the 
likelihood of ASD at all gestational ages when compared to non-exposure to 
preeclampsia in those born at ≥37 weeks’ gestation. When adjusted for potential 
confounders, exposure to preeclampsia was associated with a 25% increase in the odds 
of ASD in both male and female offspring. (Appendix 13 and Appendix 15). 
 
6.5 Discussion 
This study aimed to examine the association between preeclampsia and ASD (overall 
and with/without intellectual disability) and has yielded two principal findings. First, 
exposure to preeclampsia was associated with 25% increased odds of ASD when 
compared to those unexposed, after controlling for known potential confounders. The 
sibling-matched analysis allowed us to further control for shared genetic and familial 
factors and reduced the HR to 1.17. However, when results were stratified by ASD 
with and without intellectual disability, the HRs were 1.32 and 1.13 respectively. 
These data are largely in line with a previous systematic review, which suggested that 
preeclampsia was associated with a 50% increase in the odds of ASD, with individual 
study estimates ranging from 0.90 to 2.36(56).  
Second, as SGA is closely associated with uteroplacental dysfunction(218), we 
combined preeclampsia and SGA as a crude proxy for preeclampsia with placental 
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dysfunction. This decision is also in line with the recent guidelines put forward by 
ISSHP to include uteroplacental dysfunction in the definition of preeclampsia(2). 
Being an SGA baby and exposed to preeclampsia was associated with a 95% increased 
odds of ASD when compared to non-exposure to preeclampsia or SGA. This HR 
increased to 3.07, when stratified by ASD with intellectual disability, and reduced to 
1.63 when stratified by ASD without intellectual disability(222). This observed 
preeclampsia and SGA relationship with ASD suggests that impaired placentation may 
be a common factor increasing the likelihood of ASD. Furthermore, the post-hoc 
analysis examining SGA-alone and ASD further supports this hypothesised 
mechanism given the modest effect of preeclampsia on likelihood of ASD compared 
to that of preeclampsia and SGA combined, or SGA-alone.  
The precise biological mechanisms contributing to a preeclampsia-ASD relationship 
are still unknown however. In a previous study, we demonstrated that exposure of fetal 
neurons to maternal serum from term preeclampsia altered fetal cortical neuronal 
growth and branching(21), while treatment of fetal cortical neurons with conditioned 
media from preeclamptic placentae also had similar effects, suggesting secreted 
factors may be important(223). Such factors may include inflammatory cytokines given 
that preeclampsia is associated with chronic immune activation, leading to a 
significant increase in the circulation of pro-inflammatory cytokines. Thus, while 
uncomplicated pregnancies have a normal systemic inflammatory response(73),  
preeclampsia results in a state of exaggerated maternal inflammation(73, 224). Therefore, 
maternal inflammation, a recognised risk factor for poor neurodevelopmental 
outcome, could act as a mediator between preeclampsia and development of ASD, and 




Straughen et al, 2017(225) demonstrated that placental inflammation of any type is 
associated with an increased likelihood of ASD, while circulating levels of maternal 
IL-6 have been shown to be inversely associated with brain connectivity and offspring 
cognition at 12 months of age, as well as short and long-term influences in offspring 
behaviour in separate studies(76, 77). This may also partially explain the increased HR 
when results were stratified by ASD with intellectual disability, as elevated mid-
gestational levels of numerous cytokines and chemokines such as GM-CSF, IFN-γ, 
IL-1α, and IL-6 are associated with ASD with intellectual disability, when compared 
to mothers of children with either ASD without intellectual disability, developmental 
delay, or general population controls(222). 
In terms of mediation, while very little data exist in humans, a recent study has shown 
that maternal depressive symptoms are associated with higher maternal inflammation, 
including IL-6, and this mediated the effect on maternal report of infant negative 
affect(226), a known risk factor for later adverse neurological outcomes. This may also 
suggest that preeclampsia-induced elevations in maternal IL-6 may act as a mediator 
of the preeclampsia-ASD association. 
Finally, the role of concurrent exposure to antihypertensive medication in the 
development of ASD was beyond the scope of this paper, and needs to be explored in 
future research. This research question could possibly be addressed using animal 
models such as the reduced uterine perfusion pressure (RUPP) model in rats, which 
mimics many physiological features of preeclampsia(227), in order to study the impact 
of antihypertensive medications administered using clinical relevant treatment 





Strengths and Limitations 
This study had several strengths. It is the largest epidemiological study to investigate 
the association between preeclampsia and ASD, with data on over 2.8 million births. 
Information on exposure and outcome status was classified according to ICD-coding, 
obtained from national registers. Therefore, selection bias and recall bias were not 
likely an issue. The use of registry data allowed us to control for a wide range of 
confounding variables, while conducting a sibling-matched analysis allowed us to 
further control, at least in part, for shared genetic and familial factors.  
However, several limitations may also pose a threat to validity of findings. One, each 
individual in the present study was followed-up until they reached a minimum of six 
years of age (i.e. those born in 2010 followed-up until 2016). While it is possible that 
not enough time had lapsed for a diagnosis of ASD to be received by some individuals, 
excluding births after 2006 to ensure everyone had at least 10 years of follow-up does 
not materially change results. Two, the prevalence of ASD in the current study was 
1.9%, compared to previous ASD studies conducted on this population who had a ~1% 
prevalence of ASD(19, 29). However, we included follow-up data until the end of 2016, 
whereas Sandin et al. and Curran et al.(19, 29) included follow-up data until the end of 
2009 and 2011 respectively. This means that each child in the present study was 
followed-up for 5-7 additional years compared to the two previous studies. If we 
restrict our follow-up date to 2011, it results in a more comparable prevalence to that 
of previous studies (~1%). Given that children are often not diagnosed with ASD until 
they are of school age, it is suspected that the extended follow-up is the reason for the 
difference in ASD prevalence(228). 
Three, severe cases may have been overrepresented in our data due to a reliance on 
inpatient psychiatric diagnoses until 2001(87). While results of a sensitivity analysis by 
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decade of birth (Table 6.3) were not significantly different from our main findings, 
the HR of 4.39 for SGA babies exposed to preeclampsia in children with ASD and 
intellectual disability born 2000-2010 warrants highlighting, and could possibly reflect 
an increased awareness of ASD or increased diagnostic specificity in recent decades. 
Four, a lack of robust data on gestational hypertension limited our analysis. Results of 
existing studies suggest a non-significant gestational hypertension-ASD 
relationship(56). However, if a gestational hypertension-ASD association existed, this 
would bias our results towards the null.   
Finally, despite controlling for several potential confounders, residual confounding 
may still be an issue. While this was reduced in the sibling-matched analysis, this 
method can only adjust for factors constant between pregnancies, therefore we cannot 
rule out the possibility of unmeasured confounding factors(229).  
 
Conclusion 
The apparent preeclampsia/SGA-ASD relationship suggests that placental pathology 
may be a common factor increasing the likelihood of ASD. Further research is needed 
to investigate the role that maternal inflammation may play, as well as the potential 









Table 6.1 Perinatal and sociodemographic characteristics related to preeclampsia and 
ASD among singleton live births in Sweden between 1982 and 2010 
 No. (%) of Infants 
Characteristic Total Population Preeclampsia 
Total Population 2842230 77600  (2.7) 
ASD 54071  (1.9) 2024  (2.6) 
ASD with intellectual disability 8981 (0.3) 388 (0.5) 
ASD without intellectual disability 45090 (1.6) 1636 (2.1) 
SGA 69355  (2.5) 9761  (12.7) 
First-born child 1210413  (42.6) 49756  (64.1) 
Sex (male)  1460940  (51.4) 40475  (52.2) 
Decade of birth   
1982-1989 773489  (27.2) 19596  (25.3) 
1990-1999 1006338  (35.4) 27635  (35.6) 
2000-2010 1062403  (37.4) 30369  (39.1) 
Maternal age, years   
<20  66946  (2.4) 2393  (3.1) 
20-29 1495876  (52.6) 41463  (53.4) 
30-39 1210467  (42.6) 31217  (40.2) 
≥40 68941  (2.4) 2527  (3.3) 
Gestational age, weeks    
<34  32,332  (1.1) 6375  (8.2) 
34 17,162  (0.6) 2276  (2.9) 
35 29,982  (1.1) 3080  (4.0) 
36 60,016  (2.1) 5155  (6.7) 
37 141036  (5.0) 8583  (11.1) 
38 386963  (13.6) 12516  (16.1) 
39 657765  (23.2) 14653  (18.9) 
40 799752  (28.2) 13942  (18.0) 
>40 712440  (25.1) 10894  (14.1) 
5-Minute Apgar score   
0-3 (low) 5530  (0.2) 307  (0.4) 
4-6 (intermediate) 20589  (0.7) 1599  (2.1) 
7-10 (high) 2772613  (99.1) 74412  (97.5) 
Delivery completed by caesarean 
section 
260,650 (9.2) 19,574 (25.2) 
Mother’s country of birth   
Sweden 2272714  (80.0) 64024  (82.5) 
Other Nordic country 85743  (3.0) 2309  (3.0) 
Other country 336123  (11.8) 6602  (8.5) 
Missing 147650  (5.2) 4665  (6.0) 
Father’s country of birth   
Sweden 2244697  (79.0) 63454  (81.2) 
Other Nordic country 76280  (2.7) 2008  (2.6) 
Other country 354182  (12.5) 6909  (8.9) 
Missing 167071  (5.9) 5229  (6.7) 
Maternal depression   
Never 2473216  (87.0) 66912  (86.3) 
Before birth 44440  (1.6) 1355  (1.7) 
After birth 177106  (6.2) 4676  (6.0) 
Missing 147468  (5.2) 4657  (6.0) 
Maternal bipolar disorder   
Never 2669867  (93.9) 72242  (93.1) 
Before birth 3527  (0.1) 115  (0.1) 
After birth 21368  (0.8) 586  (0.8) 
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Missing 147468  (5.2) 4657  (6.0) 
Maternal nonaffective disorders   
Never 2674249  (94.1) 72359  (93.2) 
Before birth 6898  (0.2) 207  (0.3) 
After birth 13615  (0.5) 377  (0.5) 
Missing 147468  (5.2) 4657  (6.0) 
Paternal depression   
Never 2564110  (90.2) 69636  (89.7) 
Before birth 24621  (0.9) 698  (0.9) 
After birth 106031  (3.7) 2609  (3.4) 
Missing 147468  (5.2) 4657  (6.0) 
Paternal bipolar disorder   
Never 2679318  (94.3) 72562  (93.5) 
Before birth 2661  (0.1) 75  (0.1) 
After birth 12783  (0.4) 306  (0.4) 
Missing 147468  (5.2) 4657  (6.0) 
Paternal nonaffective disorders   
Never 2675845  (94.1) 72458  (93.4) 
Before birth 7155  (0.3) 200  (0.2) 
After birth 11762  (0.4) 285  (0.4) 
Missing 147468  (5.2) 4657  (6.0) 
Smoking at first antenatal visit   
No 2186399  (76.9) 63720  (82.1) 
1-9 cigarettes/day 300389  (10.6) 5886  (7.6) 
≥10 cigarettes/day 165015  (5.8) 2849  (3.7) 
Missing 190427  (6.7) 5145  (6.6) 
BMI at first antenatal visit   
<20 312520  (11.0) 5139  (6.6) 
20-24.9 1200271  (42.2) 27112  (34.9) 
25-29.9 441373  (15.5) 16118  (20.8) 
≥30 167717  (6.0) 10300  (13.3) 
Missing 720349  (25.3) 18931  (24.4) 
Optimal gestational weight gain by 
BMI group at first antenatal visit (230) 
  
<20   
Optimum 45641  (1.6) 514  (0.7) 
Inadequate/Excessive 158243  (5.5) 2656  (3.4) 
20-24.9   
Optimum 141430  (5.0) 1958  (2.5) 
Inadequate 2563  (0.1) 43  (0.06) 
Excessive 512433  (18.0) 12424  (16.0) 
25-29.9   
Optimum 36368  (1.3) 803  (1.0) 
Excessive 172818  (6.1) 6,996  (9.0) 
≥30   
Optimum 14994  (0.5) 606  (0.8) 
Excessive 58340  (2.1) 3893  (5.0) 
Missing 1699400  (59.8) 47,707  (61.5) 
Income quintile   
First 513347  (18.1) 11098  (14.3) 
Second 532669  (18.7) 12625  (16.3) 
Third 537973  (18.9) 14611  (18.8) 
Fourth 540823  (19.0) 16657  (21.5) 
Fifth 536843  (18.9) 17281  (22.3) 
Missing 180575  (6.4) 5328  (6.8) 
Parental level of education at IP 
birthyear (available from 1990) 
  
Pre-high school 132,995  (4.7) 3,346  (4.3) 
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High school 891,979  (31.4) 26,755  (34.5) 
Post high school 888,712  (31.3) 24,098  (31.0) 
Missing 928544  (32.7) 23401  (30.2) 
Abbreviations: SGA=small for gestational age. BMI=body mass index. IP=index person. 
Categories were collapsed if cell count <10, for example, inadequate/excessive weight gain in 
women categorised as BMI<20 were combined for the purpose of displaying data only. 
If missing data >5%, number (%) of missing data reported. 
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Table 6.2 Association between preeclampsia and ASD with and without intellectual 











 Total population Sibling pairs 
 




HR (95% CI)a 
Model 2 
HR (95% CI)b 
Model 3 
HR (95% CI)c 
Preeclampsia 2,024 1.36 (1.31, 1.43) 1.25 (1.19, 1.30) 1.17 (1.06, 1.28) 
Preeclampsia and SGAd 326 1.79 (1.61, 2.00) 1.66 (1.49, 1.85) 1.95 (1.53, 2.48) 
Preeclampsia without SGA 1673 1.32 (1.26, 1.38) 1.20 (1.14, 1.26) 1.11 (1.01, 1.23) 
SGA only 1884 1.77 (1.69, 1.85) 1.60 (1.53, 1.67) 1.82 (1.65, 2.01) 
ASD with intellectual disability (n=8981)  
Preeclampsia 388 1.59 (1.44, 1.76) 1.56 (1.41, 1.73) 1.32 (1.07, 1.62) 
Preeclampsia and SGAd 90 3.11 (2.52, 3.82) 2.95 (2.40, 3.64) 3.07 (1.97, 4.79) 
Preeclampsia without SGA 287 1.42 (1.26, 1.60) 1.40 (1.24, 1.57) 1.15 (0.91, 1.45) 
ASD without intellectual disability (n=45090)  
Preeclampsia 1636 1.32 (1.26, 1.39) 1.19 (1.13, 1.25) 1.13 (1.01, 1.26) 
Preeclampsia and SGAd 236 1.54 (1.36, 1.76) 1.42 (1.25, 1.62) 1.63 (1.22, 2.19) 
Preeclampsia without SGA 1386 1.30 (1.23, 1.37) 1.17 (1.10, 1.23) 1.10 (0.98, 1.23) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. SGA=small for gestational age. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, birth 
order, parental depression, bipolar disorder and non-affective psychiatric disorders, maternal 
smoking status, BMI at first antenatal visit, gestational weight gain, family income and parental level 
of education. 
cAdjusted for same potential confounders as above with the exception of maternal country of birth. 
dReference=no preeclampsia/no SGA. 
Missing data on SGA for 25 cases of ASD (missing data on SGA for 11 cases of ASD with 
intellectual disability, and missing data on SGA for 14 cases of ASD without intellectual disability). 
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 Children born 1982-1989 Children born 1990-1999 Children born 2000-2010 
 ASD (n=10938) ASD (n= 24237) ASD (n= 18896) 
 
All ASD (n=54071) 
Exposed cases Model 2 
HR (95% CI)a 
Exposed cases Model 2 




HR (95% CI)a 
Preeclampsia 336 1.15 (1.03, 1.28) 898 1.23 (1.15, 1.32) 790 1.30 (1.21, 1.39) 
Preeclampsia and SGAb 50 1.34 (1.01, 1.77) 124 1.39 (1.16, 1.65) 152 2.14 (1.83, 2.51) 
Preeclampsia without SGA 281 1.14 (1.01, 1.28) 760 1.21 (1.13, 1.31) 632 1.20 (1.11, 1.30) 
ASD with intellectual disability  (n=8981) 
Preeclampsia 60 1.38 (1.07, 1.80) 176 1.53 (1.32, 1.79) 152 1.64 (1.39, 1.94) 
Preeclampsia and SGAb 14 2.57 (1.51, 4.36) 26 1.87 (1.27, 2.76) 50 4.39 (3.31, 5.81) 
Preeclampsia without SGA 44 1.25 (0.92, 1.69) 144 1.52 (1.28, 1.79) 99 1.29 (1.06, 1.58) 
ASD without intellectual disability  (n=45090) 
Preeclampsia 276 1.11 (0.98, 1.25) 722 1.17 (1.09, 1.27) 638 1.23 (1.14, 1.34) 
Preeclampsia and SGAb 36 1.13 (0.81, 1.56) 98 1.30 (1.06, 1.58) 102 1.71 (1.41, 2.08) 
Preeclampsia without SGA 237 1.12 (0.98, 1.28) 616 1.16 (1.07, 1.26) 533 1.18 (1.08, 1.29) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. SGA=small for gestational age. 
aAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, birth order, parental depression, bipolar disorder and non-affective 
psychiatric disorders, maternal smoking status, BMI at first antenatal visit, gestational weight gain, family income and parental level of education. 
bReference=no preeclampsia/no SGA 
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75592 multiple births excluded 
Live births recorded between  
1st January 1982 and 31st December 2010 
N=2941628 
 
21084 excluded due to 
censoring before their first 
birthday  
Children in the final cohort 
N=2842230 
2722 excluded as they turned 
one year of age before 1987 but 
were censored before follow-up 








Chapter 7: ASSOCIATION BETWEEN PREECLAMPSIA AND 
ATTENTION DEFICIT HYPERACTIVITY DISORDER: A 
POPULATION-BASED AND SIBLING-MATCHED COHORT 
STUDY 
 
Gillian M Maher1,2 MPH, Christina Dalman3,4 PhD, Gerard W O’Keeffe1,5 PhD, 
Patricia M Kearney2 PhD, Fergus P McCarthy1 PhD, Louise C Kenny6 PhD, Ali S 
Khashan1,2 PhD 
 
1The Irish Centre for Maternal and Child Health Research (INFANT), Cork University 
Maternity Hospital and University College Cork, Cork, Ireland. 
2School of Public Health, Western Gateway Building, University College Cork, Cork, 
Ireland. 
3Department of Public Health Sciences, Division of Public Health Epidemiology, 
Karolinska Institutet, Stockholm, Sweden. 
4Center for Epidemiology and Community Medicine, Stockholm County Council, 
Stockholm, Sweden. 
5Department of Anatomy and Neuroscience, Western Gateway Building, University 
College Cork, Cork, Ireland. 
6Department of Women’s and Children’s Health, Institute of Translational Medicine, 




Published in: Acta Psychiatrica Scandinavica (2020) (Appendix 26) 
 
7.1 Abstract 
Objective: Examine the association between preeclampsia and attention deficit 
hyperactivity disorder (ADHD), using a large Swedish-based registry cohort. 
Methods: This study comprised 2,047,619 children, with 114,934 (5.6%) cases of 
ADHD. Preeclampsia was based on two alternate definitions: 1. Preeclampsia (using 
ICD-9/ICD-10) 2. Preeclampsia and small for gestational age (SGA) combined. 
ADHD was determined in one of two ways: 1. If a diagnosis of ADHD was present in 
the National Patient Register or 2. If an individual was in receipt of ADHD medication 
in the Prescribed Drug Register. Multivariate Cox proportional hazards regression 
analysis allowed adjustment for several perinatal/sociodemographic factors. Sibling-
matched analysis further controlled for shared genetic and familial confounding. 
Results: In the adjusted Cox model, preeclampsia was associated with an increase in 
likelihood of ADHD (HR: 1.15, 95% CI: 1.12, 1.19). The HR for preeclampsia and 
those born SGA was 1.43 (95% CI: 1.31, 1.55) in the adjusted model, compared to 
those unexposed to preeclampsia/SGA. The sibling-matched analysis did not 
materially change these associations (HR: 1.13, 95% CI: 1.05, 1.22) and 1.55 (95% 
CI: 1.28, 1.88).  
Conclusions: Exposure to preeclampsia or preeclampsia/SGA was associated with 
ADHD, independent of genetic/familial factors shared by siblings. However, it is 
important to note that sibling-matched analysis can only adjust for factors that are 
constant between pregnancies, therefore residual confounding cannot be ruled out. 
Further research is needed to explore modifiable risk factors and identify those most-




Preeclampsia, which affects approximately 5% of all pregnancies(4), is one of the 
leading causes of maternal morbidity and mortality, and was recently redefined by the 
International Society for the Study of Hypertension in Pregnancy (ISSHP) as 
gestational hypertension accompanied by at least two of the following: proteinuria 
and/or other maternal organ dysfunction and/or uteroplacental dysfunction(2).  
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
characterised by inattention, hyperactivity and impulsivity. ADHD has a global pooled 
prevalence of over 5%, and while this estimate varies significantly worldwide, the 
variability can mostly be explained by methodological differences between studies(37, 
38). Despite high heritability estimates, gene environment interactions may also play a 
role(80). 
Preeclampsia has been linked to adverse neurodevelopmental outcomes, including 
ADHD(43, 56). Pooled results from a recent systematic review suggest that preeclampsia 
is associated with a 30% increase in odds of ADHD(56). It is worth noting however, 
that while an apparent relationship exists in previous literature, residual confounding 
and quality of the studies may be a concern. For example, only one of ten studies 
included in the systematic review controlled for a combination of key potential 
confounders, such as maternal age, socioeconomic status, ethnicity, and maternal 
mental illness(40, 56). 
Therefore, the aim of this study was to examine the association between preeclampsia 
and ADHD using a large population-based cohort study, controlling for a wide range 
of potential confounding factors, as well as shared genetic and familial confounding 





All singleton live births in Sweden from 1990 to 2010, with a follow-up until 
December 2016, were included in the study. Data were obtained from Swedish 
National Registers. These included the Medical Birth Register, National Patient 
Register, Prescribed Drug Register, Multi-generation Register, Total Population 
Register and Register of Education, linked using personal identification numbers 
assigned to Swedish residents(84). 
Ethical approval was previously obtained from the Stockholm Regional Ethical 
Review Board (number 2010/1185-31/5), and informed consent was waived by the 




Data on preeclampsia was obtained from the Medical Birth Register which contains 
data on over 97% of all births in Sweden(85). We used two alternate definitions of 
preeclampsia: 
1. Preeclampsia: Blood pressure ≥140/90 mmHg on or after 20 weeks’ gestation 
combined with proteinuria (≥0.3 g/day or ≥1 on a urine dipstick on at least two 
occasions). Preeclampsia was classified using the Swedish version of the ICD, Ninth 
and Tenth Revision(231): ICD‐9 until 1996 (codes 642E‐G) and ICD‐10 from 1997 
(codes O14‐O15)(16, 232). 
2. Preeclampsia and small for gestational age (SGA) combined: We combined 
preeclampsia (as above) and SGA as a proxy for preeclampsia with placental 
dysfunction(2). SGA was defined as birthweight <2 standard deviations below the 




Data on ADHD were obtained from the National Patient Register and the Prescribed 
Drug Register. The National Patient Register was launched in 1964, contains inpatient 
psychiatric diagnoses from 1973, and outpatient data since 2001 (with increasingly 
better coverage until 2006)(87, 88, 233). The Prescribed Drug Register was expanded on 
1st July 2005 to include personal identification numbers allowing linkage to other 
registers(88, 89).  
A diagnosis of ADHD was determined in one of two ways:  
1. If a diagnosis of ADHD was present in the National Patient Register, using ICD-10 
(code F90 and F98.8), available since 1997(88).  
2. If the subject was in receipt of ADHD medication in the Prescribed Drug Register. 
ADHD medication data was classified according to Anatomical Therapeutic Chemical 
classification system, and included amphetamine (N06BA01), dexamphetamine 
(N06BA02), psychostimulants methyphenidate (N06BA04) and noradrenergic 
reuptake inhibitor atomoxetine (N06BA09). 
 
Confounding Factors 
Potential confounders were based on previous literature. Year of birth, infant sex, 
maternal age, parental country of birth, parity, maternal smoking status, body mass 
index (BMI) at first antenatal visit and gestational weight gain were obtained from the 
Medical Birth Register. Parental depression, bipolar disorder, and non-affective 
psychiatric disorders were obtained from the National Patient Register. Family income 
and parental level of education data were obtained from the Total Population Register 
and Register of Education. Information on all cofounders was available for the entire 
study period. Where a variable had missing data, the data were added as a separate 
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category and included in the various Cox regression analyses by means of an indicator 
variable to ensure that all cases were included in the analyses(110). (Appendix 12). 
 
Statistical Analysis 
All data were analysed using Stata/MP 14.2. We conducted Cox proportional hazards 
regression analysis to calculate a hazard ratio (HR) and 95% confidence interval for a 
preeclampsia-ADHD relationship, preeclampsia/SGA-ADHD (i.e SGA baby exposed 
to preeclampsia) relationship and the relationship between preeclampsia without SGA 
and ADHD.  
Similar to a previous ADHD study conducted on this population (and because a 
diagnosis of ADHD is less likely to occur before this time)(88), follow-up began from 
a child’s third birthday, (or 1st January 1997 for children who turned three years of 
age before 1997). Children continued to be followed up until he/she received a 
diagnosis of ADHD, prescription for ADHD, death, emigration, or the study period 
had ended (31st December 2016). 
Partially adjusted models were stratified for year of birth in order to satisfy the 
proportional hazard assumption (model 1). Fully adjusted models (model 2) controlled 
for year of birth, infant sex, maternal age, parental country of birth, parity, parental 
depression, bipolar disorder, and non-affective psychiatric disorder, family income, 
maternal smoking status, BMI at first antenatal visit, gestational weight gain and 
parental level of education. 
Sibling-matched analysis: We conducted a sibling-matched analysis (model 3) to 
control for shared genetic and familial confounding, using stratified Cox regression. 
This analysis was matched on maternal ID and consisted of a separate stratum for each 
family in order to estimate the probability of ADHD within family(51). We adjusted for 
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the same potential confounders as model 2 with the exception of maternal country of 
birth as this is the same across sibling pairs. Finally, we repeated these analyses, firstly, 
including only those with both an ICD code for ADHD and if the subject was in receipt 
of ADHD medication, and secondly, including only those with an ICD code for 
ADHD. 
Post-hoc analysis: We examined the association between SGA only and ADHD 
compared to non-exposure to SGA/non-exposure to preeclampsia. 
E-value: We calculated the E-value for the statistically significant primary effect 
estimates and lower limits of their 95% confidence interval (CI) to examine the extent 
of unmeasured confounding, using the publicly available online E-value calculator: 
(https://evalue.hmdc.harvard.edu/app/)(234, 235). In summary, an E-value is a 
continuous measure that quantifies the minimum strength of association an 
unmeasured confounder would need to have with both preeclampsia and ADHD in 
order to explain away an effect estimate(235). 
Sensitivity analyses: We conducted several sensitivity analyses, decided a priori. For 
example, while classifying preeclampsia into mild/severe is not recommended in 
clinical practice because it is a complex disorder that can deteriorate rapidly, 
gestational age is sometimes used as a proxy for preeclampsia with severe features. 
As a result, preeclampsia could be considered severe if delivery occurred before 34 
weeks’ gestation(220). Therefore, we examined the association between preeclampsia 
and ADHD by gestational age. In addition, it is possible that a mother’s lifestyle 
factors could change between pregnancies. As a result, we excluded women who had 
preeclampsia in her first pregnancy, and examined a preeclampsia-ADHD relationship 
in women who had a diagnosis of preeclampsia in subsequent pregnancies only. 
Additional sensitivity analyses included restricting the study population to 2001-2010 
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(when outpatient data on ADHD started to become available), and restricting the study 
population to 1994-2010 to ensure every child begins follow-up at their third birthday. 
Furthermore, we included ‘preeclampsia excluding chronic hypertension’ as the 
exposure, and ‘preeclampsia with chronic hypertension’ as the exposure. We 
examined preeclampsia-ADHD excluding those with a family history of mental 
illness. We analysed the relationship between preeclampsia with low/intermediate 
APGAR score at five minutes, while we also examined a preeclampsia-ADHD 
relationship by maternal age, in addition to preeclampsia-ADHD by BMI group at 
time of first antenatal visit. Finally, we investigated a preeclampsia-ADHD association 




A total of 2,142,694 live births were recorded in the Swedish Medical Birth Register 
between 1990 and 2010. After excluding 61,172 multiple births, 30,636 children who 
were censored before their third birthday, and 3267 children who turned three years 
of age before 1997 but were censored before follow-up began on 1st January 1997, a 
total of 2,047,619 children remained in the final cohort (Table 7.1).  
There were 57,493 (2.8%) children exposed to preeclampsia and 7191 (0.4%) exposed 
to preeclampsia and SGA combined. There were 114,934 (5.6%) cases of ADHD. Of 
these 101,075 (87.9%) cases were prescribed ADHD medication at some point, and 
94,708 (82.4%) cases had an ICD diagnosis. A total of 80,849 (70.3%) cases were 
recorded with both an ICD code and medication, while there were 13,859 (12.1%) 




Association between preeclampsia, preeclampsia/SGA and ADHD 
In the fully adjusted model (model 2), the results suggested an association between 
preeclampsia and ADHD (HR: 1.15, 95% CI: 1.12, 1.19) compared to those 
unexposed to preeclampsia. Result of the sibling-matched analysis (model 3) did not 
significantly change (HR: 1.13, 95% CI: 1.05, 1.22). The HR for those born SGA and 
exposed to preeclampsia was 1.43 (95% CI: 1.31, 1.55) in the adjusted model (model 
2), and 1.55 (95% CI: 1.28, 1.88) in the sibling-match model (model 3), while the HR 
for those exposed to preeclampsia but not born SGA was 1.12 (95% CI: 1.08, 1.16) in 
model 2, and 1.09 (95% CI: 1.01, 1.18) in model 3. Limiting the data to those with 
both an ICD code and medication data did not materially change results, while 




The adjusted HR for SGA only (i.e. SGA without preeclampsia) and ADHD was 1.32 
(95% CI: 1.27, 1.37), while the HR in the sibling-matched analysis was 1.29 (95% CI: 




The E-values for significant primary effect estimates were 1.51 for preeclampsia, 2.47 
for preeclampsia with SGA and 1.40 for preeclampsia without SGA, while the E-
values for corresponding lower limits of their 95% CI were 1.28, 1.88 and 1.11 





Preeclampsia and ADHD by gestational age 
When we restricted analysis to children born ≥39 weeks’ gestational age, the HR for 
a preeclampsia-ADHD relationship was 1.07 (95% CI: 1.02, 1.12). Among children 
born at 37-38 weeks’, the HR in those exposed to preeclampsia was 1.20 (95% CI: 
1.13, 1.28), while the HR among those not exposed to preeclampsia was 1.09 (95% 
CI: 1.08, 1.11), when compared to non-exposure to preeclampsia in those born ≥39 
weeks’ gestational age. Exposure to preeclampsia (among children born 34-36 
weeks’) was associated with a 24% increase in likelihood of ADHD (HR: 1.24, 95% 
CI: 1.14, 1.35), while those unexposed to preeclampsia had a 14% increased likelihood 
of ADHD among those born at a similar gestational age (HR: 1.14, 95% CI: 1.11, 
1.18). Finally, the HR among those exposed to preeclampsia (born <34 weeks’ 
gestational age) was 1.74 (95% CI: 1.60, 1.91), while the HR among those not exposed 
to preeclampsia (born <34 weeks’ gestational age) was 1.49 (95% CI: 1.42, 1.96) when 
compared to non-exposure to preeclampsia among those born ≥39 weeks’ gestational 
age (Table 7.3).  
 
Additional sensitivity analyses 
Results of additional sensitivity analyses are outlined in Appendix 17 and Appendix 
18 and were not materially different from the primary analysis. In sum, when we 
excluded women who had preeclampsia in their first pregnancy, the adjusted HR was 
1.21. When we restricted the study population to 2001-2010 and 1994-2010, the HR 
was 1.21 and 1.14 respectively. The fully adjusted HR for preeclampsia (excluding 
chronic hypertension) and preeclampsia (with chronic hypertension) were 1.15 and 
1.18 respectively. The HR for preeclampsia (excluding those with a family history of 
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mental illness was 1.16. Preeclampsia (with low/intermediate APGAR at 5 minutes) 
increased the likelihood of ADHD by 13% when compared to non-exposure to 
preeclampsia in those with a low/intermediate APGAR score. Results of the subgroup 
analysis suggested that preeclampsia was significantly associated with ADHD at each 
category of maternal age and at each category of BMI at first antenatal visit. The HR 
for preeclampsia-ADHD in males was 1.18 compared to non-exposure to 
preeclampsia in males, while the HR for preeclampsia-ADHD in females was 1.10 
compared to non-exposure to preeclampsia in females.  Finally, exposure to 
preeclampsia in males was associated with a 9% increase in likelihood of ADHD when 
compared to exposure to preeclampsia in females. 
 
7.5 Discussion 
The aim of this study was to examine the association between preeclampsia and 
preeclampsia/SGA and ADHD, using a large population-based cohort study. We have 
yielded three principal findings. First, after controlling for known potential 
confounding factors, preeclampsia was associated with a 15% increase in likelihood 
of ADHD when compared to non-exposure to preeclampsia. This finding was similar 
in the sibling-matched analysis suggesting that this apparent preeclampsia-ADHD 
relationship was not due to shared genetics or familial environment. This result is in 
line with the pooled estimate from a systematic review, which suggested that 
preeclampsia was associated with a 30% increase in odds of ADHD, with individual 
study estimates ranging from 1.19 to 1.50(56).  
Second, as SGA is associated with uteroplacental dysfunction(218), and due to recent 
guidelines put forward by ISSHP to include uteroplacental dysfunction in the 
definition of preeclampsia, we combined preeclampsia and SGA into a single exposure 
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as a crude proxy for preeclampsia with placental dysfunction. Being an SGA baby and 
exposed to preeclampsia was associated with a 43% increase in likelihood of ADHD 
in the fully adjusted model, and a 55% increase in likelihood of ADHD in the sibling-
matched analysis, when compared to non-exposure to preeclampsia or SGA. This may 
suggest that placental pathology may be a common factor increasing the likelihood of 
ADHD given the stronger association with preeclampsia/SGA than preeclampsia 
alone.  
Three, preeclampsia was associated with ADHD, independent of gestational age. For 
example, preeclampsia was associated with a 7% increase in likelihood of ADHD 
when we restricted the analysis to those born ≥39 weeks’ gestation. However, the HR 
increases to 1.74 among those exposed to preeclampsia and born at <34 weeks’ 
gestation. 
This apparent preeclampsia-ADHD association may lack specificity however, as 
preeclampsia is associated with several neurodevelopmental outcomes such as autism 
spectrum disorder (ASD), cognitive impairment and intellectual disability (ID) in 
previous literature(56). Therefore, preeclampsia could in fact be a risk factor for poor 
neurodevelopmental outcome in general, with the specificity of outcome (e.g. ADHD, 
ASD, ID etc.) being determined by underlying genetic risk factors(200). 
 
Potential Mechanisms 
The molecular basis of a preeclampsia-ADHD relationship remains unknown, and 
there are few studies that address the potential biological mechanisms of ADHD 
specifically. Animal models have shown that activation of interleukin-17a (IL-17a) in 
the fetal brain, in response to maternal immune activation, is associated with 
behavioural disturbances and an abnormal cortical phenotype in affected offspring(22, 
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236). Therefore, we can speculate that maternal inflammation may be one such 
mechanism given the role of preeclampsia in chronic immune activation and elevated 
levels of inflammatory cytokines such as IL-17a(22, 73, 224). In a separate study, maternal 
depressive symptoms throughout pregnancy were shown to be associated with ADHD 
in offspring(237). As prenatal depression is linked to an increase in levels of pro-
inflammatory cytokines(238), it is possible that the inflammatory response observed in  
preeclampsia may have a similar inflammatory mediated effect on ADHD-risk.  
However, it may also be possible that lifestyle factors not available in the registers, 
such as maternal alcohol consumption may also play a role. Alcohol consumption 
during pregnancy has been shown to affect placentation, fetal growth, and likelihood 
of ADHD(239, 240). As preeclampsia is, at least in part, a disease of placentation, leaving 
the fetus vulnerable to the effects of placental pathology, particularly fetal growth 
restriction(2), it is plausible that maternal alcohol consumption during pregnancy may 
contribute the observed preeclampsia-ADHD association.  
 
Strengths and Limitations 
There are several strengths in this study. To our knowledge, it is the largest 
epidemiological study to examine the association between preeclampsia-ADHD to 
date. Use of National Registers minimised recall bias, while also allowed us to control 
for a wide range of confounding factors. In addition, the sibling-matched analysis 
allowed us to adjust for unmeasured confounding factors shared by siblings such as 
family environment, diet, lifestyle factors, maternal characteristics, and genetic 
factors(98). Furthermore, use of the E-value allowed us to quantify Bradford-Hill’s 
consideration of ‘strength of association’ in an attempt to investigate the robustness of 
our effect estimates to unmeasured confounding(235).  
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However, this study also contains several limitations. First, sibling-matched analysis 
may have reduced confounding due to shared genetic and familial factors. However, 
this method can only adjust for factors that are constant between pregnancies(229) and 
the possibility of residual confounding cannot be ruled out in observational studies. 
Taking preeclampsia-ADHD as an example: (E-value for effect estimate = 1.51), an 
unmeasured confounder associated with both preeclampsia and ADHD by a risk-ratio 
of 1.51 may potentially explain away our preeclampsia-ADHD effect estimate of 1.13. 
However, the effect-estimate for preeclampsia/SGA combined is less likely to be 
explained away by unmeasured confounding with an E-value of 2.47. Nonetheless, we 
cannot dismiss the potential effect of factors such as maternal alcohol consumption 
could have on findings.  Second, a lack of robust data on gestational hypertension 
limited our analysis to preeclampsia-ADHD only. Therefore, our comparison groups 
may contain women with a diagnosis of gestational hypertension, and while previous 
literature suggests a positive gestational hypertension-ADHD association(241), this 
would likely bias our results towards to the null. Third, as outpatient data only started 
becoming available in 2001, more severe cases of ADHD may have been 
overrepresented in our data. However, when we restricted the study population to 
2001-2010, results were not materially different from our main findings suggesting 




This population-based cohort suggests that preeclampsia as well as preeclampsia/SGA 
was associated with ADHD. Placental pathology may be a common mechanism 
increasing the likelihood of ADHD given the stronger association with 
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preeclampsia/SGA, rather than preeclampsia alone. Further research is needed in order 
to clarify this association, explore modifiable risk factors and identify those most-at-
























Table 7.1 Perinatal and sociodemographic characteristics related to preeclampsia and 
ADHD among singleton live births in Sweden between 1990 and 2010 
 No. (%) of Infants 
Characteristic Total Population Preeclampsia 
Total Population 2047619 57493 (2.8) 
ADHD 114934 (5.6) 3941 (6.9) 
SGA 46719  (2.3) 7191 (12.6) 
First-born child 879954  (42.9) 37642 (65.5) 
Sex (male)  1052095 (51.4) 29938 (52.1) 
Maternal age, years 
<20  41285 (2.0) 1535  (2.7) 
20-29 1015666 (49.6) 29354  (51.1) 
30-39 935055 (45.7) 24569 (42.7) 
≥40 55613 (2.7) 2035 (3.5) 
Gestational age, weeks 
<34  23538 (1.1) 5048 (8.8) 
34 12181 (0.6) 1702  (3.0) 
35 20845 (1.0) 2337 (4.1) 
36 41472 (2.0) 3868  (6.7) 
37 98759 (4.8) 6385 (11.2) 
38 277445 (13.6) 9153 (15.9) 
39 472125  (23.1) 10632  (18.5) 
40 580209  (28.4) 10128 (17.6) 
>40 519037 (25.4) 8162 (14.2) 
5-Minute Apgar score 
0-3 (low) 3419 (0.2) 228 (0.4) 
4-6 (intermediate) 15330  (0.8) 1251 (2.2) 
7-10 (high) 2013115 (99.0) 55464 (97.4) 
Mother’s country of birth 
Sweden 1597528 (78.0) 47286 (82.2) 
Other Nordic country 44704  (2.2) 1301 (2.3) 
Other country 278978 (13.6) 5709  (9.9) 
Missing 126409 (6.2) 3197 (5.6) 
Father’s country of birth  
Sweden 1577672 (77.1) 46891 (81.6) 
Other Nordic country 42429 (2.1) 1184 (2.0) 
Other country 287522 (14.0) 5820 (10.1) 
Missing 139996 (6.8) 3598 (6.3) 
Maternal depression  
Never 1763485 (86.1) 49730 (86.5) 
Previously diagnosed 157876 (7.7) 4574 (7.9) 
Missing 126258 (6.2) 3189 (5.6) 
Maternal bipolar disorder 
Never 1904427 (93.0) 53772 (93.5) 
Previously diagnosed 16934  (0.8) 532 (0.9) 
Missing 126258 (6.2) 3189 (5.6) 
Maternal nonaffective disorder 
Never 1909156 (93.2) 53923 (93.8) 
Previously diagnosed 12205 (0.6) 381 (0.6) 
Missing 126258 (6.2) 3189 (5.6) 
Paternal depression 
Never 1831285  (89.4) 51886 (90.2) 
Previously diagnosed 90076 (4.4) 2418 (4.2) 
Missing 126258 (6.2) 3189 (5.6) 
Paternal bipolar disorder 
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Never 1911454 (93.3) 54058 (94.0) 
Previously diagnosed 9907 (0.5) 246 (0.4) 
Missing 126258 (6.2) 3189 (5.6) 
Paternal nonaffective disorder 
Never 1909156 (93.2) 53980  (93.9) 
Previously diagnosed 12205 (0.6) 324 (0.5) 
Missing 126258 (6.2) 3189 (5.6) 
Income quintile 
First 362540 (17.7) 8168  (14.2) 
Second 383691 (18.7) 9542 (16.6) 
Third 388138 (19.0) 11044 (19.2) 
Fourth 390219 (19.1) 12509 (21.8) 
Fifth 384890 (18.8) 12772 (22.2) 
Missing 138141 (6.7) 3458 (6.0) 
Smoking at first antenatal visit 
No 1683882 (86.4) 49417 (90.7) 
1-9 cigarettes/day 178176 (9.1) 3576 (6.5) 
≥10 cigarettes/day 87699 (4.5) 1515 (2.8) 
BMI at first antenatal visit 
<20 172519 (8.4) 3048 (5.3) 
20-24.9 868599 (42.4) 19449 (33.8) 
25-29.9 372026 (18.2) 13037 (22.7) 
≥30 154136 (7.5) 9415 (16.4) 
Missing 480339 (23.5) 12544 (21.8) 
Optimal gestational weight gain by BMI group at first antenatal visit(230)  
<20   
Optimum 15910 (0.8) 211 (0.4) 
Inadequate/Excessive 49130 (2.4) 891 (1.6) 
20-24.9   
Optimum 75448 (3.7) 1003 (1.7) 
Inadequate/Excessive 254217 (12.4) 5855 (10.2) 
25-29.9   
Optimum 25752 (1.3) 527 (0.9) 
Excessive 115893 (5.7) 4260 (7.4) 
≥30   
Optimum 12147 (0.6) 461 (0.8) 
Excessive 48240 (2.3) 3180 (5.5) 
Missing 1450882 (70.8) 41105 (71.5) 
Highest parental level of education at child’s birthyear 
Pre-high school 131210 (6.4) 3304 (5.7) 
High school 886656 (43.3) 26603 (46.3) 
Post high school 877980 (42.9) 23844 (41.5) 
Missing 151773 (7.4) 3742 (6.5) 
Abbreviations: SGA=small for gestational age. BMI=body mass index. 
Categories were collapsed if cell count <10, for example, inadequate/excessive weight gain in 
women categorised as BMI<20 were combined for the purpose of displaying data only. 







Table 7.2 Association between preeclampsia and ADHD among singleton live births 







 Total population Sibling pairs 
 




HR (95% CI)a 
Model 2 
HR (95% CI)b 
Model 3 
HR (95% CI)c 
Preeclampsia 3941 1.22 (1.18, 1.26) 1.15 (1.12, 1.19) 1.13 (1.05, 1.22) 
Preeclampsia and SGAd 582 1.49 (1.37, 1.61) 1.43 (1.31, 1.55) 1.55 (1.28, 1.88) 
Preeclampsia without SGA 3322 1.19 (1.15, 1.23) 1.12 (1.08, 1.16) 1.09 (1.01, 1.18) 
SGA without Preeclampsia 3205 1.51 (1.45, 1.56) 1.32 (1.27, 1.37) 1.29 (1.19, 1.39) 
ADHD (ICD code and in receipt of medication) (n=80849)  
Preeclampsia 2795 1.23 (1.18, 1.27) 1.16 (1.11, 1.20) 1.11 (1.02, 1.21) 
Preeclampsia and SGAd 399 1.44 (1.31, 1.59) 1.37 (1.25, 1.52) 1.54 (1.23, 1.92) 
Preeclampsia without SGA 2370 1.21 (1.16, 1.26) 1.13 (1.08, 1.18) 1.07 (0.98, 1.17) 
ADHD (ICD code only) (n=94708) 
Preeclampsia 3267 1.23 (1.18, 1.27) 1.16 (1.12, 1.20) 1.11 (1.03, 1.20) 
Preeclampsia and SGAd 480 1.48 (1.35, 1.62) 1.41 (1.29, 1.55) 1.48 (1.21, 1.82) 
Preeclampsia without SGA 2757 1.20 (1.16, 1.25) 1.13 (1.09, 1.18) 1.07 (0.99, 1.17) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. SGA=small for gestational age. 
ICD=International Classification of Disease. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, parental country of birth, parity, parental  
depression, bipolar disorder, and non-affective psychiatric disorders, family income, maternal smoking 
status, BMI at first antenatal visit, gestational weight gain and parental level of education. 
cAdjusted for same potential confounders as above with the exception of maternal country of birth. 
dReference=no preeclampsia/no SGA. 
Missing data on SGA for 37 cases of ADHD (full cohort). Missing data on SGA for 26 cases of ADHD 




Table 7.3 Association between preeclampsia and ADHD among singleton live births 
in Sweden between 1990 and 2010 by gestational age 
  
 Total population 
 




HR (95% CI)a 
Model 2 
HR (95% CI)b 
No Preeclampsia, ≥39 weeks’ gestational age (ref) 82844 1.00 1.00 
Preeclampsia, ≥39 weeks’ gestational age 1808 1.14 (1.09, 1.20) 1.07 (1.02, 1.12) 
No Preeclampsia, 37-38 weeks’ gestational age 21742 1.13 (1.12, 1.15) 1.09 (1.08, 1.11) 
Preeclampsia, 37-38 weeks’ gestational age 1066 1.28 (1.20, 1.36) 1.20 (1.13, 1.28) 
No Preeclampsia, 34-36 weeks’ gestational age 4545 1.28 (1.24, 1.32) 1.14 (1.11, 1.18) 
Preeclampsia, 34-36 weeks’ gestational age 568 1.32 (1.22, 1.44) 1.24 (1.14, 1.35) 
No Preeclampsia, <34 weeks’ gestational age 1703 1.78 (1.70, 1.87) 1.49 (1.42, 1.56) 
Preeclampsia, <34 weeks’ gestational age 491 1.85 (1.69, 2.02) 1.74 (1.60, 1.91) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. ref=reference category. SGA=small 
for gestational age. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, parental country of birth, parity, parental  
depression, bipolar disorder, and non-affective psychiatric disorders, family income, maternal smoking 
status, BMI at first antenatal visit, gestational weight gain and parental level of education. 
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Chapter 10: UPDATED SYSTEMATIC REVIEW AND META-




An updated search of the literature was conducted using similar methods as outlined 
in Chapter 4. As discussed in the original systematic review, it is possible that 
keywords such as “perinatal complication” OR “prenatal complication” OR 
“obstetric* complication” were lacking in the original search. Therefore, we included 
these words in the updated search. A search PubMed, CINAHL, EMBASE, PsycINFO 
and Web of Science was performed from June 7, 2017 through 17th January 2020.  
After removal of duplicates, this resulted in 837 new titles and abstracts to screen for 
inclusion in the updated systematic review. Of these, four new ASD studies (including 
the study presented in Chapter 6), and three new ADHD studies (including the study 
presented in Chapter 7) were identified.  
Among the ASD studies, two case-control studies(267, 268) (one US multisite study and 
one study from Northern Taiwan), and two cohort studies(242, 269) (one from South 
California and our Swedish-based study presented in Chapter 6) were included. As 
one of the studies included in the original review examined a preeclampsia-ASD 
relationship based on data from the Swedish National Registers(14), this study was 
excluded in the updated analysis. 
Among the ADHD studies, three cohort studies were included in the update(43, 241, 243) 
(one multi-centre European cohort, one study from United Kingdom, and our 
Swedish-based study presented in Chapter 7). Similar to above, as one of the studies 
included in the original review examined a preeclampsia-ADHD relationship based on 
data from the Swedish National Registers(44), this study was excluded in the updated 
analysis. 
Both crude and adjusted estimates were included in the updated forest plots. As 
chapters 6 and 7 include traditional statistical adjustment and sibling-matched 
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analysis, the latter was considered the ‘fully adjusted’ result for inclusion in the 
updated analysis. 
 
10.2 Updated meta-analysis results 
10.2.1 Autism Spectrum Disorder 
The updated, crude pooled estimate examining a HDP-ASD relationship was 1.43 
(95% CI: 1.29, 1.58). The subgroup analyses, examining a preeclampsia-ASD and 
other HDP-ASD relationship separately, resulted in an OR of 1.43 (95% CI: 1.24, 
1.64), and 1.47 (95% CI: 1.22, 1.76) respectively. These results were slightly higher 
than the crude estimates in the original systematic review, however not significantly 
different. (Table 10.1 and Figure 10.1). 
The updated, adjusted pooled estimate was 1.33 (95% CI: 1.17, 1.52). Subgroup 
analysis examining the preeclampsia-ASD relationship resulted in an OR of 1.36 (95% 
CI:  1.18, 1.58), while the relationship between other HDP-ASD produced a non-
significant OR of 1.29 (95% CI: 0.97, 1.71). Again, these results were not materially 
different from those in the original systematic review. (Table 10.1 and Figure 10.1). 
 
10.2.2 Attention Deficit Hyperactivity Disorder 
The crude pooled estimate suggested that HDP was associated with an over 30% 
increased odds of ADHD when compared to those unexposed (OR: 1.31, 95% CI: 
1.22, 1.42). In the subgroup analyses examining preeclampsia-ADHD, and other 
HDP-ADHD, the OR was 1.29 (95% CI: 1.20, 1.40) and 1.76 (95% CI: 1.27, 2.46) 
respectively. Adjusted pooled estimates suggested HDP was associated with 26% 
increased odds of ADHD (OR: 1.26, 95% CI: 1.15, 1.38). For the subgroup analysis 
examining the preeclampsia-ADHD relationship, the OR was 1.23 (95% CI: 1.13, 
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1.35), and for other HDP-ADHD relationship, the OR was 1.80 (95% CI: 1.25, 2.59). 
These results are similar to what was observed in the original systematic review. 

























Table 10.1 Comparison of pooled results between the original systematic review and 
updated systematic review 
ASD Original systematic review Updated systematic review 
Crude results OR (95% CI) OR (95% CI) 
Overall HDP-ASD 1.41 (1.22, 1.64) 1.43 (1.29, 1.58) 
Preeclampsia-ASD 1.37 (1.07, 1.75) 1.43 (1.24, 1.64)  
Other HDP-ASD 1.43 (1.17, 1.73) 1.47 (1.22, 1.76) 
Adjusted results   
Overall HDP-ASD 1.35 (1.11, 1.64) 1.33 (1.17, 1.52) 
Preeclampsia-ASD 1.50 (1.26, 1.78) 1.36 (1.18, 1.58) 
Other HDP-ASD 1.25 (0.90, 1.73) 1.29 (0.97, 1.71) 
ADHD   
Crude results   
Overall HDP-ADHD 1.32 (1.20, 1.45) 1.31 (1.22, 1.42) 
Preeclampsia-ADHD 1.31 (1.19, 1.44) 1.29 (1.20, 1.40) 
Other HDP-ADHD 1.62 (1.07, 2.47) 1.76 (1.27, 2.46) 
Adjusted results   
Overall HDP-ADHD 1.29 (1.22, 1.36) 1.26 (1.15, 1.38) 
Preeclampsia-ADHD 1.28 (1.22, 1.36) 1.23 (1.13, 1.35) 
Other HDP-ADHD 1.70 (1.06, 2.72) 1.80 (1.25, 2.59) 











































Chapter 11: DISCUSSION 
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11.1 Summary of Main Findings 
This thesis aimed to examine the association between HDP, in particular preeclampsia, 
and neurodevelopmental disorders in offspring. Specifically, this thesis includes a 
systematic review and meta-analysis of available published literature (based on a pre-
prepared protocol), and a narrative review providing a perspective on how maternal 
inflammation may lead to altered neurodevelopmental outcomes in preeclampsia-
exposed offspring. Also contained within this thesis are original investigations 
examining the association between preeclampsia and ASD, and ADHD (using 
Swedish National Registers), and child development and behavioural outcomes (using 
data from the Growing Up in Ireland study). This chapter reviews the findings of our 
analyses, and discusses the strengths and limitations, future directions and overall 
conclusions. 
 
11.1.1 Findings from Systematic Review and Meta-analysis 
A systematic review and meta-analysis was conducted to synthesise the available 
published literature on the relationship between HDP and neurodevelopmental 
disorders in the offspring (chapter 4). The systematic review was based on a pre-
prepared protocol (chapter 3) and included studies until June 2017.  
A total of 20 ASD-studies were identified for inclusion in the systematic review. Of 
these, 11 unique studies reported adjusted estimates. Pooled adjusted estimates suggest 
that exposure to HDP is associated with a 35% increased odds of ASD when compared 
to those unexposed (OR of 1.35, 95% CI: 1.11, 1.64). A subgroup analysis of adjusted 
results examining a preeclampsia-ASD relationship resulted in an OR of 1.50 (95% 
CI:  1.26, 1.78), while the relationship between other HDP-ASD was non-significant 
with an OR of 1.25 (95% CI: 0.90, 1.73). The updated search of the literature identified 
201 
 
four new ASD studies (including the study presented in Chapter 6). However, pooled 
results were not materially different from results observed in the original review (i.e. 
adjusted pooled estimate was 1.33 (95% CI: 1.17, 1.52), subgroup analyses examining 
preeclampsia-ASD and other HDP-ASD resulted in ORs of 1.36 (95% CI:  1.18, 1.58), 
and 1.29 (95% CI: 0.97, 1.71) respectively. (Table 10.1 and Figure 10.1). 
For ADHD, ten studies were identified in which a diagnosis of HDP was reported and 
ADHD was the outcome of interest. Of these, six unique studies included adjusted 
estimates. Adjusted pooled estimates suggested that offspring exposed to HDP are 
almost 30% more likely to be diagnosed with ADHD compared to those unexposed 
(OR: 1.29, 95% CI: 1.22, 1.36). Adjusted results of the subgroup analysis examining 
a preeclampsia-ADHD relationship and other HDP-ADHD relationship produced an 
OR of 1.28 (95% CI: 1.22, 1.36), and 1.70 (95% CI: 1.06, 2.72) respectively. Three 
new studies on ADHD were identified in the updated search (including the study 
presented in Chapter 7) and included in the analysis. The updated adjusted results 
indicated that exposure to HDP was associated with a 26% increased odds of ADHD 
(OR: 1.26, 95% CI: 1.15, 1.38). The subgroup analysis examining preeclampsia-
ADHD and other HDP-ADHD resulted in an OR of 1.23 (95% CI: 1.13, 1.35) and 
1.80 (95% CI: 1.25, 2.59) respectively. Therefore, updated pooled results were not 
significantly different from the original systematic review. (Table 10.1 and Figure 
10.2). 
Results from previous literature examining the relationship between HDP and other 
neurodevelopmental, cognitive or behavioural outcomes could not be pooled due to 
methodological differences between studies, particularly differences in population and 
outcome assessment methods. Results were inconsistent, however some patterns of 
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association were observed between preeclampsia and cognitive impairment(57, 58, 60, 61, 
69, 149), as well as a potential link between HDP and intellectual disability(36, 62, 63, 150). 
The systematic review also highlighted some important limitations of previous 
literature, which we attempted to address in this thesis. For example, previous 
literature was often limited by small sample sizes as a quarter of ASD-studies and 
almost a third of ADHD-studies had fewer than ten exposed cases. Furthermore, 
residual or unmeasured confounding is of particular concern. There were some studies 
that failed to control for any potential confounding factors in the analysis phase of the 
study, and only one ASD-study(21) and one ADHD-study(40) controlled for a 
combination of potential confounders such as maternal age, socio-economic status, 
ethnic origin and family history of mental illness. Therefore, while results of the 
systematic review and meta-analysis indicate that exposure to HDP is associated with 
a small increase in the likelihood of ASD and ADHD, more robust research was 
needed addressing key limitations in the literature before more definitive conclusions 
could be reached.  
 
11.1.2 Findings on Autism Spectrum Disorder 
In chapter 6, we examined the association between preeclampsia and ASD using data 
from Swedish National Registers, and yielded two principal findings. First, adjusted 
results suggest that exposure to preeclampsia was associated with 25% increased odds 
of ASD when compared to those unexposed, after controlling for potential 
confounding factors (HR: 1.25, 95% CI: 1.19, 1.30). The sibling-matched analysis 
allowed us to further control for shared genetic and familial factors and reduced the 
HR to 1.17 (95% CI: 1.06, 1.28). However, when results were stratified by ASD with 
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and without intellectual disability, the HRs were 1.32 (95% CI: 1.07, 1.62) and 1.13 
(95% CI: 1.01, 1.26) respectively, in the sibling-matched analysis.  
Second, results of the sibling-matched analysis suggest that being an SGA baby and 
exposed to preeclampsia was associated with a 95% increased odds of ASD when 
compared to non-exposure to preeclampsia or SGA (95% CI: 1.53, 2.48). This HR 
increased to 3.07, when stratified by ASD with intellectual disability, and reduced to 
1.63 when stratified by ASD without intellectual disability. 
Preeclampsia is, at least in part, a disease of placentation and/or uteroplacental 
dysfunction. As a result, exposure to preeclampsia may leave the fetus vulnerable to 
the effects of placental pathology, particularly fetal growth restriction(2, 218). As the 
definition of SGA in the Swedish Medical Birth Register (birthweight <2 standard 
deviations below the mean of the sex-specific and gestational age distributions)(98) 
approximately represents infants born with a birthweight <2.5th percentile, this could 
also be an indicator of  intrauterine growth restriction (IUGR)(270). Therefore, the 
observed preeclampsia and SGA relationship with ASD suggests that placental 
pathology may be a mechanism for the increased likelihood of ASD. On further 
investigation, our post-hoc analysis examining SGA-alone and ASD (HR: 1.82, 95% 
CI: 1.65, 2.01) supports this hypothesised mechanism given the modest effect of 
preeclampsia on likelihood of ASD compared to that of preeclampsia and SGA 
combined, or SGA-alone.  
Furthermore, as recent guidelines proposed by ISSHP now include uteroplacental 
dysfunction (such as fetal growth restriction) in the definition of preeclampsia(2), it 
could be argued that a diagnosis of preeclampsia and SGA combined could be 
characterised as a more “severe” phenotype of preeclampsia, leading to an increased 
likelihood of ASD when compared to preeclampsia alone. In addition to this, results 
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of a sensitivity analysis (Appendix 14) suggested that exposure to preeclampsia in 
those born at <34 weeks’ gestational age (used as a proxy for preeclampsia with severe 
features)(220) were over twice as likely to be diagnosed with ASD when compared to 
non-exposure to preeclampsia in those born at ≥34 weeks’ gestation (HR: 2.04, 95% 
CI: 1.81, 2.30). This analysis further supports the notion that preeclampsia with severe 
features may lead to a stronger association with ASD.  
With regards to the stronger association when results were stratified by ASD with 
intellectual disability, this could potentially be explained by increased circulating 
levels of maternal cytokines and chemokines in pregnancies complicated by 
preeclampsia(222). Previous evidence suggests that mothers of children with ASD with 
intellectual disability had significantly elevated mid-gestational levels of numerous 
cytokines and chemokines, such as GM-CSF, IFN-γ, IL-1α, and IL-6, compared to 
mothers of children with ASD without intellectual disability, developmental delay, or 
general population controls(222). These results are indicative of maternal immune 
activation leading to a shift in the immune balance during pregnancy, potentially 
affecting developmental programming and the neurodevelopmental trajectory of the 
child(222). 
 
11.1.3 Findings on Attention Deficit Hyperactivity Disorder 
In chapter 7, we examined the association between preeclampsia and ADHD using 
data from Swedish National Registers. After controlling for several perinatal and 
sociodemographic factors, preeclampsia was associated with a 15% increase in 
likelihood of ADHD when compared to non-exposure to preeclampsia (95% CI: 1.12, 
1.19). Results of the sibling-matched analysis were not materially different from the 
main findings (HR: 1.13, 95% CI: 1.05, 1.22).  
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Being an SGA baby and exposed to preeclampsia further increased the likelihood of 
ADHD (HR: 1.55, 95% CI: 1.28, 1.88), however to a lesser extent to that of the ASD 
study. Moreover, results suggest that the likelihood of ADHD increases with 
decreasing gestational age, as preeclampsia was associated with a 7% increase in 
likelihood of ADHD when we restricted the analysis to those born ≥39 weeks’ 
gestation (95% CI: 1.02, 1.12). However, the HR increases to 1.74 among those 
exposed to preeclampsia and born at <34 weeks’ gestation (95% CI: 1.60, 1.91). 
Similar to the ASD study (above), these results suggest that preeclampsia with severe 
features may lead to stronger associations with neurodevelopmental outcomes.  
There are few studies that address the potential biological mechanisms of ADHD 
specifically. However, animal models have speculated that maternal inflammation 
may be one such mechanism given the role of preeclampsia in chronic immune 
activation and elevated levels of inflammatory cytokines such as IL-17a(22, 73, 224) 
which is associated with behavioural disturbances and an abnormal cortical phenotype 
in affected offspring(22, 236). 
 
11.1.4 Findings on Intergenerational Association (ASD and ADHD) 
As previous research indicates that risk of certain outcomes can be transferred across 
generations(52, 53), chapter 8 of this thesis examined the intergenerational association 
between preeclampsia and ASD and ADHD using data from Swedish National 
Registers. Similar to our previous findings on ASD and ADHD, exposure to 
preeclampsia was associated with an increased likelihood of ASD (HR: 1.31, 95% CI: 
1.19, 1.43) and ADHD (HR: 1.23, 95% CI: 1.16, 1.30) in offspring. In addition to this, 
results suggested that preeclampsia in both the child’s mother and grandmother 
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increased the likelihood of ASD (HR: 1.59, 95% CI: 1.03, 2.47) and ADHD (HR: 1.34, 
95% CI: 1.01, 1.80) in the child. 
These results suggest that preeclampsia may be associated with adverse 
neurodevelopmental outcomes across generations given the stronger association when 
a diagnosis of preeclampsia was present in both the child’s mother and grandmother. 
However, results may also be indicative of a dose-response relationship. Women 
diagnosed as having preeclampsia with severe features are more likely to have been 
born of a pregnancy complicated by preeclampsia(244). Therefore, it is plausible that a 
more “severe” phenotype of preeclampsia could be leading to the stronger 
intergenerational association in our study. This is in line with our previous suggested 
hypothesis that a more “severe” phenotype of preeclampsia may lead to an increase in 
the likelihood of adverse neurodevelopmental outcome.  
 
11.1.5 Findings on Child Development and Behavioural Outcomes 
Chapter 9 of this thesis examined the association between preeclampsia and child 
development (using the ASQ) at age 9-months, and preeclampsia and 
emotional/behavioural problems (using the SDQ) at age 3 years, 5 years and 7-8 years 
using data from Growing Up in Ireland (GUI), a nationally representative longitudinal 
study of children living in Ireland.  
Adjusted results suggest preeclampsia was not associated with failing an ASQ domain 
at 9-months old. In addition to this, preeclampsia was not significantly associated with 
abnormal SDQ score in any of the domains at age 3 years and age 7-8 years. However, 
at age 5 years, preeclampsia was associated with abnormal SDQ cut-off of Emotional 
(OR: 1.50, 95% CI: 1.04, 2.17) and Hyperactivity (1.57, 95% CI: 1.19, 2.08) domains. 
These results support the notion that young children can sometimes transition in or out 
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of the abnormal range for behavioural issues throughout childhood(256). Furthermore, 
results are consistent with brain imaging studies conducted on young children. For 
example, previous evidence suggests an association between exposure to preeclampsia 
and altered anatomical and functional connectivity in the amygdala and other regions 
of the ‘social brain’(81, 206, 246). Therefore, this may partly explain the association 
between preeclampsia and failure of the Emotional domain of the SDQ in particular.  
 
11.2 Strengths and Limitations 
11.2.1 Strengths of Thesis (overall) 
This thesis includes a comprehensive systematic review and meta-analysis of the 
epidemiological evidence examining the association between HDP and 
neurodevelopmental outcomes. The systematic review and meta-analysis was updated 
upon completion of this thesis to include the current results and any newly published 
studies for ASD and ADHD (Figure 10.1 and Figure 10.2).  Also included in this 
thesis is a narrative review of the potential role of maternal inflammation in the 
development of ASD.  
In addition, this thesis addresses the limitations of previous literature identified in the 
systematic review, using the largest epidemiological studies, to date, to examine a 
preeclampsia-ASD and preeclampsia-ADHD relationship. This work was 
complemented by using data from the GUI study to examine the associations between 
preeclampsia and child development and behavioural outcomes, as information on 
these outcomes is not available in the Swedish National Registers.  
Furthermore, recent ISSHP guidelines suggest that uteroplacental dysfunction should 
be included in the definition of preeclampsia(2). Combining preeclampsia and SGA as 
a crude proxy for preeclampsia with placental dysfunction is in line with these 
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guidelines given that the most frequent etiology for fetal growth restriction is 
uteroplacental dysfunction(271). Finally, this thesis includes the first studies to conduct 
sibling-matched analyses when examining a preeclampsia-ASD and preeclampsia-
ADHD relationship.  
 
11.2.2 Strengths of Swedish National Register Studies 
The Swedish data studies in this thesis were the largest epidemiological studies to date 
to investigate a preeclampsia-ASD/ADHD association. For ASD, all singleton live 
births in Sweden from 1982-2010 were included, while for ADHD, all singleton live 
births from 1990 to 2010 were included, with follow-up until 2016 for both. To our 
knowledge, this is the longest study period that has been covered on this topic.  
As data were prospectively obtained from national registers, it minimised the 
likelihood of recall bias and selection bias. The national registers contained 
information on several potential confounding factors, an issue that was identified in 
previous literature, allowing us to control for a wide range of confounding variables. 
Moreover, conducting a sibling-matched analysis, allowed us to further control, at 
least in part, for shared genetic and familial factors. 
In addition, evidence suggests that risk factors for ASD with and without intellectual 
disability may differ. As the National Patient Register contained information on 
intellectual disability, it allowed us to examine the association between preeclampsia 
and ASD overall, and stratified by ASD with and without intellectual disability(36, 216). 
Furthermore, while a diagnosis of ADHD was determined using either ICD-coding or 
being in receipt of ADHD medication, we conducted a sensitivity analysis including 
only those with both a diagnosis using ICD-coding and ADHD medication, thus 
reducing the likelihood of misclassification bias. Finally, the large sample size allowed 
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several a priori sensitivity analyses to be conducted in an attempt to explain the 
observed associations.  
 
11.2.3 Strengths of Growing Up in Ireland Study 
The GUI study in this thesis used data from a nationally representative study of 
children living in Ireland, reducing the likelihood of selection bias. All data were 
weighted to represent the national sample of infants aged less than one year in the 
2008 calendar year. We conducted repeated measures analysis using linear spline 
multilevel modelling, allowing for change in SDQ score over time. To my knowledge, 
this has not previously been conducted in studies examining a preeclampsia-
behavioural outcome relationship. Finally, the GUI study data contained information 
on a wide range of potential confounders allowing us to control for several important 
confounding factors.  
 
11.2.4 Limitations of Thesis (overall) 
The systematic review and meta-analysis included English-language studies only; 
therefore, it is possible that non-English studies on this topic were overlooked. 
Moreover, we did not have access to quality data on gestational hypertension in the 
Swedish National Registers or GUI study, which limited our analyses and meant that 
the comparison groups may have contained women with a diagnosis of gestational 
hypertension. However, we are confident that if an association between gestational 
hypertension and neurodevelopment outcome were to exist, this would likely bias our 
results towards the null.  In addition to this, as the studies included in this thesis are 
based on existing data, the ability to control for confounding factors is limited to the 
data available in the various datasets.  
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Finally, as discussed in ‘Future Directions’ below, it was not possible to appropriately 
examine the association between antihypertensive medication use during pregnancy 
and ASD/ADHD in offspring due to several limitations in the data. (See Section 11.3.1 
below). 
 
11.2.5 Limitations of Swedish National Register Studies 
It is not possible to rule out the presence of residual confounding in observational 
studies. While it may have been reduced in the sibling-matched analysis, this method 
can only adjust for factors that are constant between pregnancies(229), therefore we 
cannot rule out the possibility of unmeasured confounding factors. Furthermore, 
outpatient data only started becoming available in 2001, meaning more severe cases 
of ASD/ADHD may have been overrepresented in our data(87), while less severe cases 
may have been assigned as controls. However, it is unlikely that this misclassification 
was differential based on exposure to preeclampsia (i.e. the proportion of cases and 
controls incorrectly assigned to the exposure group are similar), and thus may have 
biased results towards the null. Although, results of the sensitivity analyses attempting 
to investigate this further were not materially different from our main findings, 
suggesting the inclusion of less severe cases after 2001 may not have had a large 
impact on findings. 
 
11.2.6 Limitations of Growing Up in Ireland Study 
In contrast to the Swedish data studies, data on preeclampsia was self-reported 9-
months post-delivery in the GUI study, therefore may have been subject to recall bias. 
Similarly, outcome data was reliant on the subjective evaluation of the child’s mother, 
which may have introduced misclassification bias. However, it was not possible for 
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the child’s mother to be influenced by our study hypothesis due to the secondary 
analysis nature of our study. Therefore, it is more likely that the misclassification was 
non-differential. Furthermore, loss to follow-up may have posed a threat to validity of 
findings. Previous evidence suggests children with behavioural disorders are more 
prone to loss to follow-up, which may have introduced selection bias(113). Finally, not 
unlike the Swedish data study, we cannot rule out the possibility of residual 
confounding.  
 
11.3 Future Directions 
11.3.1 The Role of Antihypertensive Medications and Neurodevelopmental 
Outcomes 
It is important for future research to explore the role of antihypertensive medications 
used during pregnancy in the development of neurodevelopmental outcomes. We 
initially made an attempt to examine the impact of antihypertensive medication using 
Swedish National Registers. However due to some major limitations in the data, it was 
deemed irresponsible to publish findings, and the analysis was omitted from the thesis. 
In sum, antihypertensive medication data were obtained from the Swedish Prescribed 
Drug Register, which on 1st July 2005, was expanded to include the PIN, allowing 
linkage to other registers(89). The Prescribed Drug Register contains information on all 
dispensed prescribed drugs in primary care and outpatient care and coverage is almost 
100% complete(90). However, the register does not contain information on over-the-
counter medications or medications used in hospital care(90). All medications are 
classified according to Anatomical Therapeutic Chemical (ATC) classification 
system, and antihypertensive medication included in the drug register were labetalol 
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(ATC code: C07AG01), nifedipine (C08CA05), methyldopa (C02AB01) and 
hydralazine (C02DB02).  
We included all live births between 1st July 2005 and 31st December 2010 in the 
analysis. Children were considered exposed if mothers purchased prescribed 
antihypertensive medication between date of conception and date of birth. As women 
diagnosed with preeclampsia are frequently managed as inpatients(2), they would 
receive medication within the hospital. However, as the Prescribed Drug Register does 
not contain information on medications used in hospital care, we compared the 
likelihood of ASD/ADHD among those exposed to antihypertensive medication for 
reasons other than preeclampsia (for example, chronic kidney disease, chronic 
hypertension and diabetes) and those exposed to neither preeclampsia nor 
antihypertensive medication. A major limitation of this analysis is confounding by 
indication as indications for antihypertensive medication for reasons other than 
preeclampsia may play a role in the development of neurodevelopmental outcomes. 
Furthermore, as we lacked data on medications used in hospital care, we could not be 
sure that medications prescribed for preeclampsia as inpatients corresponded to 
medications prescribed for other indications, concerning dose/timing etc.  
If data on all medications used was available, it may be possible to address this 
research question. However, as confounding by indication would remain a concern, 
and can be a difficult issue to resolve in population-based epidemiological research(272, 
273), it may be best to address this research question using animal models such as the 




11.3.2 The Potential Introduction of Standardised Developmental Screening 
Despite a general consensus that early identification and intervention can lead to 
improvements in long-term neurodevelopmental outcomes, a diagnosis is frequently 
not received until the child is attending school, meaning the window for early 
intervention has closed(228, 274). However, research suggests that a stable diagnosis of 
ASD can be made as young as two years, while diagnosis and treatment of ADHD can 
begin at age four years, allowing earlier access to specialised services(134, 274). 
Therefore, investigating the effectiveness of standardised developmental screening of 
infants previously exposed to preeclampsia is timely, and may allow for intervention 
and support at an earlier age, which in turn, may aid improvement of 
neurodevelopmental outcome(134).  
However, there are arguments for and against the recommendation of introducing 
early screening for children exposed to preeclampsia. For example, the results 
observed in this thesis may not warrant the introduction of standardised screening and 
therefore, it is important not to instil unnecessary stress on women with a previous 
diagnosis of preeclampsia. Conversely, early screening is non-invasive, and can be a 
relatively straightforward process. A recent randomised controlled trial suggests that 
computer-automated screening can lead to improvements in ASD screening rates in a 
primary care setting(275). Downs and colleagues developed a computer-based clinical 
decision support system called Child Health Improvement through Computer 
Automation (CHICA), with a built-in ASD decision support and compared it to using 
CHICA without ASD decision support. Screening rates in the intervention group 
increased from 0% at baseline to 68.4% in six months and to 100% in 24 months, 
while no significant increase in screening rates was observed in the control group(275).  
However, as most children with a positive screening result will not have ASD, 
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resulting in a high false positive rate, referral may not be justified, and a cost-benefit 
analysis may be necessary before a more informed recommendation can be made(276).  
 
11.4 Conclusion 
Through rigorous investigation, including the use of multiple statistical modelling, and 
controlling for several potential confounding factors, the data presented in this thesis 
suggest that exposure to preeclampsia or preeclampsia and SGA combined (i.e. SGA 
baby exposed to preeclampsia) was associated with ASD and ADHD. The stronger 
association with preeclampsia and SGA combined than preeclampsia alone suggests 
that placental pathology may be a mechanism for the increased likelihood of ASD and 
ADHD. In addition to this, results of the current thesis suggest that preeclampsia may 
be associated with adverse neurodevelopmental outcomes across generations.  
While we did not find strong evidence of associations between preeclampsia and child 
developmental and behavioural outcomes overall, exposure to preeclampsia was 
associated with an increased likelihood of subtle behavioural issues in the emotional 
and hyperactivity domain of the SDQ. 
Overall, results of this thesis suggest an association between HDP and 
neurodevelopmental outcomes in offspring. However, it is important to note that it is 
not possible to rule out the presence of residual confounding in observational studies.  
Furthermore, the associations observed in this thesis might lack specificity, as 
preeclampsia (and preeclampsia and SGA combined) may be associated with several 
neurodevelopmental outcomes. Therefore, in conclusion, preeclampsia may in fact 
increase the likelihood of poor neurodevelopmental outcome in general, with the 













Appendix 1: Search strategy for identifying relevant studies in the systematic 
review 
Search terms 
e.g. For PubMed (1946 - June, 7th 2017) LIMIT: humans, English language 
1. pre eclampsia 
2. preeclampsia 
3. pre-eclampsia 
4. gestational hypertension 
5. hypertensive pregnancy disorder 
6. hypertensive disorders of pregnancy 
7. pregnancy induced hypertension 
8. pregnancy-induced hypertension 
9. pregnancy hypertension 
10. toxaemia 
11. toxemia 
12. maternal metabolic 
13. [#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12] 
14. autism 
15. autism spectrum 
16. autistic 
17. autism spectrum disorders 
18. autism Spectrum Disorder 
19. autistic spectrum disorders 
20. autistic Spectrum Disorder 
21. asperger 
22. asperger's 
23. asperger's Syndrome 
24. autistic Spectrum 
25. pervasive developmental disorder 
26. pervasive developmental disorders 
27. disintegrative disorder 
28. rett syndrome 




33. attention-deficit/hyperactivity disorder 
34. attention-deficit hyperactivity disorder 
35. attention-deficit-hyperactivity disorder 




40. hyperkinetic disorders 
41. hyperkinet* 
42. neurodevelopment 
43. specific learning disorder 
44. learning disorder 
45. intellectual disability 
46. mental retardation 
47. communication disorder 
48. motor disorder 
49. conduct disorder 
50. IQ 
51. reading age 
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52. school performance 
53. [#14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or 
#26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 
or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or 
#51 or #52] 





Appendix 2: Bias classification tool to appraise quality of studies included in the systematic review 
Bias NR Minimal Low Moderate High 
Selection    Consectutive unselected 
population 
 Sample selected from general 
population rather than a select 
group 
 Eligibility criteria explained 
 Rational for case and control 
selection explained 
 Follow up or assessment time 
explained 
 Sample selected from 
large population but 
selection criteria not 
defined 
 A select group of 
population (based on 
race, ethnicity, 
residence, etc.) studied 
 Sample selection 
ambiguous but sample 
may be representative 
 Eligibility criteria not 
explained 
 Rationale for case and 
controls not explained 
 Follow up or assessment 
time not explained 
 Sample selection 
ambiguous and sample 
likely not 
representative 
 Comparative groups 
differ in baseline 
characteristics 
 A very select 
population studied 
making it difficult to 
generalise findings 
Exposure    Direct questioning (interview) or 
completion of survey by mother at 
the time of exposure or close to the 
time of exposure 
 Direct measurment of exposure 
(laboratory) 
 Exposure from the chart 
 Assessment of 
exposure from a 
dataset 
 Indirect assessment 
(postal survey, mailed 
questionnaire) 
 Recall < 1 year after 
birth 
 Recall 1-5 years after 
birth 
 Extrapolating data from 
population exposure 
sample (with some 
assumptions) and not 
direct assessment at any 
time 
 Recall >5 years after 
birth 
 Indirect method of 
assessment (obtaining 
data from others and 
not from mother or 
father) 
Outcome    Assessment from hospital record, 
birth certificate or from direct 
question to mother about outcome 
 Assessment from 
administrative 
database   
 Assessment from “close-
ended” questions (Did 
you have an ectopic 
pregnancy?) 
 Assessment from non-
validated sources or 
generic estimate from 
overall population 
Confounding    Assessed for common confounders 
 
 Only certain 
confounders assessed  
 Not assessed for 
confounders 
 
Analytical    Analyses appropriate for type of 
sample  
 (if matched: paired t test, 
McNemar) 
 Analytical method accounted for 
sampling strategy in cross 
sectional study 
 Sample size calculation performed 
and adequate sample studied 




multiple analyses e.g. 
Bonferroni) when 
appropriate 
 Sample size 
calculation not 
 Sample size estimation 
unclear or only sub-
sample of eligible patients 
studied 
 Analyses inappropriate 




performed, but all 
available eligible 
patients studied 
 Sample size calculated 
and reasons for not 
meeting sample size 
given 
Attrition    None or <10% attrition and 
reasons for loss of follow up 
explained 
 All subjects from initiation of 
study to final outcome assessment 
were accounted for 
 <10% attrition AND 
reasons for loss of 
follow up not 
explained 
 11-20% attrition, 
reasons for loss of 
follow up explained 
 11-20% attrition but 
reasons for loss of follow 
up not explained 
 >20% attrition but reasons 
for loss of follow up 
explained 
 All subjects from 
initiation of study to final 
outcome assessment not 
accounted for 
 >20% attrition, reasons 




Appendix 3: Characteristics of ASD studies included in the systematic review 
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Autistic 
disorder 
DSM-III-R No NR NR 
Mason-
Brothers et 















Autism DSM-III from 
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No Sibling NR 































Birth order Sibling Excess of first 
born among 
cases 
ASD=autism spectrum disorder. HDP=hypertensive disorder of pregnancy. BMI=body mass index. HT=hypertension. n/a=not applicable. CHARGE=Childhood Autism Risks from Genetics and the 
Environment. PE=preeclampsia. NR=not reported. ADOS=Autism Diagnostic Observation Schedule. ADI-R=Autism Diagnostic Interview, Revised. DAG=directed acyclic graph. PIH=pregnancy-
induced hypertension. MBR=Medical Birth Register. BP=blood pressure. ICD=International Classification of Disease. MNS=Midwives’ Notification System. ID=intellectual disability. 
DSM=Diagnostic and Statistical Manual of Mental Disorders. UTI=urinary tract infection. HBP=high blood pressure. APHP=Alberta Perinatal Health Program. SES=socioeconomic status. 
DDSN=Department of Disabilities and Special Needs. ADDM=Autism Developmental Disabilities Monitoring Network. PCR=Psychiatric Central Register. IDA=Integrated Database for Longitudinal 






Appendix 4: Characteristics of ADHD studies included in the systematic review 
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n/a Literature 
ADHD=attention deficit/hyperactivity disorder. HDP=hypertensive disorder of pregnancy. n/a=not applicable. MNS=Midwives’ Noti fication System. MODDS=Monitoring of Drugs of Dependence 
System. PE=preeclampsia. NR=not reported. DSM=Diagnostic and Statistical Manual of Mental Disorders. ICD=International Classification of Disease. ICD-9-CM=International Classification of 
Diseases, Ninth Revision, Clinical Modification. NICU=neonatal intensive care unit. HT=hypertension. K-SADS-PL=Schedule for Affective Disorders and Schizophrenia for School Age Children-
Present and Lifetime Version. KPSC=Kaiser Permanente Southern California. K-SADS-E=Schedule for Affective Disorders and Schizophrenia for School Age Children-Epidemiological Version. 






Appendix 5: Characteristics and main findings of other neurodevelopmental outcome studies included in the systematic review 
Summary of HDP and cognitive functioning/developmental delay studies 
Preeclampsia 




Sample size Diagnosis of 
HDP 






age 1-5 years 




PE 95,  
No PE 140 
Severe PE: BP 
>140/90 mm Hg 
and proteinuria 
>300 mg/24 




Failure of Ages 
and Stages 
Questionnaire 
Severe PE v NT: 
No significant 
associations  
OR and 95% CI: 
Year 1 follow-up: 
0.90 (0.24 to 3.34)  
Year 2 follow-up: 
0.63 (0.19 to 2.09)  
Year 3 follow-up: 
2.31 (0.63 to 8.53) 

















Development delay Vineland 
Adaptive 
Behaviour Scales, 










OR and 95% CI: 
1.82 (0.72, 4.64) 
Heikura et al, 
2013(277) 
Offspring, 
age 11.5 years 












IQ between 50 and 
85 based on 
standardised 
psychometric tests  
(eg. WISC-R) 
PE v NT: 
No significant 
association 
OR and 95% CI: 
1.2 (0.5, 2.8) 







PE 31, NT 553 PE: proteinuria 
and SBP 
≥140mm Hg or 
DBP ≥90mm Hg 
Self-reported cognitive 
impairment 





for total score 0.45 





0.31 (-0.11, 0.73) 
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PE 1774,  
NT 23334 










difficulties and other 
Record in SNS NT v PE: 
No significant 
association 
OR and 95% CI: 
















PE not associated 
with lower PPVT-
R scores (MD for 
total score -3.35      
(-8.41, 1.35) or 
lower RCPM 
scores (MD for 
total score -1.82 (-
12.59, 8.95) 
Ehrenstein et al, 
2009(281) 









in second half of 
pregnancy and de 
novo proteinuria 
(>0.3g over 





PE v NT: 
PE associated with 
increased odds of 
low cognitive 
function 
PR and 95% CI: 
1.32 (1.08, 1.62) 
Eaton et al, 
2001(62) 
Offspring, 

















Seidman et al, 
1991(282) 
Offspring, 
age 17 years 
Cohort Jerusalem, 
Israel 1964-71 
PE 428,  
No PE 33117 
PE: After 24 
weeks gestation, 
SBP ≥140mm 
Hg or DBP 
≥90mm Hg or 
rise in BP of 
≥30/15mm Hg 
(two readings 
≥6hrs apart) or 
proteinuria or 
oedema of the 
face and arms or 
any combination 
of 2 or more 





correlate with the 
WAIS 
No difference in 
mean IQ test 
scores between PE 
and non PE: mean 






















sibpairs (MD in 
unaffected sibs in 
subsequent birth  -
0.7 and preceding 
birth -2.2) 
Preeclampsia (specific population) 




Sample size Diagnosis of 
HDP 
Outcome measure Assessment 
method 
Main findings 













PE: self-reported Cognitive 
development at age 2 
PARCA-R PE associated with 
increased risk of 
cognitive 
impairment. 
RR and 95% CI: 












No PE 23 
PE: >90mm Hg 




Cognitive impairment Wechsler scales IUGR infants 





unexposed to PE: 
PE: 70.1 (±19) 
Non PE: 83.3 
(±14) 
Leitner et al, 
2012(284) 






≥140mm Hg or 





in 24/hr urine 





IQ and academic 
achievement 
WISC-R95 two-


















Cohort Norway  
1999-2000 
PE 73, 
No PE 233  
PE: Medical 
Birth Registry of 
Norway 




Primary Scale of 
Intelligence-
Revised 
PE associated with 
lower full-scale IQ 
MD -7.7  
(-12.7, -2.7) 












No PE 33 
PE: proteinuria 
>300mg/d and 
DBP >90mm Hg 
in two 
measurements ≥4 



















No association:  
PE v No PE: 
OR and 95% CI: 
1.36 (0.46, 4.04) 






Cohort Pavia, Italy 
1990-2004 
PE 185, 
No PE 569 
PE: DBP 
≥110mm Hg or 
≥90mm Hg in 
two consecutive 





MDI Bayley Scales of 
Infant 
Development II 
PE associated with 
reduced risk of 
impairment. 
OR and 95% CI: 
0.52 (0.32, 0.85) 



















>300mg in 24/hr 
urine sample, 
without history 
of previous HT 
or renal disease 
MDI at 12 and 18 
months 
Bayley Scales of 
Infant 
Development II 
Mean MDI scores 
not significantly 
different.  
At 12 months: 
PE: 79.6 (±0.44) 
No PE: 79 (±0.47) 
At 18 months: 
PE: 82.9 (±0.45) 
No PE: 81.1 (±0.7) 
233 
 









No PE 61 
PE: DBP of 
110mm Hg once 
or DBP of 
≥90mm Hg twice 
and proteinuria 
of ≥300mg in 
24/hr 





lower for PE 
compared to non-
PE:  
PE: 72 (49-116) 
Non-PE: 86  
(49-114) p=0.04 









No PE 64 
PE: persistent BP 
≥140/90mm Hg 
with proteinuria 
of 100mg/dL by 
random urine 
analysis or 
>500mg in 24hr 
urine collection 
Cognitive assessment Standford Binnet-
IQ 
Growth restricted 







PE: 85.5 (±16) 


















MDI Bayley Scales of 
Infant 
Development II 




No PE: 106 
Other HDP 




Sample size Diagnosis of 
HDP 
Outcome measure Assessment 
method 
Main findings 
Heikura et al, 
2013(277) 
Offspring, 
age 11.5 years 





GH 443,  
Chronic HT or 
superimposed 




Chronic HT or 
superimposed 
PE: already using 
anti-HT 









IQ between 50 and 




GH v NT: 
GH associated 
with increased 
odds of mild 
cognitive 
limitations 
OR and 95% CI: 
2.4 (1.4, 3.9). 
Chronic HT v NT: 
No significant 
association 
OR and 95% CI: 






With a positive 
urinary dip-stick 
test (≥0.3 g/L) 
indicated 
proteinuria 







HT 292, NT 553 Gestational and 
chronic HT: SBP 
≥140mm Hg or 
DBP ≥90mm Hg 











for total score 0.12 




(-0.08, 0.22), but 
neither result 
significant 
Krakowiak et al, 
2012(10) 
Offspring, 






delay 64, typical 
development 
172 




Developmental delay Vineland 
Adaptive 
Behaviour Scales, 





HT v NT: 
No significant 
association 
OR and 95% CI: 
3.58 (0.93, 13.78) 











GH 4092,  
NT 23334 










difficulties and other 
Record in SNS NT v GH: 
No significant 
association 
OR and 95% CI: 
1.16 (0.99, 1.36) 








HT 449, NT 747 HDP: BP 
≥140/90mm Hg 
at any time 
during 
pregnancy 





MD and 95% CI in 
total intellectual 
abilities score: 













HT 146, NT 252 HDP: BP 
≥140/90mm Hg 
at any time 
during 
pregnancy 





Men born to HT 
mothers scored 
lower on tests: 
MD and 95% CI in 
total intellectual 
abilities score at 
age 69: 
-4.36 (-7.55,-1.17) 
and in decline in 
total cognitive 
ability -2.88  
(-5.06,-0.70) 
Whitehouse et 
al, 2012(280)  
Offspring, 




PE 279, NT 1076 Gestational HT: 
SBP ≥140mm 
Hg or DBP 











R scores (MD for 
total score -1.71       
(-3.39, -0.03) but 
not associated 
with lower RCPM 
scores (MD for 
total score 0.15      
(-3.60, 3.90) 
Ehrenstein et al, 
2009(281) 















GH v NT: 
GH associated 
with increased 
odds of low 
cognitive function 
PR and 95% CI: 
1.34 (1.01, 1.77) 
Lawlor et al, 
2005(287) 
Offspring, 





PIH 1977,  
No PIH 9702 





Childhood intelligence Age 7: Moray 
House Picture 
Intelligence 1&2. 





Age 11: battery of 
Moray House 




PIH v No PIH: 
MD in IQ points 
and 95% CI: 
2.35 (1.56, 3.14) 
Results attenuated 
towards the null 









Other HDP (specific population) 




Sample size Diagnosis of 
HDP 
Outcome measure Assessment 
method 
Main findings 
Leitner et al, 
2012(284) 






≥140mm Hg or 






IQ and academic 
achievement 
WISC-R95 two-















Cohort Israel  
Date: NR 
HDP 22,  
No HDP 70 
HDP: NR IQ at age 6 Wechsler 
Preschool and 
Primary Scale of 
Intelligence  
No significant 
difference in mean 
IQ 
HDP: 106 (±11) 
No HDP: 101 
(±14) 





Cohort New Zealand 
1993-97 
HDP 88,  
No HDP 132 
HDP: BP 
≥140/90mm Hg 
with an increase 
of ≥15mm Hg in 
DBP on 2 
occasions >4hrs 










without UTI  








No HDP: 93.7 
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Developmental delay Griffith’s Infant 
Ability Scale 




OR and 95% CI: 
1.33 (0.61, 2.99) 






Cohort Italy  
1986-90 
HDP 92, 
No HDP 184 
 









with increased risk 
of minor 
impairment 
OR and 95% CI: 
3.1 (1.41, 6.88) 

























with higher verbal 
IQ score  
Mean and SD: 
HDP: 105.75 
(13.50) 












Summary of HDP and other behavioral outcome studies 
Preeclampsia 
Study Population Study design Region, study 
period 







Robinson et al, 
2009(67) 
Offspring at 
age 2, 5, 8, 10 














CBCL No significant 
association 














problems at age 5 
and 8.  
OR and 95% CI: 
0.22 (0.05, 0.97) 
0.33 (0.11, 0.98) 





Cohort Denmark  
1978-2004 
PE 46384,  
No PE 1499059 





a result of mental 
and behavioural 
disorders 
PE not associated 
with increased risk 
of hospitalisation 
IRR and 95% CI: 
1.1 (1.0, 1.2)  











siblings of cases 
481 
PE: ICD9 PDD-NOS DSM No association 
between PE and 
PDD-NOS: 
OR and 95% CI: 
1.2 (0.5, 2.6) 











siblings of cases 
481 
PE: ICD9 Asperger’s DSM No association 
between PE and 
Asperger’s: 
OR and 95% CI: 
1.3 (0.6, 3.0) 
 
Eaton et al, 
2001(62) 
Offspring, age 
<15 years  
Case-control Denmark  
1973-93 
Asperger’s 














Study Population Study design Region, study 
period 







Böhm et al, 
2017(22) 
Millennium 




HDP 1069,  





PE or toxemia). 
Behavioural 
difficulties 
SDQ No association 
between HDP and 
abnormal SDQ: 
OR and 95% CI: 




















PDD ICD9 and ICD10 No association 
when results 
adjusted for SGA, 























ICD9 and ICD10 No association  
OR and 95% CI: 
1.03 (0.8, 1.4) 
Robinson et al, 
2009(67) 
Offspring at 
age 2, 5, 8, 10 














CBCL GH associated 
with increased risk 
of overall 
behavioural 
problems at age 8 
and 14.  
OR and 95% CI: 
1.40 (1.03, 1.91) 
2.07 (1.35, 3.17) 
Also associated 
with increased risk 
of externalising 
behavioural 
problems at age 10 
OR and 95% CI: 
1.63 (1.13, 2.33) 
Summary of HDP and intellectual disability studies 
Preeclampsia 
Study Population Study design Region, study 
period 







Griffith et al, 
2011(63) 




Cohort South Carolina 
1996-2002 
PE 5169,  











PE associated with 
an increased risk 
of ID 
OR and 95% CI: 
1.38 (1.16, 1.64) 
Eaton et al, 
2001(62) 
Offspring, age 
<15 years  
Case-control Denmark  
1973-93 
Mental 



















Study Population Study design Region, study 
period 






















PE and essential 
HT from MNS 
Mild-moderate 










increased risk of 
mild-moderate ID: 
OR and 95% CI: 
1.39 (1.25, 1.54) 
but not severe ID: 
1.01 (0.64, 1.59) 
Leonard et al, 
2006(65) 









No HT 238450 
HT: ICD9 Intellectual 
disability 
Mild-moderate 
ID: IQ 35 to 40 to 
69 
Severe ID: IQ<35 






OR and 95% CI: 
0.99 (0.58, 1.68) 
Severe ID:  
OR and 95% CI: 
2.48 (0.79, 7.77) 
Salonen, et al, 
1984(150) 
Children age 9-
10 years living 
in one Finnish 
county (Kuopio) 
Case-control Eastern Finland 










Screened using a 
standardised set of 





increased risk of 
mental retardation 
RR and 95% CI: 
6.1 (1.3, 28.9) 
HDP=hypertensive disorder of pregnancy. PE=preeclampsia. BP=blood pressure. NT=normotensive. OR=odds ratio. 95% CI=95% confidence interval. IQ=intelligence quotient. WISC-R=Wechsler 
Intelligence Scale for Children-Revised. SBP=systolic blood pressure. DBP=diastolic blood pressure. CFQ=Cognitive Failures Questionnaire. DEX=Dysexecutive Questionnaire. MD=mean 
difference. ADHD=attention deficit/hyperactivity disorder. SNS=Support Needs System. HT=hypertension. PPVT-R=Peabody Picture Vocabulary Test-Revised. RCPM=Ravens Colored Progressive 
Matrices. BPP=Boerge Prien Prove. ICD=International Classification of Disease. RR=relative risk. WAIS=Wechsler Adult Intelligence Scale. PARCA-R=Parent Report of Children’s Abilities-
Revised. IUGR=Intrauterine growth restricted. MDI=Mental Developmental Index. PDI=Psychomotor Developmental Index. VLBW=very low birthweight. GH=gestational hypertension. 
PIH=pregnancy-induced hypertension. UTI=urinary tract infection. NR=not recorded. SGA=small for gestational age. SD=standard deviation. CBCL=Child Behaviour Checklists. IRR=incident rate 
ratio. PDD-NOS=Pervasive Developmental Disorder-Not Otherwise Specified. DSM=Diagnostic and Statistical Manual of Mental Disorders. GH=gestational hypertension. SDQ=Strengths and 



















Appendix 7: Forest plots of the association between HDP and ASD, including 















Appendix 8: Level of bias in ASD studies 
Study Selection bias Exposure bias Outcome bias Confounding Analytic bias Attrition bias Overall risk 
of bias 
Curran et al, 
2018(21) 
Minimal: Sample 
selected from general 
population rather than 
a select group 
(Sample is 
representative of 
children born in the 
UK in 2000-01 
Low: Recall < 1 
year after birth 
Minimal: Direct 





Low: Certain confounders 
assessed - smoking during 
pregnancy, birth order, 
poverty, maternal ethnicity, 
age, education, depression, 











Walker et al, 
2015(13) 
Low: Sample from 
select group of 
population - only 
births in California 












Low: Certain confounders 
assessed - maternal 
educational level, parity, pre-
pregnancy obesity, age, sex, 
broad geographic regions 





but all available 
eligible patients 
may have been 
studied 
Minimal: Little 





selected from general 
population rather than 
a select group 
Low: Assessment 






Low: Certain confounders 
assessed - maternal age, 
maternal smoking during 
pregnancy, number of 
previous births, maternal 
psychiatric history, sex, date 





















of exposure from a 









Low: Certain confounders 
assessed - birth year, maternal 
and pregnancy conditions 
(maternal diabetes, threatened 
abortion, asthma, UTI during 
pregnancy, placenta praevia, 
placenta abruption, other 
antepartum haemorrhage), 
socio-demographics (parity, 
maternal and paternal age 
group, maternal ethnicity, 
community-level 
socioeconomic status and 
community 
accessibility/remoteness), 


















(preterm type, mode of 
delivery, breech, any 
complication of labour or 
delivery), neonatal outcomes 
(infant gender, resuscitation 
required at birth, percentage of 
optimal birthweight and head 
circumference) 
Mrozek-Budzyn 
et al, 2013(12) 
Low: Sample from 
select group of 
population - cases 
from the one 
psychiatric outpatient 
clinic for children in 







with trained nurse 





from a psychiatric 
outpatient clinic 
for children 
Moderate: Not assessed for 
confounders (but matched by 




















but sample may be 
representative 
Moderate: Recall 




Moderate: Not assessed for 














Lyall et al, 
2012(9) 
Low: A select group 
of population - nurses 










Low: Certain confounders 
assessed - race, marital status, 
income, spouse education, 
nurse’s age at baseline, age at 










Krakowiak et al, 
2012(10) 
Low: A select group 
of population - born in 











Low: Certain confounders 
assessed - mother’s age at 
delivery, race/ethnicity, 
education level, delivery 
payer, calendar time, age, 









to no attrition 
Low 




- all live births 
Low: Assessment 
of exposure from a 
























Burstyn et al, 
2010(31) 
Minimal: Sample 
selected from general 
population rather than 
a select group 
Low: Assessment 
of exposure from a 
dataset - delivery 







database - ICD-9 
codes linked to 
billing records 
Low: Certain confounders 
assessed - maternal age, 
maternal weight, maternal 
height, pre-pregnancy 
diabetes, gestational diabetes, 
bleeding, smoking, poor 
weight gain, parity, mother’s 
SES, presentation (breech 
etc.), type of labour, caesarean 
section, gestational age, 
birthweight, APGAR at 1 min 











Mann et al, 
2010(30) 
Low: A select group 











Low: Certain confounders 
assessed - maternal age, race, 
alcohol use, educational 
attainment, year of birth, 
child’s sex, and diagnosis with 
a high risk condition (alcohol 
use, tobacco use, down 
syndrome, fragile X 
















Bilder et al, 
2009(49) 
Low: A select group 
of population - 8 year 







database   
Moderate: Not assessed for 
confounders for prenatal 
factors (but matched by gender 















Buchmayer et al, 
2009(14) 




severe cases as 
inpatient care data 
available only 
Low: Assessment 
of exposure from a 









Low: Certain confounders 
assessed - parity, previous 
miscarriage, childless years, 
any maternal infection during 
pregnancy, season of delivery, 
diabetes mellitus, maternal 
age, smoking, maternal 
country of birth, whether the 
mother lived with the father, 


















gender, birth year, and birth 
hospital 
Larsson et al, 
2005(148) 
Minimal: Rational for 
case and control 
selection explained 
Low: Assessment 
of exposure from a 






database - Danish 
Psychiatric 
Register 
Moderate: Not assessed for 
confounders (but matched by 
















Glasson et al, 
2004(34) 
Minimal: Sample 
selected from general 
population rather than 
a select group 
Low: Assessment 
of exposure from a 
dataset - Maternal 










Moderate: Not assessed for 
















Hultman et al, 
2002(15) 




severe cases as 
inpatient care data 
available only 
Low: Assessment 
of exposure from a 









Low: Certain confounders 
assessed - maternal age, parity, 
smoking during pregnancy, 
mother’s country of birth, 
diabetes, pregnancy bleeding, 
mode of delivery, season of 
birth, gestational age, 
birthweight for gestational 
age, Apgar score at 5 minutes, 
congenital malformations, sex, 
















Eaton et al, 
2001(62) 
Low: A select group 




of exposure from a 






database - Danish 
Psychiatric 
Register 
Low: Certain confounders 


















Matsuishi et al, 
1999(33) 
Low: A select group 
of population - NICU 
























et al, 1990(32) 
Low: 
Epidemiological 




Diagnosed by at 
least 2 clinicians 
using DSM-III 
Moderate: Not assessed for 














Deykin et al, 
1980(147) 
Low: A select group 
of population - 
Massachusetts, 







validated sources - 
parent-reported 
symptoms by age 
6 
Low: Certain confounders 







for 81% cases 















Appendix 9: Level of bias in ADHD studies 
Study Selection bias Exposure bias Outcome bias Confounding Analytic bias Attrition bias Overall risk 
of bias 
Böhm et al, 2017(22) Minimal: Sample 
selected from 
general population 





children born in the 
UK in 2000-01) 
Low: Recall < 1 year 
after birth 
Minimal: Direct 
























Low: Assessment of 
exposure from a 
dataset - Midwives 
Notification System  
Low: Assessment 
from administrative 









assessed - year of 
birth, gender, and 
socioeconomic 
status, marital status, 
parity, smoking, 
complications of 










for gestational age) 
maternal age, Apgar 
at five minutes 
Minimal: Analyses 
appropriate for 





initiation of study 




Cak and Gokler, 
2013(48) 
Low: Sample from 
select group of 
population (30-36 














Low: Sample size 
calculation not 














Getahun et al, 
2013(40) 
Minimal: Rational 
for case and control 
selection explained 
Low: Assessment of 
exposure from a 
dataset - Perinatal 





on at least 2 
separate visits or 1 























initiation of study 




Golmirzaei et al, 
2013(42) 
Low: A select 
group of population 
- sample of 4-11 
year old school 
children, Southern 
Iran 
High: Recall >5 
years after birth 
Minimal: Conner’s 
Scales (those 














initiation of study 




Amiri et al, 2012(47) Moderate: Sample 
selection 
ambiguous but 
sample may be 
representative 
Moderate: Recall >5 





question to parent 
about outcome 
using ADHD 











initiation of study 









rather than a select 
group 
Low: Assessment of 
exposure from a 
dataset - Medical 




database - Adult 
patients who were 
approved for 
stimulant treatment 




assessed - born in the 
same time period, 
year of birth, parity, 
age of mother at 
birth, educational 
level of mother and 
marital status of 
mother 
Low: Sample size 
calculation not 





initiation of study 




Ketzer et al, 
2012(46) 
Minimal: Rational 
for case and control 
selection explained 
Moderate: Recall >5 
years after birth 
(however 
Minimal: Three 




assessed - age, 
Minimal: Analyses 
appropriate for 
type of sample - 
Minimal: All 
subjects from 





medical records in 
38% of sample) 
gender, agoraphobia 
(anxiety disorder), 













rather than a select 
group 
Low: Assessment of 
exposure from a 













Low: Sample size 
calculation not 





initiation of study 







Low: A select 
group of population 
- Medicaid eligible 
women 
Low: Assessment of 
exposure from a 









assessed - GU 
infection, infant 
race, maternal age 
and  education, 
alcohol and tobacco 
use, infant sex, 
birthweight, and 
oldest age in 
Medicaid 
Low: Sample size 
calculation not 





initiation of study 














Appendix 10: Level of bias in other neurodevelopmental outcome studies 




Warshafsky et al, 
2016(255) 
Low: Sample from 










Low: Certain confounders 
assessed - MgSO4 usage, 
smoking, SES, sex, parity, 








Johnson et al, 
2015(69) 
Low: Sample from 
four maternity 
centres, a midwife 






question to mother 
about outcome 
using Parent Report 
of Children’s 
Abilities-Revised 
Low: Certain confounders 
assessed - ethnic group, SES, 
sex, ethnic group, SES, sex, 
received breastmilk at 
discharge 
Low: Sample size 
calculation not 








Low: A select 
group of population 




from clinical data 
Minimal: 
Standardised test - 
Wechsler Scales IQ 
Test 
Low: Matched for gestational 






Little to no 
attrition  
Low 
Heikura et al, 
2013(277) 
Low: All maternal 
healthcare centres 


















Low: Certain confounders 
assessed - child’s gender, 
family SES, maternal age, pre-
pregnancy BMI, parity, 
birthweight 
Low: Sample size 
calculation not 











Tuovinen et al, 
2013(278) 
Low: Sample from 














Low: Certain confounders 
assessed - sex, length of 
gestation, weight, head 
circumference at birth, father’s 
occupation in childhood, 
parity, mother’s age, BMI at 













Leitner et al, 
2012(284) 
Low: A select 





Moderate: Not assessed for 
confounders 
Low: Sample size 
calculation not 





























Love et al, 2012(279)  Low: A select 













Low: Certain confounders 
assessed -maternal SES, 
induced labour, placental 








Little to no 
attrition 
Low 
Tuovinen et al, 
2012(285) 
Low: A select 
group of population 
- Maternity 
Hospital, Helsinki, 






database - Finnish 
Defence Forces 
Basic Ability Test 
Low: Certain confounders 
assessed - gestational age, 
weigh, head circumference at 
birth, year of birth, childhood 
SES, parity, mother’s age and 
BMI at delivery, age and height 






data on 1196 
out of 2786 
Moderate 
Tuovinen et al, 
2012(286) 
Low: A select 
group of population 
- Maternity 
Hospital, Helsinki, 






database - Finnish 
Defence Forces 
Basic Ability Test 
Low: Certain confounders 
assessed - length of gestation, 
weight and head circumference 
at birth, father’s occupational 
status in childhood, parity, 
mother’s age and BMI at 
delivery, age at testing, 
cognitive ability at 20 years, 
time interval between tests 
from 20-68 years, height at 
testing in late adulthood and 






data on 398 
out of 931 
Moderate 
Whitehouse et al, 
2012(280) 
Low: A select 
group of population 
based on residence 
- Public antenatal 
Minimal: Exposure 
from the chart and 
confirmed by 
Minimal: 
Standardised tests  - 
verbal ability and 
Low: Certain confounders 
assessed - maternal age at 
conception, maternal education 













clinics in Perth, 
Western Australia. 
Sample may be 
over representative 





income during pregnancy, 
maternal smoking and alcohol, 
maternal essential 
hypertension, maternal use of 
anti-hypertensive medication, 
spontaneous labour, parity, 
gestational age, birthweight, 
APGAR score, offspring sex, 
scores on McMaster Family 
Assessment device at 3 or 5 
years of age 








Griffith et al, 
2011(63) 
Low: A select 
group of population 
based on residence 




of exposure from a 




database - Dept. of 
Education and Dept. 
of Disabilities and 
Special Needs 
Low: Certain confounders 
assessed - maternal age, white 
race, education, birth year, 
female sex, preterm status 
Low: Sample size 
calculation not 




Little to no 
attrition  
Low 
Leversen et al, 
2011(149) 
Low: All extremely 
preterm births in 
Norway 
Low: Assessment 
of exposure from a 
dataset - Medical 





paediatrician at age 
5  
Low - Certain confounders 
assessed - gestational age, 
gender, illness severity score, 
small for gestational age, 
chorioamnionitis, prenatal 
steroids, multiple births, 
caesarean section, use of 
postnatal steroids, persistent 
ductus arteriosus, necrotizing 
enterocolitis, oxygen 
requirement at 36 weeks 
gestational age, retinopathy of 
prematurity, pathology on 
cerebral ultrasound, and high 
maternal education 
Low: Sample size 
calculation not 







Schlapbach et al, 
2010(64) 
Low: A select 
group of population 
- Zurich, preterm 
infants 
Low: Assessment 
of exposure from a 





paediatricians at age 
2 years 
Low: Certain confounders 
assessed - gestational age, 
birthweight, postnatal growth, 
mechanical ventilation, 
bronchopulmonary dysplasia 
Low: Sample size 
calculation not 




however: n=33 in 
each group) 
Minimal: 
Little to no 
attrition 
Low 
Ehrenstein et al, 
2009(281) 
Low: A select 
group of population 
- Danish men who 
Low: Assessment 
of exposure from a 
dataset - Danish 
Minimal: Direct 
assessment using 
Boerge Prien Group 
Low: Certain confounders 
assessed - small for gestational 
age, maternal age, parity, 
Low: Sample size 
calculation not 
performed, but all 
Minimal: 












converted to IQ 
scale 
marital status, history of 
diabetes, conscript’s year of 
birth, county of birth, 




Robinson et al, 
2009(67) 
Low: A select 




clinics in Perth, 
Western Australia. 
Minimal: Exposure 








Low: Certain confounders 
assessed - gestational age, 
birthweight, maternal smoking 
in pregnancy, child sex, 
maternal experience of 
stressful events during 
pregnancy, maternal age at 
conception, maternal education 
in pregnancy, family income in 
pregnancy, presence of 
biological father during 
pregnancy, family functioning 
score 
Low: Sample size 
calculation not 

























Spinillo et al, 
2009(66) 
Low: A select 
group of population 











Low: Certain confounders 
assessed - gestational age, 
proportion of expected 
birthweight, sex, umbilical 
artery, antenatal steroids 
Low: Sample size 
calculation not 
performed, but all 
available eligible 






Wu et al, 2009(293) Minimal: 
Consecutive 
unselected 
population - all 




of exposure from a 
dataset - Danish 
National Hospital 
Register 
Low: Assessment of 
exposure from a 
dataset - Danish 
National Hospital 
Register 
Low: Certain confounders 
assessed - infant sex, 
gestational age, parity, 
maternal age, maternal 
education, marriage status at 
birth, calendar year  
Low: Sample size 
calculation not 

















Silveira et al, 
2007(68) 
Low: A select 
group of population 
- very low 
birthweight infants 
in Hospital de 
Clinicas de Porto 
Alegre, Brazil 
Minimal: Exposure 
from the chart 
Minimal: Bayley 
Scales of Infant 
Development 
Moderate: Not assessed for 
confounders 
Low: Sample size 
calculation not 



















of exposure from a 
dataset - birth 
registry 
Low: Assessment of 
exposure from a 




Low: Aggregate SES measures Low: Sample size 
calculation not 















Many et al, 
2005(288) 
Low: A select 
group of population 







Primary Scale of 
Intelligence 














Lawlor et al, 
2005(287) 
Low: A select 
group of population 




of exposure from a 





database - Aberdeen 
Childhood 
Development 
Survey linked to 
routine intelligence 
tests in primary 
schools  
Moderate: Not assessed for 
confounders (not for HDP 
estimates, but associations 
between all complications of 
pregnancy and IQ attenuated 
towards the null when adjusted 
for parental characteristics) 
Low: Sample size 
calculation not 




Little to no 
attrition 
Low 
Cheng et al, 
2004(57) 
Low: A select 
group of population 
- very low 
birthweight, 
delivery before 32 
weeks gestation 
Minimal: Exposure 
from the chart 
Minimal: Evaluated 
by psychiatrist - 
Bayley Scales of 
Infant Development 
Low: Certain confounders 
assessed - parental education 
(unclear if there are others) 
 
Low: Sample size 
calculation not 
performed, but all 
available eligible 
patients may have 
been studied 
Minimal: 





Many et al, 2003(60) Low: A select 
group of population 





from the chart 
Minimal: 
Standardised IQ test 
Low: Certain confounders 
assessed - gestational age, 
birthweight, neonatal 
complications 
Low: Sample size 
calculation not 
performed, but all 
available eligible 






McCowan et al, 
2002(289) 
Low: A select 
group of population 
- small for 
gestational age 










Moderate: Not assessed for 
confounders 
Low: Sample size 
calculation not 
performed, but all 
available eligible 










Gray et al, 1998(290) Low: A select 
group of population 





from the chart 
Minimal: Griffiths’ 
Infant Ability Scale 











Spinillo et al, 
1994(291) 
Low: A select 
group of population 
- one clinical 
setting in Italy 
Low: Assessment 




database   
Low: Certain confounders 
assessed - social class and 
maternal education 
Low: Sample size 
calculation not 
performed, but all 
available eligible 






Seidman et al, 
1991(282) 
Low: A select 
group of population 
- 17 year olds 
during assessment 
for drafting to Israel 
Defence Forces 
Low: Assessment 
of exposure from a 




database - Israel 
Defence Force 
records 
Moderate: Not assessed for 
confounders 
Low: Sample size 
calculation not 
performed, but all 
available eligible 
patients may have 
been studied 
Minimal: 
Little to no 
attrition 
Low 
Szymonowicz et al, 
1987(58) 
Low: A select 
group of population 
- very low 
birthweight infants 
at one centre 
Low: Assessment 










Little to no 
attrition 
Moderate 
Salonen, et al, 
1984(150) 
Low: A select 
group of population 
- All 9-10 year olds 
in one Finnish 







database - records in 
local 
Developmental 
Defect Registries or 
screening in schools 
Low: Certain confounders 
assessed- mother’s age at birth, 
sibling with mental retardation 
or birth defect, parity, mode of 
birth, mother’s smoking status 
during pregnancy 
Low: Sample size 
calculation not 



















from the chart 
Minimal: 
Psychological 
testing (carried out 
blinded) 
Moderate: Not assessed for 
confounders 
Low: Sample size 
calculation not 
performed, but all 
available eligible 












Low: A select 
group of population 
- children in 
Birmingham who 
took the ‘Eleven 
Plus’ exam 
Minimal: Exposure 
from the chart 
Moderate: Eleven 
Plus exam 
(However, those in 
special schools or 
those in mainstream 




Moderate: Not assessed for 
confounders (but matched by 
sibpairs) 
Low: Sample size 
calculation not 










Appendix 11: Directed acyclic graph used to identify potential confounders in 
Swedish National Registers for preeclampsia-ASD study 
 
 
Appendix 12: Description of confounders in Swedish National Registers  
Year of birth: 1982-2010 for ASD study, 1990-2010 for ADHD study.  
Infant sex: Male and female. 
Maternal age: Categorised as <20years, 20-29 years, 30-39, and ≥40 years. 
Parental country of birth: Categorised as “Sweden”, “other Nordic country,” and 
“other country”. 
Parity: Number of pregnancies reaching viable gestational age. 
Maternal smoking status: Categorised as “no smoking,” “smoking 1-9 cigarettes a 
day,” and “smoking ≥10 cigarettes a day”. 




Optimal gestational weight gain: This was established for each maternal BMI 
category based on significant risk estimates of adverse maternal and fetal 
outcomes(230). 
Maternal and paternal depression: ICD-8: 29600, 3004; ICD-9: 296B, 311, 300E; 
ICD-10: F32, F33.  
Maternal and paternal bipolar disorder: ICD-8: 29610-29630; ICD-9: 296A,C-E; 
ICD-10: F30-31. 
Maternal and paternal non-affective psychiatric disorders: ICD-8: 295, 297, 298 
[excluding 29800 and 29810], 29999; ICD-9: 295, 297, 298 [excluding 298A and 
298B]; ICD-10: F20-29. 
Family income: Disposable income in the household the year the child was born. This 
was divided into quintiles, ranging from “low income” to “high income”.  
Parental level of education: Available since 1990, parental level of education was 
categorised as “pre-high school,” “high school,” and “post high school”. 
 
Appendix 13: Full description of results of sensitivity analyses examining 
association between preeclampsia and ASD 
When the study population was restricted to 1987-2010, preeclampsia was associated 
with a 25% increase in the likelihood of ASD, compared to those unexposed to 
preeclampsia (HR: 1.25, 95% CI: 1.19, 1.31). Similarly, excluding births after 2006 
did not materially change results (HR: 1.24, 95% CI: 1.18, 1.30). 
Fully adjusted results of the sensitivity analysis suggested that preeclampsia in those 
born at ≥34 weeks’ gestational age was associated with an 18% increase in the 
likelihood of ASD (HR: 1.18, 95% CI: 1.13, 1.24) when compared to those unexposed 
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to preeclampsia, and born at a similar gestational age. The fully adjusted result for 
preeclampsia in those born at <34 weeks’ gestational age (used as a proxy for 
preeclampsia with severe features) was 2.04 (95% CI: 1.81, 2.30) when compared to 
non-exposure to preeclampsia in those born at ≥34 weeks’ gestation. The HR for a 
preeclampsia-ASD relationship, excluding those with chronic hypertension, was 1.26 
(95% CI: 1.20, 1.31); and including those with both preeclampsia and chronic 
hypertension: 0.91 (95% CI: 0.63, 1.31). The fully adjusted HR for preeclampsia 
(excluding those with family history of mental illness) was 1.28 (95% CI: 1.22, 1.35). 
Including caesarean section in the multivariate model resulted in a HR of 1.21 (95% 
CI: 1.15, 1.26). Preeclampsia with a low/intermediate APGAR score at five minutes 
increased the likelihood of ASD by 30% compared to non-exposure to preeclampsia 
and low/intermediate score. Finally, preeclampsia among mothers <20 years of age 
and mothers with a BMI of <20 was associated with the highest odds of ASD (HR: 
1.37 and 1.29 respectively) compared to those of similar maternal age and BMI at first 
antenatal visit.  Adjusted subgroup analysis suggested a statistically significant 
increase in the likelihood of ASD at all gestational ages when compared to non-
exposure to preeclampsia in those born at ≥37 weeks’ gestation. When adjusted for 
potential confounders, exposure to preeclampsia was associated with a 25% increase 
in the odds of ASD in both male and female offspring (HR: 1.25, 95% CI: 1.18, 1.32) 





Appendix 14: Sensitivity analyses examining the association between 





HR (95% CI)a 
Model 2 
HR (95% CI)b 
Preeclampsia (Study population restricted to 
1987-2010) 
1843 1.37 (1.31, 1.44) 1.25 (1.19, 1.31) 
Preeclampsia (excluding births after 2006) 1830 1.35 (1.29, 1.41) 1.24 (1.18, 1.30) 
Preeclampsia (born ≥34 weeks’ gestational age)e 1755 1.30 (1.24, 1.36) 1.18 (1.13, 1.24) 
Preeclampsia (born <34 weeks’ gestational age)e 269 2.23 (1.97, 2.51) 2.04 (1.81, 2.30) 
Preeclampsia without chronic hypertensionf 1996 1.37 (1.31, 1.43) 1.26 (1.20, 1.31) 
Preeclampsia with chronic hypertensionf 28 1.03 (0.71, 1.49) 0.91 (0.63, 1.31) 
Preeclampsia excluding those with family 
history of mental illnessg 
1575 1.40 (1.33, 1.48) 1.28 (1.22, 1.35)c 
Preeclampsia-ASD (+adjusted for caesarean 
section) 
2024 1.36 (1.31, 1.43) 1.21 (1.15, 1.26)d 
Preeclampsia with low/intermediate APGAR at 
5 minutesh 
87 1.35 (1.09, 1.69) 1.30 (1.04, 1.62) 
Preeclampsia by maternal agei    
<20  99 1.46 (1.19, 1.79) 1.37 (1.12, 1.68) 
20-29 1053 1.32 (1.24, 1.40) 1.22 (1.15, 1.30) 
30-39 798 1.41 (1.31, 1.51) 1.29 (1.20, 1.38) 
≥40 74 1.19 (0.94, 1.50) 1.11 (0.88, 1.40) 
Preeclampsia by BMI at first antenatal visitj    
<20 117 1.31 (1.09, 1.57) 1.29 (1.07, 1.55) 
20-24.9 606 1.33 (1.22, 1.44) 1.27 (1.17, 1.38) 
25-29.9 392 1.16 (1.04, 1.28) 1.11 (1.01, 1.23) 
≥30 372 1.22 (1.09, 1.35) 1.18 (1.06, 1.31) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. BMI=body mass index. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, birth order, parental depression, 
bipolar disorder and non-affective psychiatric disorders, maternal smoking status, BMI at first antenatal visit, gestational weight 
gain, family income and parental level of education. 
cAdjusted for same potential confounders as above with the exception of parental mental health. 
dAdjusted for same potential confounders as ‘b’ above, in addition to adjusting for caesarean section.  
eReference=deliveries ≥34 weeks’ gestational age in mothers with no preeclampsia. fReference=no preeclampsia/no chronic 
hypertension. gReference=no preeclampsia/no family history of mental illness.  hReference=no preeclampsia/low/intermediate 










Appendix 15: Association between preeclampsia and ASD among singleton live 






HR (95% CI)a 
Model 2 
HR (95% CI)b 
Gestational agec N (%)  Preeclampsia Preeclampsia 
<34 weeks 32,332 (1.1) 269 2.25 (2.00, 2.54) 2.05 (1.82, 2.31) 
34 weeks  17,162 (0.6) 57 1.32 (1.02, 1.71) 1.19 (0.92, 1.54) 
35 weeks 29,982 (1.1) 83 1.44 (1.16, 1.78) 1.32 (1.06, 1.64) 
36 weeks 60,016 (2.1) 153 1.57 (1.34, 1.84) 1.42 (1.21, 1.67) 
37 weeks 141036 (5.0) 226 1.41 (1.24, 1.61) 1.29 (1.13, 1.47) 
38 weeks 386963 (13.6) 319 1.37 (1.23, 1.53) 1.26 (1.13, 1.41) 
39 weeks 657765 (23.2) 351 1.28 (1.15, 1.42) 1.17 (1.06, 1.30) 
40 weeks 799752 (28.2) 316 1.21 (1.08, 1.35) 1.12 (1.00, 1.25) 
>40 weeks 712440 (25.1) 240 1.18 (1.04, 1.34) 1.03 (0.91, 1.17) 
Infant sex     
Maled 1460940 (51.4) 1386 1.36 (1.29, 1.43) 1.25 (1.18, 1.32) 
Femalee 1381290 (48.6) 638 1.36 (1.26, 1.47) 1.25 (1.16, 1.35) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, birth order, parental depression, 
bipolar disorder and non-affective psychiatric disorders, maternal smoking status, BMI at first antenatal visit, gestational 
weight gain, family income and parental level of education. 
cReference=no preeclampsia/born at ≥37 weeks’ gestation. 
dReference=no preeclampsia in males. 






Appendix 16: E-value worked example for preeclampsia-ADHD(235) 
E-Value for effect estimate: = RR + sqrt[RR x (RR-1)] 
 = 1.13 + sqrt[1.13 x (1.13-1)] 
 = 1.13 + 0.38 
 = 1.51 
E-Value for lower limit (LL) of CI: = LL + sqrt[LL x (LL-1)] 
 = 1.05 + sqrt[1.05 x (1.05-1)] 
 = 1.05 + 0.23 











Appendix 17: Full description of results of sensitivity analyses examining 
association between preeclampsia and ADHD 
When we excluded women who had preeclampsia in their first pregnancy, the adjusted 
HR was 1.21 (95% CI: 1.13, 1.30). When we restricted the study population to 2001-
2010 and 1994-2010 the HR was 1.21 (95% CI: 1.16, 1.28) and 1.14 (95% CI: 1.10, 
1.18) respectively. The adjusted HR for preeclampsia (excluding chronic 
hypertension) and preeclampsia (with chronic hypertension) were 1.15 (95% CI: 1.12, 
1.19) and 1.18 (95% CI: 0.93, 1.50) respectively. The HR for preeclampsia (excluding 
those with a family history of mental illness was 1.16 (95% CI: 1.12, 1.21). The HR 
for preeclampsia (with low/intermediate APGAR at 5 minutes) was 1.13 (95% CI: 
0.94, 1.36) when compared to non-exposure to preeclampsia in those with a 
low/intermediate APGAR score. Results of the subgroup analysis by maternal age 
were not significantly different from each other. Similarly, results of the subgroup 
analysis by BMI at first antenatal visit did not significantly differ from each other. The 
HR for preeclampsia-ADHD in males was 1.18 (95% CI: 1.14, 1.23) compared to non-
exposure to preeclampsia in males. The HR for preeclampsia-ADHD in females was 
1.10 (1.04, 1.17) compared to non-exposure to preeclampsia in females. Finally, 
exposure to preeclampsia in males was associated with a 9% increase in likelihood of 






Appendix 18: Sensitivity analyses examining the association between 





HR (95% CI)a 
Model 2 
HR (95% CI)b 
Preeclampsia (excluding women who had 
preeclampsia in first pregnancy) 
726 1.29 (1.20, 1.39) 1.21 (1.13, 1.30) 
Preeclampsia (Study population restricted to 
2001-2010) 
1660 1.35 (1.29, 1.42) 1.21 (1.16, 1.28) 
Preeclampsia (Study population restricted to 
1994-2010) 
3237 1.22 (1.18, 1.27) 1.14 (1.10, 1.18) 
Preeclampsia excluding chronic 
hypertensiond 
3872 1.21 (1.18, 1.25) 1.15 (1.12, 1.19) 
Preeclampsia with chronic hypertensiond 69 1.31 (1.04, 1.66) 1.18 (0.93, 1.50) 
Preeclampsia excluding those with family 
history of mental illnesse 
2803 1.23 (1.19, 1.28) 1.16 (1.12, 1.21)c 
Preeclampsia with low/intermediate APGAR 
at 5 minutesf 
123 1.17 (0.97, 1.41) 1.13 (0.94, 1.36) 
Preeclampsia by maternal ageg    
<20  235 1.19 (1.04, 1.36) 1.19 (1.05, 1.36) 
20-29 2145 1.15 (1.11, 1.20) 1.12 (1.07, 1.17) 
30-39 1439 1.26 (1.20, 1.33) 1.20 (1.14, 1.26) 
≥40 122 1.25 (1.04, 1.49) 1.18 (0.98, 1.42) 
Preeclampsia by BMI at first antenatal visith    
<20 192 1.19 (1.03, 1.37) 1.24 (1.08, 1.44) 
20-24.9 1064 1.09 (1.03, 1.16) 1.09 (1.03, 1.16) 
25-29.9 874 1.12 (1.04, 1.19) 1.13 (1.06, 1.21) 
≥30 877 1.10 (1.02, 1.17) 1.13 (1.06, 1.21) 
Infant sex    
Malesi 2655 1.25 (1.21, 1.30) 1.18 (1.14, 1.23) 
Femalesj 1286 1.14 (1.07, 1.20) 1.10 (1.04, 1.17) 
Males v Femalesk 2655 1.10 (1.03, 1.18) 1.09 (1.02, 1.17) 
Abbreviations: HR=hazard ratio. 95% CI=95% confidence interval. SGA=small for gestational age. BMI=body mass index. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, firstborn, parental  depression, 
bipolar disorder, and non-affective psychiatric disorders, family income, maternal smoking status, BMI at first antenatal visit, 
gestational weight gain and parental level of education. 
cAdjusted for same potential confounders as ‘b’ above with the exception of parental depression, bipolar disorder, and non -
affective psychiatric disorders 
dReference=no preeclampsia/no chronic hypertension eReference=no preeclampsia/no family history of mental illness.  
fReference=no preeclampsia/with low/intermediate APGAR. gReference=no preeclampsia at corresponding maternal age. 
hReference=no preeclampsia with corresponding BMI. iReference=non-exposure to preeclampsia in male offspring. 
jReference= non-exposure to preeclampsia in female offspring. kReference=exposure to preeclampsia in females. 










Appendix 19: Summary of data collection process in GUI study 
Wave (age at time of wave) Data collected Method of collection 
Wave 1 (age 9-months) 1. Preeclampsia  
    (and Preeclampsia+SGA) 
Face-to-face interview with 
Primary Caregiver 
2. Potential confounding 
factors 
Face-to-face interview with 
Primary Caregiver 
3. ASQ Face-to-face interview with 
Primary Caregiver 
Wave 2 (age 3 years) SDQ Face-to-face interview with 
Primary Caregiver 
Wave 3 (age 5 years) SDQ Face-to-face interview with 
Primary Caregiver 
SDQ Postal survey completed by 
study child’s teacher 
Wave 4 (age 7-8 years) SDQ Postal survey completed by 
Primary Caregiver 





Appendix 20: Repeated measures analysis examining the association between preeclampsia and emotional/behavioural problems 
(by SDQ domain) among singleton live births in Ireland 
Adjusted modela 
Emotional 
Mean trajectory (95% CI)  
(No Preeclampsia) 
Mean trajectory (95% CI)  
(Preeclampsia) 
Mean difference in trajectory (95% CI) 
comparing no preeclampsia to preeclampsia 
Age 3 SDQ 1.71 (1.30, 2.12) 1.79 (1.36, 2.21) -0.08 (-0.19, 0.03) 
Change SDQ Age 5 -0.61 (-2.23, 1.02) -0.44 (-2.07, 1.20) -0.17 (-0.03, -0.31) 
Change SDQ Age 7-8 2.93 (-0.65, 6.51) 2.91 (-0.68, 6.49) 0.03 (0.19, 0.24) 
Age 7-8 SDQ 4.03 (0.36, 7.70) 4.26 (0.58, 7.94) -0.22 (-0.01, -0.44) 
Conduct 
Age 3 SDQ 2.70 (2.29, 3.11) 2.78 (2.36, 3.21) -0.08 (-0.21, 0.04) 
Change SDQ Age 5 -0.69 (-0.73, -0.66) -0.61 (-0.75, -0.47) -0.08 (-0.23, 0.06) 
Change SDQ Age 7-8 -0.09 (-0.13, -0.04) -0.31 (-0.48, -0.14) 0.22 (0.04, 0.40) 
Age 7-8 SDQ 1.92 (1.51, 2.33) 1.87 (1.43, 2.31) 0.05 (-0.12, 0.22) 
Hyperactivity 
Age 3 SDQ 5.73 (5.11, 6.36) 5.66 (5.01, 6.30) 0.08 (-0.09, 0.25) 
Change SDQ Age 5 0.57 (-1.68, 2.81) 0.88 (-1.37, 3.14) -0.32 (-0.51, -0.12) 
Change SDQ Age 7-8 0.67 (-3.28, 4.62) 0.48 (-3.48, 4.44) -0.19 (-0.05, 0.43) 
Age 7-8 SDQ 6.97 (2.91, 11.03) 7.02 (2.95, 11.09) -0.05 (-0.30, 0.19) 
Peer Problems 
Age 3 SDQ 2.36 (1.98, 2.75) 2.39 (1.99, 2.79) -0.03 (-0.14, 0.08) 
Change SDQ Age 5 0.19 (-1.24, 1.63) 0.29 (-1.15, 1.73) -0.10 (-0.23, 0.03) 
Change SDQ Age 7-8 -0.33 (-3.15, 2.48) -0.51 (-3.33, 2.31) 0.17 (0.01, 0.35) 
Age 7-8 SDQ 2.22 (-0.58, 5.02) 2.17 (-0.64, 4.98) 0.05 (-0.11, 0.21) 
Prosocial Behaviourb 
Age 3 SDQ 7.39 (6.90, 7.89) 7.49 (6.98, 7.80) -0.09 (-0.23, 0.04) 
Change SDQ Age 5 0.75 (-0.97, 2.47) 0.66 (-1.07, 2.39) 0.09 (-0.06, 0.24) 
Change SDQ Age 7-8 1.73 (-1.46, 4.91) 1.80 (-1.39, 4.99) -0.07 (-0.27, 0.13) 
Age 7-8 SDQ 9.87 (6.69, 13.04) 9.94 (6.76, 13.12) -0.07 (-0.26, 0.11) 
Abbreviations: 95% CI=95% confidence interval. SDQ=Strengths and Difficulties Questionnaire. 
aAdjusted for maternal education, maternal age, maternal ethnicity, maternal body mass index (BMI) at time of interview, family social class, gestational diabetes, 
and infant sex. 
bProsocial Behaviour is reversed scored (i.e. higher scores indicate more positive outcomes). 
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Appendix 21: Assessment of repeated measures model fit from GUI study. 
Comparison of predicted values (from multilevel model) with observed values at 




























SDQ score     
Age 3 7.77 (4.53) 7.78 (2.95) -0.01 -4.31, 4.31 
Age 5 7.18 (4.75) 7.23 (3.34) -0.05 -4.05, 4.05 
Age 7-8 7.10 (5.30) 7.44 (3.72) -0.33 -3.63, 3.63 




Appendix 22: Sensitivity analysis examining associations between preeclampsia 
and child development and emotional/behavioural problems among singleton live 
births in Ireland 
 
Failure of ASQ domains  (including primiparous women only) 
Adjusted modela  
OR (95% CI) 
Communication  1.32 (0.80, 2.19) 
Gross Motor 1.15 (0.78, 1.71) 
Fine Motor 0.73 (0.45, 1.17) 
Problem Solving 0.74 (0.48, 1.14) 
Personal Social 1.25 (0.84, 1.86) 
Abnormal SDQ age 3 years (including primiparous women only)  
Emotional 1.38 (0.74, 2.57) 
Conduct 1.06 (0.76, 1.48) 
Hyperactivity 0.93 (0.56, 1.55) 
Peer Problems 0.69 (0.42, 1.14) 
Prosocial Behaviour 1.32 (0.60, 2.91) 
Abnormal SDQ age 5 years (including primiparous women only)  
Emotional 1.75 (1.09, 2.82) 
Conduct 0.78 (0.47, 1.30) 
Hyperactivity 1.64 (1.11, 2.42) 
Peer Problems 1.53 (0.90, 2.60) 
Prosocial Behaviour 1.21 (0.42, 3.55) 
Abnormal SDQ age 7/8 years (including primiparous women only)  
Emotional 1.18 (0.70, 1.99) 
Conduct 0.99 (0.53, 1.89) 
Hyperactivity 0.98 (0.52, 1.84) 
Peer Problems 1.02 (0.52, 1.97) 
Prosocial Behaviour 0.30 (0.07, 1.38) 
 
Total SDQ score age 5 years (Maternal reported) 
Adjusted modela  
Coefficient (95% 
CI) 
Preeclampsia 0.79 (0.26, 1.31) 
Total SDQ score age 5 years (Teacher reported)  
Preeclampsia 0.71 (0.12, 1.31) 
Abbreviations: OR=odds ratio. 95% CI=95% confidence interval. ASQ=Ages and Stages 
Questionnaire. SDQ=Strengths and Difficulties Questionnaire. 
aAdjusted for maternal education, maternal age, maternal ethnicity, maternal body mass index (BMI) 












Appendix 23: Bland-Altman agreement plot comparing parent-reported SDQ 
scores to teacher-reported SDQ scores at age 5 years in GUI Study  
 
 
Appendix 24: Sensitivity analysis of repeated measures analysis examining the 
association between preeclampsia/SGA and emotional/behavioural problems 
(using total SDQ Score) among singleton live births in Ireland  






Mean trajectory  




Mean trajectory  
(95% CI)   
(Preeclampsia+SGA) 
Mean difference in 




Age 3 SDQ 11.56 (10.05, 13.06) 11.89 (10.09, 13.68) -0.33 (-1.31, 0.64) 
Change SDQ Age 5 -4.16 (-10.25, 1.93) -3.42 (-9.59, 2.75) -0.74 (-1.78, 0.30) 
Change SDQ Age 7-8 1.42 (-0.21, 3.05) 0.51 (-1.66, 2.67) 0.91 (-0.57, 2.40) 
Age 7-8 SDQ 8.81 (2.39, 15.24) 8.98 (2.37, 15.58) -0.16 (-1.73, 1.40) 
Abbreviations: 95% CI=95% confidence interval. SDQ=Strengths and Difficulties Questionnaire. 
SGA=small for gestational age. 
aAdjusted for maternal education, maternal age, maternal ethnicity, maternal body mass index (BMI) 
at time of interview, family social class, gestational diabetes, and infant sex. 
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Appendix 25: Sensitivity analysis examining associations between preeclampsia 
and child development and emotional/behavioural problems among singleton live 
births in Ireland by gestational age 
 
Failure of ASQ domains (Preeclampsia, born <37 weeks’ gestation)b 
Adjusted modela 
OR (95% CI) 
Communication  3.10 (1.49, 6.45) 
Gross Motor 2.80 (1.63, 4.85) 
Fine Motor 1.54 (0.77, 3.07) 
Problem Solving 1.74 (0.96, 3.16) 
Personal Social 1.42 (0.77, 2.61) 
Failure of ASQ domains (Preeclampsia, born ≥37 weeks’ gestation)b  
Communication  0.96 (0.64, 1.46) 
Gross Motor 0.93 (0.70, 1.23) 
Fine Motor 0.88 (0.63, 1.22) 
Problem Solving 0.80 (0.60, 1.08) 
Personal Social 0.92 (0.70, 1.20) 
Abnormal SDQ age 3 years (Preeclampsia, born <37 weeks’ gestation)b  
Emotional 1.43 (0.46, 4.49) 
Conduct 0.75 (0.40, 1.38) 
Hyperactivity 1.40 (0.64, 3.08) 
Peer Problems 1.07 (0.46, 2.49) 
Prosocial Behaviour 1.82 (0.60, 5.53) 
Abnormal SDQ age 3 years (Preeclampsia, born ≥37 weeks’ gestation)b  
Emotional 1.28 (0.77, 2.13) 
Conduct 1.10 (0.87, 1.40) 
Hyperactivity 0.87 (0.59, 1.29) 
Peer Problems 0.85 (0.57, 1.25) 
Prosocial Behaviour 1.06 (0.59, 1.90) 
Abnormal SDQ age 5 years  (Preeclampsia, born <37 weeks’ gestation)b  
Emotional 2.39 (1.07, 5.37) 
Conduct 1.45 (0.69, 3.04) 
Hyperactivity 2.22 (1.12, 4.39) 
Peer Problems 2.56 (1.15, 5.69) 
Prosocial Behaviour 1.60 (0.33, 7.81) 
Abnormal SDQ age 5 years  (Preeclampsia, born ≥37 weeks’ gestation)b  
Emotional 1.46 (0.96, 2.20) 
Conduct 1.08 (0.76, 1.54) 
Hyperactivity 1.50 (1.11, 2.03) 
Peer Problems 1.31 (0.86, 1.99) 
Prosocial Behaviour 1.42 (0.72, 2.80) 
Abnormal SDQ age 7/8 years (Preeclampsia, born <37 weeks’ gestation)b  
Emotional 1.52 (0.59, 3.88) 
Conduct 0.58 (0.19, 1.79) 
Hyperactivity 0.49 (0.11, 2.10) 
Peer Problems 1.14 (0.35, 3.74) 
Prosocial Behaviour - 
Abnormal SDQ age 7/8 years (Preeclampsia, born ≥37 weeks’ gestation)b  
Emotional 1.11 (0.73, 1.69) 
Conduct 0.90 (0.54, 1.50) 
Hyperactivity 0.87 (0.52, 1.45) 
Peer Problems 0.69 (0.39, 1.21) 
Prosocial Behaviour 0.67 (0.24, 1.89) 
Abbreviations: OR=odds ratio. 95% CI=95% confidence interval. ASQ=Ages and Stages 
Questionnaire. SDQ=Strengths and Difficulties Questionnaire. 
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aAdjusted for maternal education, maternal age, maternal ethnicity, maternal body mass index (BMI) 
at time of interview, family social class, gestational diabetes, and infant sex. 
bReference=no preeclampsia/born ≥37 weeks’ gestation). 
Reason for empty cells: n too small to estimate. 
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